The Alternative Renin-Angiotensin System: exploration of its therapeutic potential by Sevá Pessôa, B. (Bruno)

 
 
 
 
 
 
THE ALTERNATIVE RENIN-ANGIOTENSIN SYSTEM: 
EXPLORATION OF ITS THERAPEUTIC POTENTIAL 
 
 
 
 
 
 
Bruno Sevá Pessôa 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The alternative renin-angiotensin system: exploration of its therapeutic 
potential 
ISBN: 978-94-6203-745-8 
Cover design: Philippe Simons Ribeiro  
Printing: CPI Koninklijke Wöhrmann B. V.   
Copyright © Bruno Sevá Pessôa, Rotterdam, The Netherlands 
All right reserved. No part of this thesis maybe reproduced, stored in a retrieval 
system of any nature, or transmitted in any form or means, without written 
permission of the author, or when appropriate, of the publishers of the 
publications. 
  
 
THE ALTERNATIVE RENIN-ANGIOTENSIN SYSTEM: 
EXPLORATION OF ITS THERAPEUTIC POTENTIAL 
Het alternatieve renine-angiotensine systeem:  
verkenning van de therapeutische mogelijkheden 
Proefschrift 
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam 
op gezag van de rector magnificus 
Prof.dr. H.A.P. Pols 
en volgens besluit van het College voor Promoties 
De openbare verdediging zal plaatsvinden op 
woensdag 25 februari 2015 om 11.30 uur 
door 
Bruno Sevá Pessôa 
geboren te Campinas, Brazilië  
 
 
 
 
  
Promotiecommissie 
 
Promotor:                                Prof.dr. A.H.J. Danser 
Overige leden:            Prof.dr. D.J. Duncker 
                                               Prof.dr. J.W. Roos-Hesselink 
                                               Prof.dr. C.G. Schalkwijk                                            
  
Copromotor:                          Dr. A.J.M. Roks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The research described in this thesis was supported by a grant of the Dutch 
Heart Foundation (DHF-2010B009) 
 
Financial support for the publication of this thesis was generously provided by 
Erasmus University Rotterdam. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       To my wife and children 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE OF CONTENTS 
Chapter 1 Introduction 9 
Chapter 2 Multiple ascending dose study with the new renin 
inhibitor VTP-27999: nephrocentric consequences 
of too much renin inhibition 
43 
Chapter 3 Angiotensin II type 2 receptor- and acetylcholine-
mediated relaxation:  the essential contribution of 
female sex hormones and chromosomes 
71 
Chapter 4 The renin-angiotensin system, bone marrow and 
progenitor cells 
91 
Chapter 5 The effect of a stable angiotensin-(1-7) analogue on 
progenitor cell recruitment and cardiovascular 
function post-myocardial infarction 
133 
Chapter 6 Development of the local renin-angiotensin system 
during differentiation of mesenchymal stem cells  
157 
Chapter 7 Summary, conclusions and perspectives 183 
Chapter 8 Nederlandse samenvatting, conclusies en 
vooruitzichten 
       189 
PhD portifolio  197 
List of 
publications 
 201 
Curriculum vitae  203 
Acknowledgments  205 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 1 
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Based on: Key developments in renin-angiotensin-aldosterone system inhibition. 
Sevá Pessôa B, van der Lubbe N, Verdonk K, Roks AJM, Hoorn EJ, Danser AHJ. 
Nat Rev Nephrol. 2013;9:26-36.  
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ABSTRACT 
The renin–angiotensin system (RAS) was initially thought to be fairly simple. 
However, this idea has been challenged following the development of RAS 
blockers, including renin inhibitors, angiotensin-converting-enzyme (ACE) 
inhibitors, type 1 angiotensin II (AT1)-receptor blockers and mineralocorticoid-
receptor antagonists. Consequently, new RAS components and pathways that 
might contribute to the effectiveness of these drugs and/or their adverse effects 
have been identified. For example, an increase in renin levels during RAS 
blockade might result in harmful effects via stimulation of the prorenin 
receptor (PRR), and prorenin—the inactive precursor of renin—might gain 
enzymatic activity on PRR binding. The increase in angiotensin II levels that 
occurs during AT1-receptor blockade might result in beneficial effects via 
stimulation of type 2 angiotensin II receptors. Moreover, angiotensin 1–7 levels 
increase during ACE inhibition and AT1-receptor blockade, resulting in Mas 
receptor activation and the induction of cardioprotective and renoprotective 
effects, including stimulation of tissue repair by stem cells. Finally, a role of 
angiotensin II in sodium and potassium handling in the distal nephron has 
been identified. This finding is likely to have important implications for 
understanding the effects of RAS inhibition on whole body sodium and 
potassium balance. 
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INTRODUCTION 
In the past few decades our understanding of the complexity of the renin–
angiotensin system (RAS) has increased considerably, largely as a result of 
knowledge obtained following the introduction of RAS blockers, such as renin 
inhibitors, angiotensin-converting-enzyme (ACE) inhibitors, type 1 
angiotensin II (AT1) receptor blockers (ARBs) and mineralocorticoid receptor 
antagonists (MRAs). Although these agents do not always uniformly suppress 
angiotensin II and aldosterone levels or activity—breakthroughs, during which 
angiotensin II and aldosterone levels return to, or even increase above, their 
pretreatment levels often occur1, 2—they have been used successfully to treat 
cardiovascular and renal diseases.3 The efficacy of RAS blockers despite the 
occurrence of angiotensin II and aldosterone breakthroughs suggests that their 
beneficial effects are not solely attributable to blockade of the angiotensin II–
AT1 receptor–aldosterone–mineralocorticoid receptor axis. For example, high 
angiotensin II levels, particularly during AT1 receptor blockade, might stimulate 
activation of type 2 angiotensin II (AT2) receptors, which are thought to oppose 
the effects of AT1 receptor activation. The latter include vasoconstriction, 
stimulation of growth and remodelling, sympathetic nervous system activation, 
and Na+ and water retention.4, 5 Similarly, treatment with ACE inhibitors and 
ARBs results in the production of high levels of angiotensin II metabolites 
(Figure 1), most importantly angiotensin 1-7 (Ang-(1-7)), which exerts 
cardioprotective and renoprotective  effects via the Mas receptor.6 Ang-(1-7)–
Mas receptor interactions might also contribute to the success of RAS 
blockade.  
11 
  
Figure 1: New developments in the renin–angiotensin-system cascade. Binding of the renin 
precursor, prorenin, to the PRR activates the protein, enabling prorenin to cleave 
angiotensinogen and generate angiotensin 1. Renin and prorenin also act as agonists of the 
PRR and induce angiotensin-independent effects, such as ERK1/2 activation. APA generates 
angiotensin III from angiotensin II, and APN subsequently degrades angiotensin III to 
angiotensin IV. Binding of angiotensin II to the AT1 receptor induces vasoconstriction, 
stimulation of growth and remodelling, sympathetic nervous system activation, and sodium 
and water retention. Angiotensin III is thought to be the preferred endogenous agonist of the 
AT2 receptor, which mediates effects that either resemble or oppose those of AT1- receptor 
activation. ACE2 generates angiotensin 1–7 from angiotensin II, and this metabolite activates 
the Mas receptor (and possibly AT2 receptors), thereby inducing beneficial effects (such as 
improvement in endothelial function, reduced fibrosis and enhanced tissue repair by stem 
cells) that oppose those of AT1-receptor activation. New drugs in development include 
antagonists of the PRR (HRP), AT2 receptor (PD123319) and Mas receptor (A779), and 
activators of the AT2 receptor (C21), Mas receptor (AVE 0991, cyclic angiotensin 1–7) and ACE2 
(XNT). Abbreviations: ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting-
enzyme 2; Ang, angiotensin; APA, aminopeptidase A; APN, aminopeptidase N; AT1, type 1 
angiotensin II; AT2, type 2 angiotensin II; ERK1/2, extracellular signal-regulated kinase 1/2; 
HRP, handle region peptide; PRR, prorenin receptor.  
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RAS blockade causes an increase in renin levels7 as a result of 
interference with the negative feedback loop between angiotensin II and renin 
release. This effect explains, at least in part, why angiotensin II and 
aldosterone breakthroughs occur. In addition to renin, the levels of its 
precursor, prorenin, might also increase. Since the discovery of the prorenin 
receptor (PRR),8 which in vitro induces profibrotic effects following renin or 
prorenin binding, it has been proposed that increases in renin and prorenin 
levels will not only result in diminished RAS suppression, but also in unwanted 
effects via PRR stimulation.9 
Aldosterone interacts with angiotensin II in a synergistic manner and 
might exert nongenomic, acute effects via a mineralocorticoid-receptor-
independent mechanism.10-12 Unravelling this interaction at the level of the 
kidney is of importance to obtain a full understanding of the different effects of 
aldosterone during hypovolemia (sodium retention, potassium conservation) 
and hyperkalemia (potassium secretion), that is the aldosterone paradox. A 
better understanding of this paradox and of the specific roles of angiotensin II 
and aldosterone in sodium and potassium handling in the kidney is likely to be 
important to fully appreciate the effects of RAS inhibition on sodium and 
potassium balance. 
 In this Review, we describe the available evidence regarding the roles of 
the PRR, AT2 receptor, Ang-(1–7) and aldosterone-angiotensin II interactions in 
the RAS cascade. Focusing mainly on the kidney, we discuss the potential of 
agents such as PRR blockers, AT2-receptor agonists and Mas-receptor agonists 
to further enhance the degree of RAS blockade with potentially beneficial 
effects in patients with cardiovascular and renal diseases. 
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THE PRORENIN RECEPTOR 
Activation of prorenin 
The PRR is an almost ubiquitously expressed 350-amino-acid protein that can 
bind both renin and prorenin.8, 13, 14 Binding to the PRR induces prorenin to 
undergo a conformational change, which allows the prosegment to move out of 
the catalytic cleft, resulting in full, nonproteolytic activation of the protein.8, 13 
This mechanism differs from the proteolytic activation of prorenin in the kidney, 
during which the prosegment is cleaved off by an as yet unidentified enzyme.15 
Given the much higher levels of prorenin (which is largely derived from the 
kidney, but also from extrarenal sources)15 than renin in blood plasma, and the 
fact that prorenin–renin converting enzymes are only expressed in the kidney, 
the hypothesis that PRR binding enables the normally inactive prorenin to gain 
angiotensin-generating activity at tissue sites is attractive.16 However, a study 
showed that following renin or prorenin exposure, the PRR directly activated 
the extracellular signal-regulated kinase 1/2 (ERK1/2) signalling pathway 
independently of the formation of angiotensin II.8, 17 This activation was not 
blocked by renin inhibitors, suggesting that binding of these inhibitors to 
prorenin does not prevent binding of prorenin to the PRR, although inhibitor 
binding did prevent the generation of angiotensin I.13, 17  
As the affinity of prorenin for the human PRR is 3–4-fold higher than 
that of renin,14 the assumption that the prosegment facilitates binding to the 
PRR seems reasonable. The prosegment contains a ‘handle region’ (peptides 
10–19), which is thought to bind to the PRR and enable catalytic activation of 
prorenin.18 Peptidic antagonists, known as handle region peptides (HRPs), bind 
competitively to the PRR, thereby preventing PRR-mediated prorenin activation 
and reducing RAAS activity in tissues.19, 20 The structure of prorenin is highly 
species-specific so different HRPs have been designed for use in humans, rats 
and mice. 
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RAS-dependent function 
In rats, ubiquitous overexpression of the human PRR resulted in proteinuria, 
glomerulosclerosis21 and renal cyclooxygenase-2 (COX-2) upregulation.22 The 
human PRR binds, but does not activate rat prorenin,21 therefore, it was not 
surprising that overexpression of the human PRR did not alter angiotensin 
levels in the plasma and tissues of transgenic rats.22 However, these animals 
showed increased levels of aldosterone in their blood plasma.23 This increase 
was unlikely to be the result of prorenin-induced PRR stimulation because 
neither renin nor prorenin affected aldosterone synthesis in the human 
adrenocortical cell lines H295R and HAC15.23 An infusion of HRP prevented 
the development of glomerulosclerosis in transgenic rats that expressed the 
human PRR.21 
In diabetic rats, HRP therapy normalized high renal angiotensin levels 
without affecting blood pressure, and prevented the development of 
nephropathy.19 HRP therapy also prevented the development of nephropathy in 
diabetic type 1a angiotensin II (AT1A) receptor-deficient mice,20 suggesting that 
this effect was not dependent on the suppression of local angiotensin 
generation. Interestingly, extracellular signal-regulated kinase 1 and 2 
(ERK1/2) as well as phospho-p38 mitogen-activated protein kinase (MAPK) and 
phospho-Jun N-terminal kinase (MAPK) were upregulated in the diabetic 
kidneys of both wild-type and AT1A receptor-deficient mice, and HRP (but not 
ACE inhibitor) therapy fully normalized this increased phosphorylation.20 
Evidence supporting a renin–PRR interaction came from a study that 
showed that renin activated ERK1/2 in mesangial cells, even in the presence of 
renin inhibitors, ACE inhibitors or ARBs.24 This activation resulted in 
production of transforming growth factor-β1 (TGF-β1) and the subsequent 
upregulation of genes encoding profibrotic molecules, such as plasminogen-
activator inhibitor-1 (PAI-1), fibronectin and collagens.8, 24 ERK1/2 activation 
occurred in response to <1 nmol/l of renin, and could be fully prevented by 
15 
  
PRR small interfering RNA (siRNA).24 Similar profibrotic effects with both renin 
and prorenin were observed in human embryonic kidney cells, although 
concentrations of 100 nmol/L were required to induce gene upregulation.25 
Remarkably, in podocytes, 2 nmol/l human prorenin increased ERK1/2 
activation without affecting TGF-1 or PAI-1 levels.26 These data suggest that 
the PRR–ERK1/2-mediated activation of profibrotic pathways does not occur in 
all cell types. Interestingly, in cultured nephritic glomeruli from rats with 
glomerulonephritis, concomitant PRR inhibition (using siRNA) and 
angiotensin II blockade (using an ACE inhibitor) had a greater suppressive 
effect on TGF-1 and PAI-1 expression than either inhibitor alone.27 The 
authors attributed this effect to the fact that ACE inhibition increases renin 
mRNA levels, thereby counteracting the consequences of angiotensin II 
suppression, since renin upregulates TGF-β1 and PAI-1 by stimulating the 
PRR.27 
In a gene expression profiling study, treatment of human mesangial cells 
with renin (20 nmol/l) and prorenin (50 nmol/L) activated pathways implicated 
in organ damage.28 For example, upregulation of COX-2 and activation of the 
TGF-1–PAI-1 pathway were observed. Although the effects of renin were 
greater than the effects of prorenin, there was extensive overlap between the 
gene signatures, indicating that renin and prorenin act through similar 
pathways. In podocytes, COX-2 overexpression exacerbated diabetic 
nephropathy by increasing PRR expression.29 Thus, not only does PRR 
stimulation result in COX-2 upregulation,22 but the reverse is also true, 
possibly because COX-2 metabolites promote PRR activation.29 Indeed, the 
presence of this positive feedback loop was confirmed in a study that showed 
that high glucose levels upregulated expression of the PRR and prorenin in rat 
mesangial cells, thereby facilitating generation of angiotensin II, which 
subsequently induced expression of COX-2 and interleukin-1.30 In addition, 
COX-2 inhibition reduced glucose-induced PRR upregulation, suggesting that 
products generated by COX-2 upregulate the PRR.29, 30 Expression of the PRR 
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in glomeruli and renal tubules was increased in diabetic rats, possibly as a 
result of enhanced AT1 receptor and NADPH oxidase activity.31 In diabetic rats, 
HRP treatment did not seem to affect PRR expression in vivo, whereas ARB 
therapy reduced PRR expression.32 
Effects of RAS blockade 
Consistent with the stimulatory effects of AT1 receptors on PRR expression,31 
RAAS blockade reduced PRR expression in the kidneys of diabetic rats.33 
However, in a Goldblatt rat (high angiotensin II) model of hypertension, parallel 
increases in PRR expression and renin levels were observed.34 PRR 
upregulation also occurred in the remnant kidneys (particularly in the tubular 
cells) of five-sixths nephrectomized rats,35 and in the kidneys (mainly in the 
tubular cells and collecting ducts) of patients with end-stage renal disease 
caused by diabetic nephropathy.36 These contrasting findings suggest that PRR 
expression might also be regulated in a RAS-independent manner, for example 
via the NADPH oxidase-dependent generation of reactive oxygen species.25, 31 
Despite the above data, we still do not know for certain whether 
prorenin–PRR interactions occur in vivo, and whether the therapeutic effects of 
HRPs are attributable to interference with such interactions. Importantly, the 
affinity of the PRR for renin and prorenin is in the high nanomolar range 
(possibly even 20 nmol/l for renin),14 which is difficult to reconcile with the 
picomolar levels of renin (~0.5 pmol/l) and prorenin (~5 pmol/l) in extracellular 
fluid. Which is difficult to reconcile with the picomolar levels of renin 
(~0.5 pmol/l) and prorenin (~5 pmol/l) in extracellular fluid.37 However, this 
affinity is consistent with the findings that PRR overexpression did not alter the 
levels of RAS components in rats,22, 38 and that in most in vitro studies in 
which prorenin–PRR interaction were investigated, high nanomolar prorenin 
concentrations (≤100 nmol/L) were required for activation of ERK1/2 and 
upregulation of profibrotic genes.6, 25, 28, 39 Moreover, in rodents, prorenin 
overexpression (which resulted in an up to 400-fold increase in plasma 
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prorenin levels), increased blood pressure in an angiotensin-dependent 
manner40-42 but did not cause the fibrosis or glomerulosclerosis that was 
expected based upon the findings of in vitro studies with renin and prorenin. 17, 
25, 28, 29 Even larger increases in plasma prorenin levels might be required to 
produce such effects. However, under pathological conditions and/or during 
RAS blockade, prorenin and renin levels do not normally increase more than 
three orders of magnitude above baseline. Whether such high levels occur in 
prorenin-synthesizing tissues, such as in renal interstitial fluid, is not known. 
The maximum increases in plasma prorenin levels that have been shown in 
humans—for example during severe heart failure or RAS blockade—are ~50–
100-fold for renin (although the increase is normally well below 10-fold), and 
twofold to threefold for prorenin.1, 37, 43 
Not surprisingly, as a result of the negative feedback loop between 
angiotensin II and renin, the largest increases in renin levels occur during the 
highest levels of RAS blockade. Consequently, dual or even triple RAS blockade 
(using a combination of RAS blockers) resulted in a greater increase in renin 
levels than did RAS blockade using a single RAS blockade approach.44 Studies 
of spontaneously hypertensive rats kept on a low-sodium diet, showed that 
dual RAS blockade resulted in massive increases (up to several-hundred-fold) 
in both plasma and renal renin levels, and depletion of angiotensinogen.44 As a 
consequence, a large decrease in blood pressure and severe renal failure 
occurred. These findings are reminiscent of those of the ALTITUDE study, in 
which the efficacy of the renin inhibitor aliskiren was evaluated versus placebo 
in high-risk patients with type 2 diabetes mellitus and renal dysfunction, 
whose blood pressure was normalized using one or more antihypertensive 
drugs, including ACE inhibitors and ARBs.45 The trial was stopped prematurely 
because of a lack of beneficial effects and an increased incidence of serious 
adverse events, including hypotension, hyperkalaemia and renal complications, 
in the patients who received aliskiren. The latter adverse-effect profile is 
entirely consistent with the consequences of angiotensin II and/or aldosterone 
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depletion, and thus deleterious PRR stimulation in response to increased renin 
and/or prorenin levels during combined aliskiren and ACE inhibitor or 
aliskiren and ARB treatment does not need to be invoked to explain these 
adverse effects. Moreover, although the levels of prorenin and renin in the 
patients who received aliskiren in the ALTITUDE trial have not yet been 
reported, it is highly unlikely that they were ≥10,000 times greater than the 
levels in untreated patients and, therefore, within the range required to 
stimulate the human PRR in vivo.39 In addition, as discussed above, RAS 
blockade in rodents induced a decrease, rather than an increase, in PRR 
expression.31-33  
RAS-independent functions 
If prorenin levels in vivo are too low to induce PRR stimulation, even during 
RAS blockade or under pathological conditions, the phenotype that develops in 
response to PRR overexpression per se must be the result of RAS-independent 
effects of PRR stimulation. Colocalization of the PRR with V-type proton ATPase 
(V-ATPase) in the kidney has been reported.46 This colocalization might occur 
because the 8.9 kDa accessory protein ATP6AP2 of V-ATPase is a post-
translationally truncated version of the PRR, which resembles the C-terminal 
domain of the receptor.14 V-ATPases have an important role in the acidification 
of subcellular compartments and the PRR is indispensable for V-ATPase 
integrity; in mice with podocyte-specific PRR knockout, the abundance of 
several V-ATPase subunits in podocytes was reduced, resulting in defective 
autophagy, severe endoplasmatic stress, and podocyte necrosis.47 As a 
consequence, the mice died at 2–4 weeks of age due to renal failure. The PRR 
also functions as an adaptor between V-ATPase and receptors for members of 
the Wnt family of signalling molecules.48 These findings clearly indicate the 
importance of the PRR beyond renin/prorenin binding, and raise doubt that 
the PRR binds to and activates prorenin in vivo. However, they do not rule out 
the possibility that the PRR has an important role in tissue damage, or that the 
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beneficial effects of RAS blockade occur as a result of a reduction in PRR 
expression. 
The available data on the effects of HRPs are inconclusive, mainly 
because no study has convincingly shown that these drugs block PRR–prorenin 
interactions in vivo. A possibility exists that HRPs are partial PRR agonists that 
exert their effects independently of renin and prorenin,49 thus explaining some 
of the conflicting results. However, given the interference with V-ATPase, PRR 
blockade per se would not necessarily have beneficial effects.  
AT2 RECEPTORS 
AT2 receptors are generally thought to oppose classical AT1-receptor-mediated 
effects, such as vasoconstriction, sodium retention and inflammation. In the 
kidney, AT2 receptors are expressed in the proximal tubules, collecting duct 
and renal resistance arteries,4 suggesting a role in renal haemodynamics and 
tubular function. Pathological conditions, such as diabetes and kidney injury, 
usually increase renal AT2-receptor expression, and concomitant ARB 
treatment further enhances this upregulation.50-52 AT2-receptor-knockout mice 
had either increased blood pressure at baseline or an increased hypertensive 
response to angiotensin II compared with wildtype mice, supporting a 
vasodilatory role of AT2 receptors.53, 54 The knockout mice also showed a 
rightward shift of the pressure-natriuresis curve and a more pronounced 
antinatriuretic response to angiotensin II than wildtype mice, again supporting 
a counter-regulatory role of AT2 receptors.55 Moreover, unilateral urethral 
obstruction resulted in increased renal interstitial fibrosis and apoptosis in AT2 
receptor knockout mice compared with wildtype mice.56, 57 However, an 
important consideration is that AT2-receptor-null mice showed increased 
expression of the AT1 receptor, which might explain these findings.58 
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Effects of stimulation 
ARB pretreatment is usually required to allow angiotensin II-induced, AT2-
receptor-mediated hypotensive and natriuretic effects to be observed in wild-
type animals,4, 59 suggesting that the opposing actions of the AT1 receptor 
usually predominate. Interestingly, in rats angiotensin III (angiotensin 2–8) 
rather than angiotensin II seems to be the preferred agonist of the AT2 receptor 
(Figure 1);60 blockers of aminopeptidase type A, which converts angiotensin II 
into angiotensin III, inhibited AT2-receptor-mediated natriuresis, whereas 
blockers of the degradation of angiotensin III (by aminopeptidase N) enhanced 
this effect.61, 62 
Development of the selective AT2 receptor agonist C21 has made 
investigation of the effects of AT2 receptor stimulation without concomitant 
ARB treatment possible. In obese Zucker rats, C21 induced natriuresis in a 
NO/cGMP-dependent manner.63, 64 This effect was prevented by preinfusion of 
the AT2 receptor antagonist PD123319.63, 64 C21 infusion also increased the 
fractional excretion of lithium, suggesting involvement of the proximal tubules 
in AT2 receptor-mediated natriuresis.63 Although AT2 receptor stimulation has 
been reported to increase renal blood flow in Sprague-Dawley rats, AT2 receptor 
stimulation did not affect glomerular filtration rate, and thus altered renal 
hemodynamics are unlikely to underlie the increased natriuresis.65 AT2 
receptor-mediated anti-inflammatory effects have been observed in the rat 2-
kidney, 1-clip model of hypertension; C21 decreased the renal interstitial levels 
of TNF-α, interleukin-6, and TGF-β1, and activated the NO/cGMP cascade in a 
blood-pressure-independent manner.64 
Based upon findings in AT2 knockout animals, AT2 receptor-mediated 
natriuresis, and C21-induced activation of the NO/cGMP cascade, one would 
expect that C21 infusion lowers blood pressure. Remarkably, however, the 
majority of studies have shown no effect of C21 on blood pressure, whereas 
other studies showed hypertension or hypotension in response to C21 
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treatment.66 Increases in blood pressure in response to C21 treatment might be 
a result of nonselective AT1 receptor stimulation occurring at high C21 doses.4 
C21-induced decreases in blood pressure could not be blocked by PD123319, 
and might be the result of a C21-dependent blockade of calcium transport into 
the cell.66 
Effects of blockade 
Studies of the effects of AT2 receptor blockade using PD123319 have also 
yielded conflicting results. In subtotally nephrectomized rats, PD123319, alone 
or in combination with ARB treatment, decreased proteinuria as well as 
monocyte and macrophage infiltration into the remnant kidney.67 Similarly, 
dual AT1-receptor blockade and AT2-receptor blockade, using PD123319 and 
the AT1 antagonist losartan, prevented activation of the NFB pathway in the 
mouse unilateral ureteral obstruction model of renal injury,68 and in rats, the 
glomerular infiltration of monocytes and macrophages following angiotensin II 
infusion depended on AT2-receptor-mediated chemokine induction.69 In a rat 
renal wrap hypertension model, angiotensin II–AT2 receptor interactions 
increased renal interstitial bradykinin, thus activating the protective NO/cGMP 
pathway.70 In rats, however, PD123319 treatment following renal ablation 
increased renal damage and blood pressure, most likely because AT2-receptor-
mediated vasodilation was prevented, and, therefore, ischaemic damage was 
increased in the remnant tissue.50 Finally, AT2-receptor stimulation in stroke-
prone, spontaneously hypertensive rats reduced monocyte and macrophage 
infiltration in the aorta and the kidney.71 
Detrimental effects 
Although data from a wide range of studies in healthy and diseased animal 
models support a beneficial role of AT2-receptor stimulation, resulting in anti-
inflammatory, hypotensive and natriuretic effects,50, 53-65, 71 the opposite has 
also been reported.66-69 One explanation for these contrasting data is that the 
phenotype of AT2 receptors is altered under pathological conditions and/or 
22 
  
with age. Indeed, AT2-receptor-mediated vasoconstriction has been observed in 
spontaneously hypertensive rats,72 and only lowering blood pressure enabled 
the return of bradykinin/NO-mediated relaxant responses.73 The change of 
phenotype might relate to the location of the receptor (endothelium or smooth 
muscle cell), as well as its capacity to heterodimerize with AT1 receptors.4 At 
this stage, the clinical application of an AT2-receptor agonist seems premature, 
particularly because a comparison of the effects of ACE inhibitors and ARBs in 
humans has not revealed major outcome differences.74 Nevertheless, the 
availability of a selective AT2-receptor agonist will help obtain a better 
understanding of the location, age and disease-dependent roles of the AT2 
receptor and determine in which diseases such drugs might be applied.  
ACE2–ANGIOTENSIN 1-7–MAS RECEPTOR AXIS 
The ACE homologue ACE2 cleaves angiotensin II to generate Ang-(1–7), which 
opposes AT1-receptor-mediated effects via stimulation of the Mas receptor 
(Figure 1).6 Ang-(1–7) can also be generated from angiotensin I, via angiotensin 
1–9, again with the help of ACE2.75 According to some studies, Ang-(1–7) binds 
to AT2 receptors, and high levels of Ang-(1–7) might stimulate AT1 receptors.76 
ACE2 and Mas receptors are expressed in kidney, heart and vascular tissue, 
suggesting that Ang-(1–7) might have a physiological, protective role in these 
organs.77 Indeed, in rodent models of cardiac ischemia and heart failure, Ang-
(1–7) infusion or ACE2 overexpression preserved cardiac and endothelial 
function, and in models of hypertension and diabetes, such treatment 
prevented renal and cardiovascular anomalies.77, 78 In spontaneously 
hypertensive rats, the Mas receptor antagonist A779 abrogated the 
antihypertensive and antiproteinuric effects of ACE inhibitors, suggesting that 
these effects depend, at least in part, on activation of the Mas receptor.79, 80 
Mas-receptor activation increased endothelial NO release and reduced oxidative 
stress, thereby eliminating the pro-oxidant properties of angiotensin II, and 
thus resulting in antihypertrophic, antifibrotic and renoprotective effects.81-83 
Somewhat confusingly, transfection of the Mas receptor into murine renal 
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proximal tubular cells attenuated angiotensin II-stimulated TGF-β1 expression, 
whereas in human mesangial cells, Ang-(1–7) stimulated the TGF-β1-
dependent profibrotic pathway—an effect that was inhibited by A779.84, 85 
These conflicting data, which are reminiscent of the contrasting data regarding 
AT2-receptor-mediated effects, might relate to the existence of Mas–AT1 
receptor heterodimers.86 
Role in stem cell regulation 
In the bone marrow, haematopoietic stem cells (HSCs) and mesenchymal stem 
cells (MSCs) differentiate into cardiovascular and renal progenitor cells, which 
have a major role in tissue repair. Importantly, clinical studies have shown that 
cardiac grafting of autologous bone marrow cells improved cardiac performance 
in patients with ischaemic heart disease, an effect that appeared to be mainly 
due to improved angiogenesis.87 Similarly, MSC infusion improved kidney 
function in patients with chronic kidney disease.88, 89 Given that all of the 
major components of the RAAS are present in bone marrow,90 this system is 
now believed to have an important role in HSC and MSC regulation. In mice, 
treatment with Ang-(1–7) after irradiation or chemotherapy stimulated 
regeneration of bone marrow.91, 92 Another rodent study showed that activation 
of the Ang-(1–7)–Mas-receptor pathway stimulated bone marrow cells to form 
early endothelial progenitor cells,93 although, paradoxically, antiangiogenic 
properties of Ang-(1–7) have also been reported.94 Nevertheless, stimulation of 
Mas receptors in bone marrow might be a strategy to improve tissue repair by 
stem cells. 
Novel therapies 
Given the rapid breakdown of the peptide Ang-(1–7) in vivo, novel therapies are 
now being developed to stimulate the ACE2–angiotensin 1–7–Mas receptor axis. 
Ang-(1–7) encapsulation in an oligosaccharide (hydroxypropyl β-cyclodextrin) 
offers protection during gastrointestinal passage, and oral application of 
encapsulated Ang-(1–7) was cardioprotective in infarcted rats.95 Cyclic 
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angiotensin 1–7 (cAng-(1–7)), an Ang-(1–7) analogue with a thioether bridge 
between amino acid residues 4 and 7, is resistant to metabolism, and can be 
delivered via oral and pulmonary routes.96 Interestingly, cAng-(1–7) selectively 
activated Mas receptors without binding to AT1 or AT2 receptors97 and improved 
cardiac remodelling and endothelial function after myocardial infarction.98 
Furthermore, the nonpeptide Ang-(1–7) analogue AVE 0991 prevented 
endorgan damage in spontaneously hypertensive rats treated with a NO 
synthesis inhibitor80 and also enhanced acetylcholine-induced vasodilation in 
Wistar rats.99 Finally, the ACE2 activator XNT improved cardiac function, and 
reduced cardiac, renal and pulmonary fibrosis in diabetic rats and in 
spontaneously hypertensive rats.100, 101 
In summary, Mas-receptor stimulation is a promising new approach to 
improve tissue repair by stem cells. Current strategies are directed either at 
generating high endogenous levels of Ang-(1–7) using ACE2 activators, 
administering stable Ang-(1–7) analogues or encapsulating Ang-(1–7) in 
oligosaccharides to slow down its breakdown following oral administration. 
ANGIOTENSIN–ALDOSTERONE INTERACTIONS 
The classical paradigm 
Physiologically, the RAS operates in the kidney to increase renal sodium 
retention during hypovolaemia and potassium secretion during hyperkalaemia. 
The classical paradigm states that angiotensin II primarily increases sodium 
reabsorption by the proximal tubule, whereas aldosterone stimulates sodium 
uptake and potassium secretion in the more distal parts of the nephron—the 
distal convoluted tubule, connecting tubule, and collecting duct.102  
Sodium potassium transporters 
In the past two decades, the major sodium and potassium transport proteins in 
the nephron have been cloned and characterized. In the proximal tubule, 
angiotensin II mediates sodium bicarbonate reabsorption through 
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sodium/hydrogen exchanger 3,103 and in the distal nephron, the sodium 
chloride cotransporter (NCC),104 epithelial sodium channel (ENaC),105 and the 
renal outer medullary potassium channel (ROMK)106, 107 have all been shown to 
be sensitive to aldosterone. The NCC is located in the ‘early’ distal convoluted 
tubule, whereas the ENaC is located in the ‘late’ distal convoluted tubule, 
connecting tubule and collecting duct, and the ROMK is expressed along the 
entire distal nephron.108 These aldosterone-sensitive transporters are 
important clinically because they are direct or indirect targets of several 
antihypertensive drugs, including ACE inhibitors, ARBs, thiazide diuretics, 
amiloride and MRAs. 
Angiotensin II actions in the distal nephron 
The paradigm that angiotensin II acts proximally in the kidney has now been 
challenged. Several studies, including ours, have shown that angiotensin II 
also regulates sodium and potassium handling in the distal nephron.109-115 
Although abundantly located in the proximal tubule, 125I– angiotensin II 
binding studies have shown that AT receptors are also present in the thick 
ascending limb, distal convoluted tubule and collecting duct.116 Wang and 
Giebisch were some of the first to investigate the effects of angiotensin II on 
sodium and potassium transport in the distal tubule.117 Using isolated 
perfused tubules, they showed that administration of angiotensin II increased 
sodium transport and decreased potassium transport in the early and late 
distal convoluted tubule.117 Treatment with either an ARB or the ENaC blocker, 
amiloride, abolished these effects.117 These data suggest that angiotensin II 
activates the ENaC and NCC, although the effect of NCC blockade using 
thiazides was not investigated. More compelling evidence that angiotensin II 
activates the NCC came from a rat study, which showed that ACE inhibition 
stimulated acute trafficking of the NCC from the apical plasma membrane to 
subapical cytoplasmic vesicles.109 This effect was reversed by angiotensin II 
infusion. However, because angiotensin II also induces aldosterone secretion 
26 
  
and aldosterone also activates NCC,104 the effect of angiotensin II on NCC was 
still not proven unequivocally. 
To more clearly determine the effect of angiotensin II and aldosterone on 
the NCC, we treated adrenalectomized rats with a chronic infusion of either 
aldosterone or angiotensin II.110 The latter therapy increased the levels of both 
total NCC and phosphorylated NCC in plasma membrane fractions 
independently of aldosterone. We also showed that angiotensin II caused 
sodium retention and that this was reversed by thiazides.110  In a subsequent 
study, we investigated whether aldosterone required angiotensin II to activate 
the NCC.111 We showed that aldosterone treatment increased the expression of 
NCC and ENaC in adrenalectomized rats, even in the presence of losartan; 
therefore, aldosterone alone is sufficient for these effects. However, the addition 
of losartan to the infusion of aldosterone reduced the levels of phosphorylated, 
and, therefore, active, NCC. These data suggest that angiotensin II might have 
an additive effect on aldosterone-induced NCC activation. 
In our studies, the effects of angiotensin II on ENaC expression were less 
pronounced in terms of plasma membrane abundance than the effects on NCC 
expression; angiotensin II increased the expression of the β-subunit of the 
ENaC only.110 However, more functional studies have shown that angiotensin II 
increases the open probability of the ENaC.112, 113 In freshly isolated, split-
opened murine distal nephrons, angiotensin II acutely increased the open 
probability of the ENaC, whereas more prolonged exposure to angiotensin II 
induced a translocation of α-ENaC to the apical plasma membrane.112 
Interestingly, aldosterone did not acutely increase the open probability of the 
ENaC and the effect of angiotensin II on the ENaC persisted when 
mineralocorticoid receptors were saturated during the infusion of high doses of 
aldosterone. Thus, angiotensin II seems to have an additive effect to that of 
aldosterone in the activation of both the NCC and the ENaC.111, 112 The effects 
of angiotensin II on the ROMK have also been investigated using patch clamp 
recordings in split-opened collecting ducts.114 Angiotensin II dose-dependently 
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inhibited ROMK channel activity in rats on a low potassium diet, but not in 
rats on a normal potassium diet.114 Conversely, a high potassium diet inhibited 
NCC and increased ROMK activity.114, 118 In summary, the observations of 
Wang and Giebisch117 can now be explained by a stimulatory effect of 
angiotensin II on the NCC and the ENaC, and an inhibitory effect on the 
ROMK. 
Regulation of sodium and potassium transporters 
In addition to receptor–transporter interactions, the intracellular signalling 
pathways that regulate sodium and potassium transporters have also been a 
matter of intense research. This interest was stimulated by the discovery that 
mutations in with-no-lysine (WNK) kinases directly affected transporter activity 
and caused hypertension.119 The current model of kidney transporter 
regulation by kinases has evolved to a complex kinase network that also 
includes the serine/threonine-protein kinase Sgk1 (SGK1) and STE20/SPS1-
related proline-alanine-rich protein kinase (SPAK). This kinase network 
regulates the NCC, ENaC, and ROMK.120 For example, in oocytes, cells115 and 
WNK4-knockout mice,121 angiotensin II has been shown to activate the NCC 
through a SPAK-WNK4 dependent pathway. In rodents, a low sodium diet or an 
infusion of aldosterone or angiotensin II increased the SPAK-mediated 
phosphorylation of NCC.110, 122 The response of NCC to dietary sodium and 
potassium is mediated by SGK1,123 whereas the inhibition of ROMK activity by 
angiotensin II is mediated by both SGK1 and WNK4.124 These kinases are, 
therefore, obvious drug target candidates.125 
The aldosterone paradox 
The findings discussed above increase our understanding of the aldosterone 
paradox; the question as to how the same hormone can cause sodium retention 
during hypovolaemia and potassium secretion during hyperkalemia.126, 127 
During hypovolaemia, levels of both angiotensin II and aldosterone are 
increased, causing a synergistic activation of both NCCs and ENaCs, which 
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promotes maximal sodium reabsorption (Figure 2). At the same time, 
potassium is conserved because sodium reabsorption through the NCCs is 
electroneutral and does not require potassium secretion through the ROMK, 
which is inhibited by angiotensin II.114, 124 Conversely, during hyperkalaemia, 
aldosterone levels are maximally increased, whereas angiotensin II levels are 
suppressed, resulting in NCC inhibition and increased sodium delivery to 
ENaCs. Maximum ENaC activity facilitates electrochemical sodium 
reabsorption that promotes kaliuresis through the ROMK. Hyperkalaemia or a 
high potassium diet might also directly inhibit NCC activity by increasing 
expression of WNK4.128 
A better understanding of the aldosterone paradox is not only important 
physiologically, but also to understand the effects of RAS inhibition on sodium 
and potassium homeostasis. For example, the synergistic activation of NCCs 
and ENaCs by angiotensin II and aldosterone could provide a rationale for dual 
blockade, that is, a combination of an ARB with an MRA to inhibit the 
combined effects of angiotensin II and aldosterone on NCCs and ENaCs. 
Notably, high doses (>25–50 mg per day) of the MRAs spironolactone and 
eplerenone might be required to establish a diuretic effect.129, 130 However, any 
combination of RAS inhibitors confers a risk of hyperkalaemia and acute or 
chronic kidney injury, as discussed above.45 Whether more selective inhibition 
of NCCs or ENaCs using drugs that interfere with WNK and SPAK kinases is a 
promising strategy for the treatment of hypertension remains to be determined. 
Finally, it should be noted that in addition to their natriuretic and 
antihypertensive effects, RAS inhibitors also exert renoprotective effects by 
suppressing renal fibrosis and improving glomerular and podocyte function.130 
 
 
 
29 
  
 
 
 
 
 
Figure 2: The aldosterone paradox. Aldosterone exerts differential effects during hypovolaemia 
and hyperkalaemia. a | During hypovolaemia, angiotensin II and aldosterone act 
synergistically to increase the activity of the NCC and the ENaC. Angiotensin II also inhibits the 
activity of the ROMK. These actions results in maximal sodium reabsorption to correct 
hypovolaemia and conserve potassium. b | Hyperkalaemia directly stimulates aldosterone 
secretion independently of renin and angiotensin II. In the absence of high angiotensin II levels 
the ROMK is not inhibited and hyperkalaemia reduces the activity of the NCC. However, the 
ENaC and the ROMK are maximally activated by aldosterone. These combined effects result in 
maximal sodium delivery to the ENaC, which facilitates the coupled secretion of potassium 
through the ROMK. Abbreviations: Ang, angiotensin; ENaC, epithelial sodium channel; NCC, 
sodium chloride cotransporter; ROMK, renal outer medullary potassium channel. 
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CONCLUSIONS 
The PRR was initially thought to be the key to prorenin activation at tissue 
sites. However, recent findings suggest that the PRR has other, perhaps more 
important, RAS-independent functions. Contradictory data regarding the 
effects of HRPs—the only PRR blockers that currently exist—are therefore, 
perhaps unsurprising. Given the lethal consequences of PRR knockout, 
whether PRR blockade should be a therapeutic target is questionable. 
Similarly, the contrasting data regarding AT2-receptor function suggest that a 
complete understanding of why the actions of this receptor differ depending on 
age, disease and location is required before AT2-receptor agonists can be 
utilized in the clinic. Compelling evidence suggests a beneficial effect of Mas-
receptor stimulation on stem-cell-mediated tissue repair. Thus, stable agonists 
are required to either stimulate the receptor or activate ACE2, the enzyme that 
generates the endogenous Mas-receptor agonist, Ang-(1–7). If acting locally, 
such ACE2 activators might overcome the rapid metabolism of Ang-(1–7) in 
vivo. Finally, the emerging role of angiotensin II in sodium and potassium 
handling in the distal nephron is likely to improve our understanding of the 
effects of RAS inhibition on total body sodium and potassium balance. For 
example, the synergistic actions of angiotensin II and aldosterone on sodium 
and potassium transport in the distal nephron could be targeted to better treat 
diseases characterized by avid sodium reabsorption, including salt-sensitive 
hypertension and the cardiorenal syndrome, while at the same time preventing 
hyperkalaemia.  
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AIM OF THE THESIS 
As described above, the RAS is a major physiological regulator of blood 
pressure and volume homeostasis and, consequently, it is involved in the 
pathogenesis of renal and cardiovascular diseases. Therefore, this system plays 
a central role on many of the cardiovascular and renal pathologies that are not 
inborn or non-communicable. The classical treatment of heart failure and 
hypertension is directed at inhibition of the Ang II-producing enzymes renin 
and ACE, and of the AT1 receptor. ACE inhibition and AT1 receptor blockade 
have been developed and explored exhaustively and are widely applied in the 
clinic. However, although being explored for over 3 decades as an 
interventional target, renin inhibition is relatively less developed as a therapy. 
Optimal use of renin inhibition, as compared to ACE inhibition and AT1 
receptor blockade, does not seem to have been accomplished yet. Perhaps this 
is partly due to the lack of diversity in available compounds, aliskiren being the 
only clinically used renin inhibitor until now. Since most drugs have unique 
properties, the exploration of novel renin-inhibiting compounds might offer 
opportunities to improve therapy. To this end we compared the 
pharmacodynamic and pharmacokinetic profile of the new renin inhibitor VTP-
27999 versus placebo and aliskiren in salt-depleted healthy volunteers in 
Chapter 2. 
It is widely believed that optimization of RAS modulation as a therapy 
can also be achieved in other ways. As discussed here, in the past 15 years 
new components of the RAS have been identified, including ACE2,131 Mas and 
AT2 receptor signaling,6 and the PRR13, and with them new possible treatments 
for cardiovascular and renal diseases have emerged. In addition, progenitor 
cells have been identified as potential treatment targets in the cardiovascular 
system. Their interaction with the RAS may particular occur at the level of 
these new RAS components.132 Moreover, there is emerging evidence that 
regulation of at least some of the components of the RAS might be sex-
dependent. This is already known in the case of the AT2 receptor which is 
located on the X chromosome.133  
32 
  
In this thesis, we focused on the ‘alternative RAS’, and its additional link 
to sex-differences with respect to AT2 signaling, to explore new ways of 
modulating RAS activity.  In Chapter 3 we investigated the sexual dimorphism 
in response to Ang II. Using C57bl/6 mice and the genetically modified “four 
core genotype” mouse model (on a C57bl/6 background), in which the sex 
chromosome complement (XX or XY) is unrelated to the animal's gonadal sex, 
we investigated the dependency of the constrictor effects of Ang II on sex 
hormones and sex chromosomes, making use of both intact and 
gonadectomized animals.  Moreover, in Chapter 4 we review the role of Ang II 
and Ang-(1-7) and their respective receptors in hematopoietic and 
mesenchymal stem cells, and discuss possible therapeutical implications. 
Subsequently, we investigated alternative intervention strategies based 
on stimulation of the Ang-(1-7)-Mas receptor axis. In Chapter 5 we present the 
data of a metabolically stable Ang-(1-7) analogue, cyclic Ang-(1-7), on 
progenitor cell recruitment and on the heart post-myocardial infarction. 
Moreover, in Chapter 6, we explored the relationship between angiotensin 
receptor signalling and the differentiation process of stem / progenitor cells. 
Finally, in Chapter 7 we summarize the main findings of this thesis. We 
also discuss the limitations of the studies and the implications of our findings.   
 
 
 
 
 
 
 
 
 
 
 
 
33 
  
REFERENCES 
1. Klotz S, Burkhoff D, Garrelds IM, Boomsma F and Danser AH. The impact of left 
ventricular assist device-induced left ventricular unloading on the myocardial renin-
angiotensin-aldosterone system: therapeutic consequences? Eur Heart J. 2009;30:805-
12. 
2. van Kats JP, Duncker DJ, Haitsma DB, Schuijt MP, Niebuur R, Stubenitsky R, 
Boomsma F, Schalekamp MADH, Verdouw PD and Danser AHJ. Angiotensin-converting 
enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac 
remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation. 
2000;102:1556-1563. 
3. Ma TK, Kam KK, Yan BP and Lam YY. Renin-angiotensin-aldosterone system blockade 
for cardiovascular diseases: current status. Br J Pharmacol. 2010;160:1273-92. 
4. Verdonk K, Danser AHJ and van Esch JHM. Angiotensin II type 2 receptor agonists: 
where should they be applied? Expert Opin Investig Drugs. 2012;21:501-13. 
5. van Esch JHM, Schuijt MP, Sayed J, Choudry Y, Walther T and Danser AHJ. AT2 
receptor-mediated vasodilation in the mouse heart depends on AT1A receptor 
activation. Br J Pharmacol. 2006;148:452-458. 
6. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-
Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-
Santos MJ, Schultheiss HP, Speth R and Walther T. Angiotensin-(1-7) is an endogenous 
ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258-
63. 
7. Danser AHJ. Novel drugs targeting hypertension: renin inhibitors. J Cardiovasc 
Pharmacol. 2007;50:105-11. 
8. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T and Sraer J-D. Pivotal role of the 
renin/prorenin receptor in angiotensin II production and cellular responses to renin. J 
Clin Invest. 2002;109:1417-1427. 
9. Danser AHJ. The increase in renin during renin inhibition: does it result in harmful 
effects by the (pro)renin receptor? Hypertens Res. 2010;33:4-10. 
10. Batenburg WW, Jansen PM, van den Bogaerdt AJ and Danser AHJ. Angiotensin II-
aldosterone interaction in human coronary microarteries involves GPR30, EGFR, and 
endothelial NO synthase. Cardiovasc Res. 2012;94:136-43. 
11. Chai W, Hofland J, Jansen PM, Garrelds IM, de Vries R, van den Bogaerdt AJ, Feelders 
RA, de Jong FH and Danser AHJ. Steroidogenesis vs. steroid uptake in the heart: do 
corticosteroids mediate effects via cardiac mineralocorticoid receptors? . J Hypertens. 
2010;28:1044-1053. 
12. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP and Danser AHJ. 
Nongenomic effects of aldosterone in the human heart. Interaction with angiotensin II. 
Hypertension. 2005;46:701-706. 
13. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJ, Burckle CA, Muller DN, 
Bader M, Nguyen G and Danser AH. Prorenin is the endogenous agonist of the 
(pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth 
muscle cells overexpressing the human (pro)renin receptor. J Hypertens. 2007;25:2441-
53. 
14. Lu X, Danser AH and Meima ME. HRP and prorenin: focus on the (pro)renin receptor 
and vacuolar H+-ATPase. Front Biosci (Schol Ed). 2011;3:1205-15. 
15. Krop M and Danser AHJ. Circulating versus tissue renin-angiotensin system: on the 
origin of (pro)renin. Curr Hyp Rep. 2008;10:112-118. 
16. Saris JJ, Derkx FHM, Lamers JMJ, Saxena PR, Schalekamp MADH and Danser AHJ. 
Cardiomyocytes bind and activate native human prorenin: role of soluble mannose 6-
phosphate receptors. Hypertension. 2001;37:710-5. 
17. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, 
Fiebeler A, Burckle C, Contrepas A, Jan Danser AH, Bader M, Nguyen G, Luft FC and 
Muller DN. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 
34 
  
activation in monocytes is not blocked by aliskiren or the handle-region peptide. 
Hypertension. 2008;51:682-8. 
18. Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, Iwasawa A, Ishida Y, 
Nakamura Y and Murakami K. Human prorenin has "gate and handle" regions for its 
non-proteolytic activation. J Biol Chem. 2003;278:22217-22. 
19. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, 
Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T and Saruta T. 
Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" 
region for nonproteolytic activation of prorenin. J Clin Invest. 2004;114:1128-35. 
20. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AH, 
Nishiyama A, Sugaya T, Hayashi M and Inagami T. Prorenin receptor blockade inhibits 
development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient 
mice. J Am Soc Nephrol. 2006;17:1950-61. 
21. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AH, Uddin MN, Nakagawa T, 
Nishiyama A, Suzuki F, Inagami T and Itoh H. Slowly progressive, angiotensin II-
independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc 
Nephrol. 2007;18:1789-95. 
22. Kaneshiro Y, Ichihara A, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Hayashi M 
and Inagami T. Increased expression of cyclooxygenase-2 in the renal cortex of human 
prorenin receptor gene-transgenic rats. Kidney Int. 2006;70:641-646. 
23. Jansen PM, Hofland J, van den Meiracker AH, de Jong FH and Danser AHJ. Renin and 
prorenin have no direct effect on aldosterone synthesis in the human adrenocortical cell 
lines H295R and HAC15. J Renin Angiotensin Aldosterone Syst. 2012;13:360-6. 
24. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA and 
Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix 
proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney 
Int. 2006;69:105-13. 
25. Clavreul N, Sansilvestri-Morel P, Magard D, Verbeuren TJ and Rupin A. (Pro)renin 
promotes fibrosis gene expression in HEK cells through a Nox4-dependent mechanism. 
Am J Physiol Renal Physiol. 2011;300:F1310-8. 
26. Sakoda M, Ichihara A, Kurauchi-Mito A, Narita T, Kinouchi K, Murohashi-Bokuda K, 
Saleem MA, Nishiyama A, Suzuki F and Itoh H. Aliskiren inhibits intracellular 
angiotensin II levels without affecting (pro)renin receptor signals in human podocytes. 
Am J Hypertens. 2010;23:575-80. 
27. Zhang J, Gu C, Noble NA, Border WA and Huang Y. Combining angiotensin II blockade 
and renin receptor inhibition results in enhanced antifibrotic effect in experimental 
nephritis. Am J Physiol Renal Physiol. 2011;301:F723-32. 
28. Melnyk RA, Tam J, Boie Y, Kennedy BP and Percival MD. Renin and prorenin activate 
pathways implicated in organ damage in human mesangial cells independent of 
angiotensin II production. Am J Nephrol. 2009;30:232-43. 
29. Cheng H, Fan X, Moeckel GW and Harris RC. Podocyte COX-2 exacerbates diabetic 
nephropathy by increasing podocyte (pro)renin receptor expression. J Am Soc Nephrol. 
2011;22:1240-51. 
30. Huang J and Siragy HM. Glucose promotes the production of interleukine-1beta and 
cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression. 
Endocrinology. 2009;150:5557-65. 
31. Siragy HM and Huang J. Renal (pro)renin receptor upregulation in diabetic rats through 
enhanced angiotensin AT1 receptor and NADPH oxidase activity. Exp Physiol. 
2008;93:709-14. 
32. Matavelli LC, Huang J and Siragy HM. (Pro)renin receptor contributes to diabetic 
nephropathy by enhancing renal inflammation. Clin Exp Pharmacol Physiol. 
2010;37:277-82. 
33. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Müller DN, Feldt S, Cumin 
F, Maniara W, Persohn E, Schuetz H, Danser AHJ and Nguyen G. Effects of aliskiren on 
35 
  
blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mREN-
2)-27 rats. Hypertension. 2008;52:130-136. 
34. Krebs C, Hamming I, Sadaghiani S, Steinmetz OM, Meyer-Schwesinger C, Fehr S, Stahl 
RA, Garrelds IM, Danser AHJ, van Goor H, Contrepas A, Nguyen G and Wenzel U. 
Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped 
kidney of Goldblatt hypertensive rats. Kidney Int. 2007;72:725-30. 
35. Hirose T, Mori N, Totsune K, Morimoto R, Maejima T, Kawamura T, Metoki H, Asayama 
K, Kikuya M, Ohkubo T, Kohzuki M, Takahashi K and Imai Y. Increased expression of 
(pro)renin receptor in the remnant kidneys of 5/6 nephrectomized rats. Regul Pept. 
2010;159:93-9. 
36. Takahashi K, Yamamoto H, Hirose T, Hiraishi K, Shoji I, Shibasaki A, Kato I, Kaneko K, 
Sasano H, Satoh F and Totsune K. Expression of (pro)renin receptor in human kidneys 
with end-stage kidney disease due to diabetic nephropathy. Peptides. 2010;31:1405-8. 
37. Danser AHJ, Derkx FHM, Schalekamp MADH, Hense HW, Riegger GAJ and Schunkert 
H. Determinants of interindividual variation of renin and prorenin concentrations: 
evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens. 
1998;16:853-62. 
38. Burcklé CA, Danser AHJ, Müller DN, Garrelds IM, Gasc JM, Popova E, Plehm R, Peters 
J, Bader M and Nguyen G. Elevated blood pressure and heart rate in human renin 
receptor transgenic rats. Hypertension. 2006;47:552-6. 
39. Batenburg WW, Lu X, Leijten F, Maschke U, Müller DN and Danser AHJ. Renin- and 
prorenin-induced effects in rat vascular smooth muscle cells overexpressing the human 
(pro)renin receptor: does (pro)renin-(pro)renin receptor interaction actually occur? 
Hypertension. 2011;58:1111-9. 
40. Peters B, Grisk O, Becher B, Wanka H, Kuttler B, Ludemann J, Lorenz G, Rettig R, 
Mullins JJ and Peters J. Dose-dependent titration of prorenin and blood pressure in 
Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J 
Hypertens. 2008;26:102-9. 
41. Campbell DJ, Karam H, Ménard J, Bruneval P and Mullins JJ. Prorenin contributes to 
angiotensin peptide formation in transgenic rats with rat prorenin expression targeted 
to the liver. Hypertension. 2009;54:1248-1253. 
42. Mercure C, Prescott G, Lacombe MJ, Silversides DW and Reudelhuber TL. Chronic 
increases in circulating prorenin are not associated with renal or cardiac pathologies. 
Hypertension. 2009;53:1062-9. 
43. Campbell DJ, Nussberger J, Stowasser M, Danser AHJ, Morganti A, Frandsen E and 
Ménard J. Activity assays and immunoassays for plasma renin and prorenin: 
information provided and precautions necessary for accurate measurement. Clin Chem. 
2009;55:867-77. 
44. Richer-Giudicelli C, Domergue V, Gonzalez MF, Messadi E, Azizi M, Giudicelli JF and 
Ménard J. Haemodynamic effects of dual blockade of the renin-angiotensin system in 
spontaneously hypertensive rats: influence of salt. J Hypertens. 2004;22:619-27. 
45. de Boer RA, Azizi M, Danser AHJ, Nguyen G, Nussberger J, Ruilope LM, Schmieder RE 
and Volpe M. Dual RAAS suppression: recent developments and implications in light of 
the ALTITUDE study. J Renin Angiotensin Aldosterone Syst. 2012;13:409-12. 
46. Advani A, Kelly DJ, Cox AJ, White KE, Advani SL, Thai K, Connelli KA, Yuen D, 
Trogadis J, Herzenberg AM, Kuliszewski MA, Leong-Poi H and Gilbert RE. The (pro)renin 
receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. 
Hypertension. 2009;54:261-269. 
47. Riediger F, Quack I, Qadri F, Hartleben B, Park JK, Potthoff SA, Sohn D, Sihn G, 
Rousselle A, Fokuhl V, Maschke U, Purfurst B, Schneider W, Rump LC, Luft FC, 
Dechend R, Bader M, Huber TB, Nguyen G and Muller DN. Prorenin receptor is 
essential for podocyte autophagy and survival. J Am Soc Nephrol. 2011;22:2193-202. 
48. Cruciat CM, Ohkawara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D, 
Boutros M and Niehrs C. Requirement of prorenin receptor and vacuolar H+-ATPase-
mediated acidification for Wnt signaling. Science. 2010;327:459-63. 
36 
  
49. van Esch JHM, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM and Danser AHJ. 
Handle region peptide counteracts the beneficial effects of the renin inhibitor aliskiren 
in spontaneously hypertensive rats. Hypertension. 2011;57:852-8. 
50. Vazquez E, Coronel I, Bautista R, Romo E, Villalon CM, Avila-Casado MC, Soto V and 
Escalante B. Angiotensin II-dependent induction of AT(2) receptor expression after renal 
ablation. Am J Physiol Renal Physiol. 2005;288:F207-13. 
51. He M, Zhang L, Shao Y, Xue H, Zhou L, Wang XF, Yu C, Yao T and Lu LM. Angiotensin 
II type 2 receptor mediated angiotensin II and high glucose induced decrease in renal 
prorenin/renin receptor expression. Mol Cell Endocrinol. 2010;315:188-94. 
52. Ruiz-Ortega M, Esteban V, Suzuki Y, Ruperez M, Mezzano S, Ardiles L, Justo P, Ortiz A 
and Egido J. Renal expression of angiotensin type 2 (AT2) receptors during kidney 
damage. Kidney Int Suppl. 2003:S21-6. 
53. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, 
Hogan BLM and Inagami T. Effects on blood pressure and exploratory behaviour of mice 
lacking angiotensin II type-2 receptor. Nature. 1995;377:748-50. 
54. Hein L, Barsh GS, Pratt RE, Dzau VJ and Kobilka BK. Behavioural and cardiovascular 
effects of disrupting the angiotensin II type-2 receptor in mice. Nature. 1995;377:744-7. 
55. Gross V, Schunck WH, Honeck H, Milia AF, Kargel E, Walther T, Bader M, Inagami T, 
Schneider W and Luft FC. Inhibition of pressure natriuresis in mice lacking the AT2 
receptor. Kidney Int. 2000;57:191-202. 
56. Benndorf RA, Krebs C, Hirsch-Hoffmann B, Schwedhelm E, Cieslar G, Schmidt-Haupt 
R, Steinmetz OM, Meyer-Schwesinger C, Thaiss F, Haddad M, Fehr S, Heilmann A, 
Helmchen U, Hein L, Ehmke H, Stahl RA, Boger RH and Wenzel UO. Angiotensin II type 
2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney 
disease in mice. Kidney Int. 2009;75:1039-49. 
57. Ma J, Nishimura H, Fogo A, Kon V, Inagami T and Ichikawa I. Accelerated fibrosis and 
collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null 
mutant mice during ureteral obstruction. Kidney Int. 1998;53:937-44. 
58. Tanaka M, Tsuchida S, Imai T, Fujii N, Miyazaki H, Ichiki T, Naruse M and Inagami T. 
Vascular response to angiotensin II is exaggerated through an upregulation of AT1 
receptor in AT2 knockout mice. Biochem Biophys Res Commun. 1999;258:194-8. 
59. Padia SH, Howell NL, Siragy HM and Carey RM. Renal angiotensin type 2 receptors 
mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. 
Hypertension. 2006;47:537-44. 
60. van Esch JHM, Oosterveer CR, Batenburg WW, van Veghel R and Danser AHJ. Effects 
of angiotensin II and its metabolites in the rat coronary vascular bed: is angiotensin III 
the preferred ligand of the angiotensin AT2 receptor? Eur J Pharmacol. 2008;588:286-
93. 
61. Padia SH, Kemp BA, Howell NL, Fournie-Zaluski MC, Roques BP and Carey RM. 
Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated 
natriuresis in rats. Hypertension. 2008;51:460-5. 
62. Padia SH, Kemp BA, Howell NL, Siragy HM, Fournie-Zaluski MC, Roques BP and Carey 
RM. Intrarenal aminopeptidase N inhibition augments natriuretic responses to 
angiotensin III in angiotensin type 1 receptor-blocked rats. Hypertension. 2007;49:625-
30. 
63. Ali Q and Hussain T. AT(2) receptor non-peptide agonist C21 promotes natriuresis in 
obese Zucker rats. Hypertens Res. 2012;35:654-60. 
64. Matavelli LC, Huang J and Siragy HM. Angiotensin AT2 receptor stimulation inhibits 
early renal inflammation in renovascular hypertension. Hypertension. 2011;57:308-13. 
65. Hilliard LM, Jones ES, Steckelings UM, Unger T, Widdop RE and Denton KM. Sex-
specific influence of angiotensin type 2 receptor stimulation on renal function: a novel 
therapeutic target for hypertension. Hypertension. 2012;59:409-14. 
66. Verdonk K, Durik M, Abd-Alla N, Batenburg WW, van den Bogaerdt AJ, van Veghel R, 
Roks AJ, Danser AHJ and van Esch JHM. Compound 21 induces vasorelaxation via an 
37 
  
endothelium- and angiotensin II type 2 receptor-independent mechanism. Hypertension. 
2012. 
67. Cao Z, Bonnet F, Candido R, Nesteroff SP, Burns WC, Kawachi H, Shimizu F, Carey 
RM, De Gasparo M and Cooper ME. Angiotensin type 2 receptor antagonism confers 
renal protection in a rat model of progressive renal injury. J Am Soc Nephrol. 
2002;13:1773-87. 
68. Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, Blanco J, Kretzler M, Sugaya 
T, Egido J and Ruiz-Ortega M. Angiotensin II, via AT1 and AT2 receptors and NF-
kappaB pathway, regulates the inflammatory response in unilateral ureteral 
obstruction. J Am Soc Nephrol. 2004;15:1514-29. 
69. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, Zahner G, 
Helmchen U and Stahl RA. Angiotensin II stimulates expression of the chemokine 
RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J 
Clin Invest. 1997;100:1047-58. 
70. Siragy HM and Carey RM. Protective role of the angiotensin AT2 receptor in a renal 
wrap hypertension model. Hypertension. 1999;33:1237-42. 
71. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P and Schiffrin EL. 
Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and 
myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension. 
2012;59:291-9. 
72. Moltzer E, Verkuil AV, van Veghel R, Danser AHJ and van Esch JHM. Effects of 
angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive 
rat: loss of angiotensin II type 2 receptor-mediated vasodilation. Hypertension. 
2010;55:516-22. 
73. You D, Loufrani L, Baron C, Levy BI, Widdop RE and Henrion D. High blood pressure 
reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into 
vasodilation in spontaneously hypertensive rats. Circulation. 2005;111:1006-11. 
74. Blood Pressure Lowering Treatment Trialists C, Turnbull F, Neal B, Pfeffer M, Kostis J, 
Algert C, Woodward M, Chalmers J, Zanchetti A and MacMahon S. Blood pressure-
dependent and independent effects of agents that inhibit the renin-angiotensin system. 
J Hypertens. 2007;25:951-8. 
75. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas 
E, Hsieh F, Acton S, Patane M, Nichols A and Tummino P. Hydrolysis of biological 
peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol 
Chem. 2002;277:14838-43. 
76. Iusuf D, Henning RH, van Gilst WH and Roks AJ. Angiotensin-(1-7): pharmacological 
properties and pharmacotherapeutic perspectives. Eur J Pharmacol. 2008;585:303-12. 
77. Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ and Raizada 
MK. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system 
in cardiovascular diseases. Hypertension. 2010;55:207-13. 
78. Moon JY, Tanimoto M, Gohda T, Hagiwara S, Yamazaki T, Ohara I, Murakoshi M, Aoki 
T, Ishikawa Y, Lee SH, Jeong KH, Lee TW, Ihm CG, Lim SJ and Tomino Y. Attenuating 
effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 
2 diabetic nephropathy of KK-A(y)/Ta mice. Am J Physiol Renal Physiol. 
2011;300:F1271-82. 
79. Benter IF, Yousif MH, Al-Saleh FM, Raghupathy R, Chappell MC and Diz DI. 
Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular 
protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl 
ester. J Cardiovasc Pharmacol. 2011;57:559-67. 
80. Benter IF, Yousif MH, Anim JT, Cojocel C and Diz DI. Angiotensin-(1-7) prevents 
development of severe hypertension and end-organ damage in spontaneously 
hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol. 
2006;290:H684-91. 
38 
  
81. Raffai G, Durand MJ and Lombard JH. Acute and chronic angiotensin-(1-7) restores 
vasodilation and reduces oxidative stress in mesenteric arteries of salt-fed rats. Am J 
Physiol Heart Circ Physiol. 2011;301:H1341-52. 
82. Rabelo LA, Xu P, Todiras M, Sampaio WO, Buttgereit J, Bader M, Santos RA and 
Alenina N. Ablation of angiotensin (1-7) receptor Mas in C57Bl/6 mice causes 
endothelial dysfunction. J Am Soc Hypertens. 2008;2:418-24. 
83. Sampaio WO, Henrique de Castro C, Santos RA, Schiffrin EL and Touyz RM. 
Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. 
Hypertension. 2007;50:1093-8. 
84. Wolf G, Ziyadeh FN, Zahner G and Stahl RA. Angiotensin II-stimulated expression of 
transforming growth factor beta in renal proximal tubular cells: attenuation after stable 
transfection with the c-mas oncogene. Kidney Int. 1995;48:1818-27. 
85. Zimpelmann J and Burns KD. Angiotensin-(1-7) activates growth-stimulatory pathways 
in human mesangial cells. Am J Physiol Renal Physiol. 2009;296:F337-46. 
86. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, 
Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P, Schultheiss HP and 
Walther T. G-protein-coupled receptor Mas is a physiological antagonist of the 
angiotensin II type 1 receptor. Circulation. 2005;111:1806-13. 
87. Strauer BE and Steinhoff G. 10 years of intracoronary and intramyocardial bone 
marrow stem cell therapy of the heart: from the methodological origin to clinical 
practice. J Am Coll Cardiol. 2011;58:1095-104. 
88. El-Ansary M, Saadi G and Abd El-Hamid S. Mesenchymal stem cells are a rescue 
approach for recovery of deteriorating kidney function. Nephrology (Carlton). 2012. 
89. Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, Capelli C, 
Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Marasa M, Golay J, Noris M and Remuzzi 
G. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of 
safety and clinical feasibility. Clin J Am Soc Nephrol. 2011;6:412-22. 
90. Strawn WB, Richmond RS, Ann Tallant E, Gallagher PE and Ferrario CM. Renin-
angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br 
J Haematol. 2004;126:120-6. 
91. Rodgers KE, Espinoza T, Roda N, Meeks CJ, Hill C, Louie SG and Dizerega GS. 
Accelerated hematopoietic recovery with angiotensin-(1-7) after total body radiation. Int 
J Radiat Biol. 2012;88:466-76. 
92. Rodgers KE, Xiong S and diZerega GS. Accelerated recovery from irradiation injury by 
angiotensin peptides. Cancer Chemother Pharmacol. 2002;49:403-11. 
93. Wang Y, Qian C, Roks AJ, Westermann D, Schumacher SM, Escher F, Schoemaker RG, 
Reudelhuber TL, van Gilst WH, Schultheiss HP, Tschope C and Walther T. Circulating 
rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial 
infarction. Circ Heart Fail. 2010;3:286-93. 
94. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA and Torti FM. Phase I and 
pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. 
Clin Cancer Res. 2009;15:7398-404. 
95. Marques FD, Ferreira AJ, Sinisterra RD, Jacoby BA, Sousa FB, Caliari MV, Silva GA, 
Melo MB, Nadu AP, Souza LE, Irigoyen MC, Almeida AP and Santos RA. An oral 
formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and 
isoproterenol-treated rats. Hypertension. 2011;57:477-83. 
96. de Vries L, Reitzema-Klein CE, Meter-Arkema A, van Dam A, Rink R, Moll GN and 
Akanbi MH. Oral and pulmonary delivery of thioether-bridged angiotensin-(1-7). 
Peptides. 2010;31:893-8. 
97. Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, Wang Y, Walther T, 
Kuipers A, Moll GN and Haas M. Angiotensin-(1-7) with thioether bridge: an 
angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J Pharmacol 
Exp Ther. 2009;328:849-54. 
98. Durik M, van Veghel R, Kuipers A, Rink R, Haas Jimoh Akanbi M, Moll G, Danser AH 
and Roks AJ. The effect of the thioether-bridged, stabilized Angiotensin-(1-7) analogue 
39 
  
cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial 
infarction. Int J Hypertens. 2012;2012:536426. 
99. Faria-Silva R, Duarte FV and Santos RA. Short-term angiotensin(1-7) receptor MAS 
stimulation improves endothelial function in normotensive rats. Hypertension. 
2005;46:948-52. 
100. Murca TM, Almeida TC, Raizada MK and Ferreira AJ. Chronic activation of endogenous 
angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic 
dysfunction. Experimental physiology. 2012;97:699-709. 
101. Hernandez Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano 
RK, Lampkins AJ, Gubala V, Ostrov DA and Raizada MK. Structure-based identification 
of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive 
agents. Hypertension. 2008;51:1312-7. 
102. Meneton P, Loffing J and Warnock DG. Sodium and potassium handling by the 
aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting 
tubule. Am J Physiol Renal Physiol. 2004;287:F593-601. 
103. Saccomani G, Mitchell KD and Navar LG. Angiotensin II stimulation of Na(+)-H+ 
exchange in proximal tubule cells. Am J Physiol. 1990;258:F1188-95. 
104. Kim GH, Masilamani S, Turner R, Mitchell C, Wade JB and Knepper MA. The thiazide-
sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci U S 
A. 1998;95:14552-7. 
105. Masilamani S, Kim GH, Mitchell C, Wade JB and Knepper MA. Aldosterone-mediated 
regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. J Clin 
Invest. 1999;104:R19-23. 
106. Beesley AH, Hornby D and White SJ. Regulation of distal nephron K+ channels (ROMK) 
mRNA expression by aldosterone in rat kidney. J Physiol. 1998;509 ( Pt 3):629-34. 
107. Wald H, Garty H, Palmer LG and Popovtzer MM. Differential regulation of ROMK 
expression in kidney cortex and medulla by aldosterone and potassium. Am J Physiol. 
1998;275:F239-45. 
108. McCormick JA, Yang CL and Ellison DH. WNK kinases and renal sodium transport in 
health and disease: an integrated view. Hypertension. 2008;51:588-96. 
109. Sandberg MB, Riquier AD, Pihakaski-Maunsbach K, McDonough AA and Maunsbach 
AB. ANG II provokes acute trafficking of distal tubule Na+-Cl(-) cotransporter to apical 
membrane. Am J Physiol Renal Physiol. 2007;293:F662-9. 
110. van der Lubbe N, Lim CH, Fenton RA, Meima ME, Danser AHJ, Zietse R and Hoorn EJ. 
Angiotensin II induces phosphorylation of the thiazide-sensitive sodium chloride 
cotransporter independent of aldosterone. Kidney Int. 2011;79:66-76. 
111. van der Lubbe N, Lim CH, Meima ME, van Veghel R, Rosenbaek LL, Mutig K, Danser 
AHJ, Fenton RA, Zietse R and Hoorn EJ. Aldosterone does not require angiotensin II to 
activate NCC through a WNK4-SPAK-dependent pathway. Pflügers Arch. 2012;463:853-
863. 
112. Mamenko M, Zaika O, Ilatovskaya DV, Staruschenko A and Pochynyuk O. Angiotensin 
II increases activity of the epithelial Na+ channel (ENaC) in distal nephron additively to 
aldosterone. J Biol Chem. 2012;287:660-71. 
113. Sun P, Yue P and Wang WH. Angiotensin II stimulates epithelial sodium channels in the 
cortical collecting duct of the rat kidney. Am J Physiol Renal Physiol. 2012;302:F679-87. 
114. Wei Y, Zavilowitz B, Satlin LM and Wang WH. Angiotensin II inhibits the ROMK-like 
small conductance K channel in renal cortical collecting duct during dietary potassium 
restriction. J Biol Chem. 2007;282:6455-62. 
115. San-Cristobal P, Pacheco-Alvarez D, Richardson C, Ring AM, Vazquez N, Rafiqi FH, 
Chari D, Kahle KT, Leng Q, Bobadilla NA, Hebert SC, Alessi DR, Lifton RP and Gamba 
G. Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a 
WNK4-SPAK-dependent pathway. Proc Natl Acad Sci U S A. 2009;106:4384-9. 
116. Mujais SK, Kauffman S and Katz AI. Angiotensin II binding sites in individual segments 
of the rat nephron. J Clin Invest. 1986;77:315-8. 
40 
  
117. Wang T and Giebisch G. Effects of angiotensin II on electrolyte transport in the early 
and late distal tubule in rat kidney. Am J Physiol. 1996;271:F143-9. 
118. Frindt G and Palmer LG. Effects of dietary K on cell-surface expression of renal ion 
channels and transporters. Am J Physiol Renal Physiol. 2010;299:F890-7. 
119. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, 
Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin 
RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X and Lifton RP. Human hypertension 
caused by mutations in WNK kinases. Science. 2001;293:1107-12. 
120. Welling PA, Chang YP, Delpire E and Wade JB. Multigene kinase network, kidney 
transport, and salt in essential hypertension. Kidney Int. 2010;77:1063-9. 
121. Castaneda-Bueno M, Arroyo JP and Gamba G. Independent regulation of Na+ and K+ 
balance by the kidney. Med Princ Pract. 2012;21:101-14. 
122. Chiga M, Rai T, Yang SS, Ohta A, Takizawa T, Sasaki S and Uchida S. Dietary salt 
regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride 
cotransporter through aldosterone. Kidney Int. 2008;74:1403-9. 
123. Vallon V, Schroth J, Lang F, Kuhl D and Uchida S. Expression and phosphorylation of 
the Na+-Cl- cotransporter NCC in vivo is regulated by dietary salt, potassium, and 
SGK1. Am J Physiol Renal Physiol. 2009;297:F704-12. 
124. Yue P, Sun P, Lin DH, Pan C, Xing W and Wang W. Angiotensin II diminishes the effect 
of SGK1 on the WNK4-mediated inhibition of ROMK1 channels. Kidney Int. 
2011;79:423-31. 
125. Glover M and O'Shaughnessy K M. SPAK and WNK kinases: a new target for blood 
pressure treatment? Curr Opin Nephrol Hypertens. 2011;20:16-22. 
126. Arroyo JP, Ronzaud C, Lagnaz D, Staub O and Gamba G. Aldosterone paradox: 
differential regulation of ion transport in distal nephron. Physiology (Bethesda). 
2011;26:115-23. 
127. Hoorn EJ, Nelson JH, McCormick JA and Ellison DH. The WNK kinase network 
regulating sodium, potassium, and blood pressure. J Am Soc Nephrol. 2011;22:605-14. 
128. O'Reilly M, Marshall E, Macgillivray T, Mittal M, Xue W, Kenyon CJ and Brown RW. 
Dietary electrolyte-driven responses in the renal WNK kinase pathway in vivo. J Am Soc 
Nephrol. 2006;17:2402-13. 
129. Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387-95. 
130. Vogt L, Navis G and de Zeeuw D. Renoprotection: a matter of blood pressure reduction 
or agent-characteristics? J Am Soc Nephrol. 2002;13 Suppl 3:S202-7. 
131. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, 
Woolf B, Robison K, Jeyaseelan R, Breitbart RE and Acton S. A novel angiotensin-
converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to 
angiotensin 1-9. Circ Res. 2000;87:E1-9. 
132. Durik M, Seva Pessoa B and Roks AJ. The renin-angiotensin system, bone marrow and 
progenitor cells. Clin Sci (Lond). 2012;123:205-23. 
133. Hein L, Dzau VJ and Barsh GS. Linkage mapping of the angiotensin AT2 receptor gene 
(Agtr2) to the mouse X chromosome. Genomics. 1995;30:369-71. 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
  
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
MULTIPLE ASCENDING DOSE STUDY WITH  
THE NEW RENIN INHIBITOR VTP-27999:  
NEPHROCENTRIC CONSEQUENCES OF TOO MUCH RENIN INHIBITION 
 
 
 
 
 
 
 
 
Based on: Multiple ascending dose study with the new renin inhibitor VTP-27999: 
nephrocentric consequences of too much renin inhibition. Balcarek J, Sevá 
Pessôa B, Bryson C, Azizi M, Ménard J, Garrelds IM, McGeehan G, Reeves RA, 
Griffith SG, Danser AHJ, Gregg R. Hypertension. 2014;63:942-50. 
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ABSTRACT 
This study compared the pharmacodynamic/pharmacokinetic profile of the 
new renin inhibitor VTP-27999 in salt-depleted healthy volunteers, 
administered once daily (75, 150, 300, and 600 mg) for 10 days, versus placebo 
and 300 mg aliskiren. VTP-27999 was well tolerated with no significant safety 
issues. It was rapidly absorbed, attaining maximum plasma concentrations at 
1 to 4 hours after dosing, with a terminal half-life of 24 to 30 hours. Plasma 
renin activity remained suppressed during the 24-hour dosing interval at all 
doses. VTP-27999 administration resulted in a dose-dependent induction of 
renin, increasing the concentration of plasma renin maximally 350-fold. This 
induction was greater than with aliskiren, indicating greater intrarenal renin 
inhibition. VTP-27999 decreased plasma angiotensin II and aldosterone. At 24 
hours and later time points after dosing on day 10 in the 600-mg group, 
angiotensin II and aldosterone levels were increased, and plasma renin activity 
was also increased at 48 and 72 hours, compared with baseline. VTP-27999 
decreased urinary aldosterone excretion versus placebo on day 1. On day 10, 
urinary aldosterone excretion was higher in the 300- and 600-mg VTP-27999 
dose groups compared with baseline. VTP-27999 decreased blood pressure to 
the same degree as aliskiren. In conclusion, excessive intrarenal renin 
inhibition, obtained at VTP-27999 doses of 300 mg and higher, is accompanied 
by plasma renin rises, that after stopping drug intake, exceed the capacity of 
extrarenal VTP-27999 to block fully the enzymatic reaction. This results in 
significant rises of angiotensin II and aldosterone. Therefore, renin inhibition 
has an upper limit. 
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INTRODUCTION 
The renin–angiotensin–aldosterone system (RAAS) is a hormone system that 
regulates blood pressure, plasma sodium and potassium levels, and 
extracellular fluid volume in the body. The RAAS sequentially processes 
angiotensinogen to angiotensin II (Ang II), a peptide hormone that is a potent 
vasoconstrictor. Renin catalyzes the first and rate-limiting step of the RAAS 
cascade and is a specific protease for angiotensinogen. Direct renin inhibition 
leads to a decrease in plasma renin activity (PRA) and is expected to decrease 
Ang II and aldosterone levels.1, 2 Plasma renin concentration (PRC) and 
prorenin levels are expected to increase through a compensatory feedback 
induction mechanism. The only direct renin inhibitor currently available for 
clinical use is aliskiren, marketed at 150 and 300 mg/d. Its use at doses >300 
mg/d is hampered by the occurrence of gastrointestinal side effects including 
cramping and diarrhea.  
VTP-27999 is a highly potent direct renin inhibitor being developed for 
the treatment of chronic renal disease and end-organ protection.3, 4 Its oral 
bioavailability is ≈10-fold higher than that of aliskiren. This study examines the 
safety and tolerability, pharmacokinetics, and pharmacodynamics of VTP-
27999 compared with a placebo and to the full marketed dose of aliskiren, 300 
mg/d, after 10 days of administration to salt-depleted healthy volunteers.  
MATERIALS AND METHODS 
The Methods section is available in the Data Supplement. 
RESULTS 
Subject Demography and Disposition 
A total of 37 subjects participated in the study (35 men, 2 women: 3 Asian, 8 
black, and 26 white; age, 18–45 years; mean age, 27 years; weight, 60–111 kg; 
and mean weight, 80 kg). Two subjects were discontinued from the study: 1 
subject because of an adverse event (AE) unrelated to study medication and 1 
subject who was discontinued by the investigator for having a prestudy 
measurement that did not meet entry criteria.  
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Pharmacokinetics 
After oral administration in the fasted state, VTP-27999 was rapidly absorbed, 
attaining Cmax at 1 to 4 hours (Figure 1; Table S1 in the Data Supplement), 
after which plasma concentrations decreased slowly in a multi-exponential 
manner. Administration of VTP-27999 exhibited dose-proportional 
pharmacokinetics, based on area under the curve (AUC)0–24 and Cmax (Table S1). 
The t1/2 for VTP-27999 ranged from 24 to 30 hours across all doses and 
steady-state levels were reached by day 7 (data not shown). Plasma VTP-27999 
exposures (AUC) on day 10 were ≈2-fold higher than on day 1, also consistent 
with a t1/2 of 24 to 30 hours. Aliskiren pharmacokinetic parameters were in 
agreement with those reported previously, its t1/2 being ≈30 to 40 hours.5 Urine 
was collected on days 1 and 10, and at steady state on day 10, between 5% 
and 10% of the daily dose was excreted unchanged into the urine (Table S2). 
 
                                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Drug levels (pharmacokinetics 
[PK] on treatment days 1(top) and 10 
(bottom), and after stopping treatment. 
Data are mean±SEM of n=4 to 6. 
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Changes in Plasma RAAS Components  
As expected with the low-salt diet, baseline PRA, PRC, plasma Ang II, and 
aldosterone levels were increased when compared with reference values from 
healthy volunteers on a normal sodium diet.6 PRA declined rapidly and dose 
dependently after dosing on day 1, reaching a blockade of >90% within 15 
minutes at all doses of VTP-27999 (Figures 2 and 3). Although PRA started to 
rise again after 4 to 6 hours, suppression was maintained for 24 hours post 
dose on day 1 at all doses of VTP-27999 and with aliskiren, with little 
difference in the PRA values between the various VTP-27999 doses and 
aliskiren during the 24 hours. There was little change in PRA during the 24 
hours with placebo. On day 10, predose PRA was below baseline (and similar to 
the 24-hour value on day 1) in all active dose groups, and there was an acute 
drop in PRA after dosing. The PRA returned to day 10 predose levels by 12 
hours and remained stable during the subsequent 60 hours (through 72 hours 
post dose) except for the 600-mg group, in which the PRA continued to rise 
through 48 hours post dose, ending at 1.5 to 2× the day 10 predose level. There 
was a minor decrease in day 10, predose PRA in the placebo group (perhaps 
reflecting temporal changes during clinic confinement) with no intraday 
reduction.  
Plasma Ang II levels largely followed PRA (Figures 2 and 3; Figure S1) on 
day 1 except that recovery to baseline levels occurred by 24 hours. On day 10, 
the predose Ang II levels were similar to baseline in all dose groups. After 
dosing on day 10, Ang II again decreased after VTP-27999 or aliskiren 
administration and returned to day 10, predose levels by 6 hours. At 72 hours 
in the 600-mg group, and similar to the PRA values, the mean Ang II value was 
higher than baseline by 2- to 3-fold.  
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Figure 2: Plasma renin 
activity (PRA) and the 
plasma concentration of 
renin (PRC) and prorenin, 
angiotensin II, and 
aldosterone, respectively, 
on treatment days 1 (left) 
and 10 (right), and after 
stopping treatment. Data 
are mean±SEM of n=4 to 6. 
Note that the PRC scale is 
10-fold greater for day 10 
compared with day 1. 
48 
  
For plasma aldosterone, the degree of suppression on day 1 was less 
than that for PRA or Ang II, and the levels generally recovered by 24 hours 
(Figures 2 and 3). The day-1 plasma aldosterone levels were higher in the 
placebo group than the drug-treated groups at all time points, including the 
baseline time point, for unknown reasons, but the values were stable during 
the 24 hours. On day 10, aldosterone levels were lower in the placebo group 
than on day 1, and similar to the day-1 baseline values for the other groups. In 
the VTP-27999 75-and 150-mg groups and the aliskiren group, baseline 
aldosterone levels on day 10 were similar to those on day 1. In the 300- and 
600-mg dose groups, levels tended to be somewhat higher at predose on day 10. 
The aldosterone levels for all groups returned to day 10, predose levels by 6 
hours and remained stable through 72 hours post dose except for the 600-mg 
group. In that group, and similar to the PRA and Ang II values, the aldosterone 
levels continued to rise through the 72-hour final measurement.  
VTP-27999 dose dependently increased PRC and prorenin on day 1, with 
up to a 35-fold increase over baseline for the Cmax of PRC in the 600-mg VTP-
27999 group (Figures 2 and 4). Peak levels were reached after ≈6 and >12 
hours, respectively, for PRC and prorenin, with persistent elevations through 
hour 24. Substantial further rises in PRC (≤350-fold for the Cmax of PRC at 600 
mg VTP-27999) occurred during treatment on day 10, when the placebo group 
showed a minor reduction in PRC and no change in prorenin levels. Note that 
in Figure 2, the PRC scale for day 10 is 10-fold greater than the day-1 scale. 
After stopping treatment, PRC decreased roughly in parallel with plasma VTP-
27999 concentrations, albeit somewhat more slowly (see terminal slopes in 
Figure 4). However, at 72 hours after the last dose of drug, the PRC levels were 
still ≈10-fold higher for aliskiren and the lower VTP-27999 dose groups, and to 
≤50-fold higher for the 600-mg dose group compared with the baseline levels 
on day 1. Prorenin levels increased in a dose-dependent manner, and this was 
particularly apparent after 10 days of dosing (Figures 2 and 4). The prorenin 
levels remained high after stopping treatment and started to decrease only after 
48 hours consistent with the known longer half-life of prorenin.  
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Figure 3: Plasma renin 
activity (PRA), plasma 
angiotensin II concentration, 
and plasma aldosterone 
concentration on treatment 
days 1 and 10, and after 
stopping treatment. Each 
panel represents a different 
dose of drug. Data are 
mean±SEM of n=4 to 6.  
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Drug levels correlated positively with PRC (Figure 5). PRC variation 
versus drug levels diminished when comparing AUC0–24 for both drug and PRC 
(Figure 5). To measure the relative level of inhibition of renin in the circulation, 
the PRA values were divided by the PRC values, and the PRA/PRC ratio was 
then normalized such that 100% was set to the predose ratio in the placebo 
group on day 1 (Figure 6). Renin was inhibited between 90% and 99.8% on day 
1 in a dose- and exposure-dependent fashion and between 95% and 99.9% on 
day 10. Even at 72 hours after the last dose, renin was inhibited by 90% to 
98%, with the greatest inhibition being in the 600-mg group. 
Changes in Urinary RAAS Components 
The urinary renin excretion rate increased dose dependently during VTP-27999 
treatment on day 1, and the increases were even more prominent on day 10 
(Figure 7). Note the different scales used on the graphs for the 2 different days. 
These changes generally reflected the changes seen in PRC and were greatest in 
the VTP-27999 600-mg dose group. Changes in urinary renin resulting from 
aliskiren administration were comparable with those observed with 75 and 150 
mg VTP-27999. Urinary angiotensinogen and prorenin excretion rates were 
unaffected by drug treatment (data not shown).  
The urinary aldosterone excretion rate was decreased during all 
treatments on day 1 versus placebo, particularly in the 0- to 6-hour interval 
(Figure 7). On day 10, urinary aldosterone excretion rates for the 2 lower doses 
of VTP-27999 and aliskiren were again below the placebo group for 0 to 6 
hours and were near placebo for the remainder of the day. Conversely, 
aldosterone excretion rates on day 10 were above placebo for the 300- and 600-
mg doses of VTP-27999. The aldosterone urinary excretion rates reflected the 
elevated plasma aldosterone levels for these 2 groups. On day 1, 24-hour 
urinary sodium excretion rates (normalized for creatinine excretion) were, as 
expected, higher at all doses of VTP-27999 and aliskiren than with placebo 
(Table S3). On day 10, these rates had decreased and were similar to that 
observed in the placebo group.  
 
51 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Plasma prorenin, 
renin, and drug 
concentrations on treatment 
days 1 and 10, and after 
stopping treatment. Each 
panel represents a different 
dose of drug. Data are 
mean±SEM of n=4 to 6. PRC 
indicates plasma renin 
concentration.  
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Safety Profile and Hemodynamic Effects 
Two of the 37 subjects who received study medication were discontinued from 
the study. One subject was withdrawn for an AE of sinus tachycardia that was 
also present pretreatment; the investigator considered this AE to be because of 
anxiety and unrelated to study medication (VTP-27999 75 mg). One subject 
was discontinued by the investigator after 1 dose of placebo when it was 
noticed that the subject’s predose ECG did not meet entry criteria. There were 
no serious AEs. Eleven of the 25 subjects who received VTP-27999 reported ≥1 
AE (Table S4). AEs were mild to moderate in intensity and all were reported as 
resolved by the follow-up visit on day 17. The greatest number of AEs was 
reported at the 600-mg dose of VTP-27999; the majority of which were nausea 
and vomiting. There were no important findings on physical examinations, 
ECGs, or laboratory tests; serum potassium levels were not elevated (Table S5). 
Figure 5: Correlation between the plasma concentrations of VTP-27999 and renin on treatment 
days 1 and 10, either expressed as individual data points (A) or as area under the curve 
(AUC)0–24 for the plasma concentrations of VTP-27999 and renin (ng/mL×hours and 
pg/mL×hours, respectively; B). Day 1 values are represented by closed symbols and day 10 
values by open symbols. PRC indicates plasma renin concentration.  
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In these normotensive but sodium-depleted subjects, VTP-27999 and 
aliskiren decreased blood pressure on days 1 and 10 compared with placebo 
(Figure 8). However, because of the small sample size and the inherent 
variability in blood pressure within and between days, the relative effects on 
blood pressure between the different doses of VTP-27999 and aliskiren could 
not be differentiated. Heart rates tended to be somewhat elevated in all dose 
groups on day 10 versus placebo, with a more substantial increase in the heart 
rate in the 600-mg dose group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Plasma renin 
activity (PRA)/plasma 
renin concentration (PRC) 
ratios on treatment days 
1 and 10, and after 
stopping treatment. Data 
are mean±SEM of n=4 to 
6.  
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DISCUSSION 
This is the first description of the pharmacokinetic and pharmacodynamic 
characteristics of a new renin inhibitor, VTP-27999, in human subjects. VTP-
27999 is rapidly absorbed, reaching Cmax between 1 and 4 hours after oral 
dosing, and it had a multi-exponential decay curve from plasma. There was a 
rapid distribution phase followed by a terminal removal phase with a t1/2 of 24 
to 30 hours. The pharmacokinetics were dose-proportional, and the day-10 
pharmacokinetic parameters were as predicted from the day 1 kinetics; day 10 
Cmax values were ≈50% greater than the day 1 values, and the AUC was 
approximately doubled. Relatively little of the drug was excreted in the urine 
(<10%), and thus the liver and metabolism are apparently the major routes of 
clearance. With the long terminal t1/2 and dose proportionate exposure, the 
pharmacokinetics supports once a day dosing for VTP-27999.  
Figure 7: Urinary renin (A) and aldosterone (B) excretion for 0 to 6, 6 to 12, and 12 to 24 hours 
on treatment days 1 and 10. Data are mean±SEM of n=4 to 6. 
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VTP-27999 was generally safe and well tolerated in these salt-restricted, 
healthy, normal volunteers. Nausea and some vomiting were observed in the 
600-mg dose group, but this was not observed at the lower doses of VTP-27999, 
and no subject discontinued drug because of tolerability issues. There were no 
clinically significant changes in laboratory values or ECGs, and more 
specifically, no significant changes in serum potassium levels. Changes in 
blood pressure are not easily seen in normotensive volunteers, even when 
following a low-salt diet, and differences in blood pressure in drug-treated 
versus placebo only could be observed. There were no drug-related 
discontinuations or significant AEs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Change 
from baseline in 
systolic blood 
pressure (SBP; A), 
diastolic blood 
pressure DBP; B), 
and heart rate (HR; 
C) on days 1 and 10, 
and after stopping 
treatment. Data are 
mean±SEM of n=4 
to 6.  
56 
  
The pharmacodynamics of VTP-27999 demonstrated a rapid onset and 
almost complete inhibition of PRA; >90% at 15 minutes after dosing on day 1 at 
all dose levels, and significant inhibition of PRA was maintained for 24 hours 
on day 1. There was also substantial inhibition of PRA at all dose levels on day 
10, supporting once a day dosing, consistent with the pharmacokinetics. There 
was a clear dose–response for PRC and a significant induction between days 1 
and 10, with a 2- to 10-fold higher Cmax on day 10 compared with day 1 for the 
different doses of drug. With the PRC providing the clearest dose–response, one 
can compare the relative pharmacodynamics potency of orally administered 
VTP-27999 with aliskiren. With the day-1 PRC measurements, on an oral dose 
basis, VTP-27999 was ≈2- to 3-fold more potent than aliskiren, and on day 10, 
it was ≈2-fold more potent. Given the comparable IC50 of both inhibitors,3, 4 it 
can be concluded that the greater oral potency of VTP-27999 is related to its 
greater bioavailability.  
The full pharmacodynamic data set demonstrates an interesting and 
surprising relationship between the dose of VTP-27999 administered, the 
intrarenal inhibition of renin, and the blockade of the systemic RAAS. Because 
the majority of renin is synthesized and secreted from juxtaglomerular cells in 
the renal glomeruli,7 and because renin secretion by the kidney is 
downregulated by Ang II, plasma levels of renin are inversely related to, and are 
a reflection of, inhibition of renin in the kidney.8  
Biochemical data obtained from day 10 and out to 72 hours after the day 
10 dose are consistent with the 600-mg dose of VTP-27999 being less effective 
than 300 mg on decreasing PRA, Ang II production, and aldosterone 
production at 48 and 72 hours after dosing. After the 600-mg dose, the rise in 
the PRC Cmax on day 10 was ≤350-fold compared with the day 1 baseline values. 
PRA remained below baseline (ie, predose level) during the full 24 hours after 
the last dose, and thereafter started to rise. Ang II and aldosterone also started 
to rise 24 hours after the last dose in the 600-mg cohort, even reaching plasma 
concentrations that were several fold above baseline. These rises were not seen 
for the other doses of VTP-27999 or for aliskiren, except for a 50% rise in 
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plasma aldosterone in the VTP-27999 300 mg cohort at 72 hours after the day 
10 dose.  
Thus, a dissociation occurs in the 600-mg dose group at the later time 
points (>24 hours after dosing) between the intrarenal blockade of renin, which 
increases the synthesis and secretion of renin, and the systemic blockade of 
renin. This dissociation occurs at times when there are declining plasma levels 
of the renin inhibitor. After the last dose of drug on day 10, the decrease in 
PRC generally paralleled the decrease in renin inhibitor concentration (Figure 
3). However, in the case of 600-mg VTP-27999 cohort, PRC decreased 
significantly more slowly than VTP-27999 (≈1/3 as fast) after stopping 
treatment, and this is the likely cause of the PRA and plasma Ang II and 
aldosterone overshoot. Renin is still inhibited 98% to 99% at these times 
(Figure 6), but because the renin levels are so elevated, the absolute PRA 
values are increased 1.5- to 2-fold.  
When high doses of VTP-27999, aliskiren, and other renin inhibitors, 
such as ciprokiren and remikiren, are administered, all of which are known to 
accumulate in the kidney,9, 10 the degree of renal/juxtaglomerular RAAS 
blockade may be greater than that outside the kidney. Under such conditions, 
there is a sustained stimulation of renal renin release secondary to the 
intrarenal inhibition of renin and subsequent decrease of Ang II at the level of 
the juxtaglomerular cells, even when extrarenal renin inhibitor levels are no 
longer sufficient to fully block renin systemically. However, once released into 
the circulation, these VTP-27999–bound renin molecules face declining VTP-
27999 concentrations in plasma, and thus dissociation of the renin–VTP-27999 
complex is likely to occur.  
The capacity of the human body to counteract RAAS blockade through 
the synthesis and secretion of renin did not reach its limit in the present study, 
and interestingly, the renin levels observed at 600 mg VTP-27999 were 
comparable with those in patients with renin-producing tumors.11 If a 
stimulation for renin secretion persists during a long period of time, the 
increased secretory capacity involves increased synthesis of prorenin through 
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hypertrophy of juxtaglomerular cells and metaplastic transformation of 
preglomerular vascular smooth muscle cells into renin-producing cells.12, 13 On 
day 10, the PRC AUC values were 2 to 10× higher than the AUC values on day 
1. Thus, there is a large increase in renin secretion with drug treatment and 
also with drug treatment between days 1 and 10. This is almost certainly 
because of both strong inhibition of intrarenal renin and an increase in the 
overall secretory capacity, particularly at the higher doses of VTP-27999. This 
hypertrophy and metaplastic transformation may also contribute to the 
overshoot or escape of the systemic RAAS. For the same level of decrease in 
intrarenal Ang II, there will be a greater capacity for renin production and 
release by the increased mass of the juxtaglomerular cells in the glomeruli.  
When the degree of renal RAAS blockade exceeds that outside the kidney, 
plasma renin will increase as will the PRA, and this rise in PRA will lead to a 
counter-regulatory increase in the concentrations of Ang II and aldosterone 
(escape). It is likely that this would occur with aliskiren too, had it been able to 
be tested at higher doses. Our findings are reminiscent of the nephrocentric 
view of angiotensin-converting enzyme inhibition noted 25 years ago in patients 
with congestive heart failure.14 It was asked why the kidneys continue to 
release renin in such patients; the answer being that they do everything 
possible to preserve renal function and glomerular filtration, apparently at the 
expense of the hemodynamic burden on the heart. This situation mimics our 
findings, although obtained in healthy volunteers, at the highest dose of VTP-
27999 where the kidneys respond to renal RAAS suppression by releasing large 
quantities of renin, resulting in elevations of PRA, Ang II, and aldosterone. 
Such elevated Ang II levels might also, either directly or indirectly (via the 
facilitation of norepinephrine release), be responsible for the rise in heart rate 
that was observed at the highest VTP-27999 dose.  
The PRC correlated with the plasma levels VTP-27999, and if 
assessments are limited to the PRC-VTP-27999 concentration relationship on 
day 1 (ie, before the induction of renin synthesis) or day 10 (ie, after the 
induction of renin synthesis), the variation in PRC levels for a given drug 
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concentration varies between 30- and 100-fold. There are several potential 
reasons for this variation. First, there are biological interindividual variations 
in renin levels. Second, peak levels for renin occurred 2 to 4 hours after peak 
levels of VTP-27999. When the time/drug level/PRC relationship was plotted, 
there was clear hysteresis for the relationship between drug levels and the 
PRCs (plots not shown). To compensate for this hysteresis, we compared the 
AUC0–24 for VTP-27999 versus the AUC0–24 for PRC, and did this for both on 
days 1 and 10. By doing this, the variation in the PRC AUC for a given VTP-
27999 AUC was reduced to <10. PRA also correlated strongly with Ang II and 
less with aldosterone (Figure S1).  
Prorenin, like renin, increased dose dependently, the only difference 
being that this rise required >12 hours on day 1, because of the fact that it 
depends on the actual induction of prorenin synthesis, because prorenin is not 
stored in the kidney. On day 10, prorenin was elevated compared with day 1 
predose values, and there was little change in prorenin for 24 hours, reflecting 
the longer half-life of prorenin in the circulation. This was followed by a slow 
decline in concentration during the subsequent 2 days. Changes in urinary 
renin and aldosterone levels generally reflected the alterations in their levels in 
plasma at the various doses and various times of collection, suggesting that 
urinary renin originates largely, if not completely, from filtration from the 
systemic circulation into the urine and not from direct secretion from the 
kidney into the urine. 
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PERSPECTIVES 
The data obtained in the present study support that VTP-27999 is a potent and 
generally well-tolerated, renin inhibitor, capable of effectively suppressing the 
RAAS with once a day dosing, and on an oral dose-basis, VTP-27999 is 
approximately twice as potent as aliskiren. VTP-27999, which is known to be 
sequestered in the kidney, has a temporal asynergism, dependent on the tissue 
and plasma levels of the inhibitor, between intrarenal renin inhibition, with its 
consequent stimulation of renin synthesis and release, and extrarenal 
inhibition with its consequent decrease in PRA, Ang II, and aldosterone. With 
VTP-2799 at doses >300 mg/d, the high level of intrarenal renin inhibition, 
with subsequent dramatic increases in renin release, results in systemic renin 
levels that are greater than the systemic levels of VTP-27999 can fully inhibit at 
24 to 72 hours after the last dose. This raises the interesting possibility of VTP-
27999 at the highest dose having superior renal renin inhibition and protection 
while having increased systemic PRA, Ang II, and aldosterone levels. This study 
also demonstrates once more the variability of local renin–angiotensin systems 
when stressed by a renin inhibitor, and the need for more studies investigating, 
with an appropriate and complex technology, the pharmacodynamics of the 
RAAS, within and outside the kidneys. The dose of VTP-27999 to optimally 
balance the antiproteinuric, nephroprotective, antihypertensive, and 
cardioprotective effects remains to be determined. 
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SUPPLEMENTAL INFORMATION 
MATERIAL AND METHODS 
Study Protocol 
This was a randomized, double-blind, placebo- and active-controlled study in 
which once daily doses of 75, 150, 300, or 600 mg VTP-27999 were 
administered orally as 75 mg tablets for 10 days to healthy subjects (males and 
females not of childbearing potential, aged between 18-45 years, and with a 
BMI ranging from 18-32 kg/m2) in 4 sequential ascending dose cohorts. The 
study was approved by the PRACS Institute, Ltd. Institutional Review Board. 
All subjects provided written, informed consent and the study was conducted 
in accordance with accepted standards of Good Clinical Practice (GCP), as 
defined in the International Conference on Harmonization (ICH) E6 Guideline 
for Good Clinical Practice, in agreement with the latest revision of the 
Declaration of Helsinki. 
Subjects visited the clinic on Day -5 to receive dietary instructions and 
low salt meals (10 mEq/day) for outpatient consumption. Subjects were 
admitted to the clinic on Day -1 to undergo baseline assessments and were 
verified to have a spot urinary Na+/creatinine ratio of <30 mEq/g creatinine 
before they could continue in the study. Subjects were randomized within each 
dose cohort to receive VTP-27999, placebo or aliskiren 300 mg, all 
administered orally once daily in the fasted state at approximately 08:00 hours. 
VTP-27999 75 mg tablets and a matching placebo were supplied to the clinical 
site by Vitae Pharmaceuticals, Inc. Aliskiren 300 mg tablets were purchased by 
the site pharmacy from a commercial source. The 75 mg and 150 mg cohorts 
each included 8 subjects (6 on VTP-27999, 1 on aliskiren and 1 on placebo 
matching VTP-27999). The 300 mg and 600 mg cohorts each included 10 
subjects (6 on VTP-27999, 2 on aliskiren and 2 on placebo). Dosing began on 
the morning of Day 1 and continued through Day 10. Subjects were released 
from the clinic on Day 13 and returned for a safety visit on Day 17±2 days, 
after which they were discharged from the study.  
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Tolerability and Safety Assessments 
Routine safety assessments included vital signs, physical examination, 
standard laboratory tests, and 12-lead ECGs. Adverse events (AE) were 
monitored throughout the study.  
Pharmacokinetic and Pharmacodynamic Assessments 
Blood samples for the determination of plasma VTP-27999 and aliskiren 
concentrations were collected at 0 hour (pre-dose), at 0.25, 0.5, 1, 2, 4, 6, 8, 12, 
and 24 hours after dosing on Days 1 and 10, predose on Days 5 and 7, and at 
48 and 72 hours after dosing on Day 10. Samples were processed on ice in the 
presence of a serine protease inhibitor and stored at -70°C until shipment to 
the bioanalytical laboratory.  
Blood samples for determination of plasma renin activity (PRA), plasma 
renin concentration (PRC), plasma prorenin concentration, Ang II, and 
aldosterone were obtained as described previously1 at -30 and -15 minutes 
(pre-dose) and at 0.5, 2, 4, 6, 12, and 24 hours post-dose on Day 1 and Day 10, 
pre-dose on Day 5 and Day 7, and at 48 and 72 h after the last dose on Day 10. 
PRA, PRC, prorenin, and aldosterone samples were processed at room 
temperature and stored at -70°C until analysis. Ang II samples were placed on 
ice, processed at 4°C and stored at -70°C until analysis.  
Urine was collected for the measurement of VTP-27999, Na+, creatinine, 
renin, angiotensinogen, aldosterone, Ang II, and prorenin over the intervals of 
0-6, 6-12, and 12-24 hours post-dose on Days 1 and 10. Urine samples were 
stored at -20°C until analysis. Blood pressure and heart rate were measured in 
triplicate, after quiet semi-supine rest before each blood sample collection, 
using an automated device.  
Bioanalytical Methods 
Plasma VTP-27999 concentrations were measured using a solid phase 
extraction method and LC-MS/MS analysis developed and validated by Cetero 
Research, Houston, TX, USA. The standard curve ranged from 1-200 ng/mL. 
The analytes and internal standard peak areas were exported to Watson 
Laboratory Information Management System (LIMS) to create calibration curves 
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using weighted (1/x2) least squares regression fit to a linear model. The 
concentrations of the standards, QCs, and samples were calculated using 
Watson LIMS. Plasma aliskiren concentrations were determined using a of solid 
phase extraction method and LC-MS/MS analysis developed at Vitae 
Pharmaceuticals. The standard curve ranged from 1-500 ng/mL. The analyte 
and internal standard peak areas were calculated by Analyst 1.4.2® Software 
to create a calibration curve using weighted (1/x2) least squares regression fit 
to a linear model. The concentrations of the standards, QCs, and samples were 
calculated using Analyst 1.4.2® Software.  
PRA was determined by measuring Ang I generation during incubation of 
plasma at 37°C and pH 7.4. PRC was measured with an immunoradiometric kit 
(Renin III, Cisbio, Gifsur-Yvette, France).2 Urinary renin was measured with the 
same renin kit after concentrating the samples as described before.3 Plasma 
Ang II was measured by radioimmunoassay after SepPak extraction as 
described before. Plasma aldosterone and free urine aldosterone were 
measured by solid phase radioimmunoassay (Diagnostic Products Corporation, 
Los Angeles, CA, USA).4 Plasma prorenin was measured with a direct prorenin 
enzyme-linked immunosorbent assay (Molecular Innovations, Novi, MI, USA).5 
Urinary angiotensinogen was measured as the maximum quantity of Ang I that 
was generated during incubation with excess recombinant renin. 
Pharmacokinetic Parameters 
Peak concentration (Cmax), concentration at trough (Cmin), time to Cmax (tmax), 
terminal half–life (t1/2), renal clearance (Clr), and area under the concentration-
time curve up to 24 h postdose (AUC0-24) for each individual plasma 
concentration-time profile were determined by a non-compartmental method, 
using WinNonlin® (Pharsight® Corporation, Mountain View, CA, USA), Version 
5.0.1. Values below the lower limit of quantitation (BLQ) were presented as zero 
in the plasma concentration tables and were treated as zero when calculating 
the descriptive summary of the concentrations by time point. When calculating 
PK parameters, BLQ values were treated as zero when occurring at the 
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beginning of the profile and missing when occurring at the end of the profile or 
between two values that were above lower limit of quantitation (LLOQ). 
Statistical Analysis 
All subjects who received at least one dose of study drug (VTP-27999, aliskiren 
or placebo) are included in the safety analyses. Concentration data from all 
subjects who received VTP-27999 were used in the calculation of PK 
parameters and no subjects were excluded from the final VTP-27999 plasma 
and urine PK analysis. One subject was excluded from the aliskiren PK 
analysis dataset because this subject inadvertently received placebo on Day 1. 
Only subjects with samples from Day 1 and Day 10 were included in the 
pharmacodynamic (PD) dataset. Two subjects (one each for the aliskiren and 
placebo cohorts) were excluded from the PD analysis because they 
inadvertently had their doses switched on Day 1.  
Safety data from all subjects who received at least one dose of study 
medication were reported and summarized. Plasma VTP-27999 PK parameters 
included Cmax, Cmin, tmax, AUC0-24, and t1/2. All available plasma VTP-27999 
concentration and PK results were summarized using appropriate descriptive 
statistics. Mean and individual concentration versus time curves were plotted 
for each analyte. Descriptive statistics, including changes from baseline were 
calculated for all plasma PD analytes and BP (mean of triplicate readings at 
each time point), by dose and time point. Percent change from baseline was 
also calculated for plasma PD analytes. Descriptive statistics for urine 
excretion amount and rates for aldosterone and renin were calculated by dose 
and collection interval. 
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Table S1. Plasma Pharmacokinetic parameters for VTP-27999 and Aliskiren. Data are 
mean±SD or median and range. VTP=VTP-27999, ALI=aliskiren. 
 
 
 
 
 
 
 
Table S2. Summary of urinary excretion (Ae(0-24)) and renal clearance (Clr) for VTP-27999. 
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Table S3. Renal excretion of sodium and creatinine. Data are mean±SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S4. Summary of number of subjects with treatment-emergent adverse events (AE), 
presented in order of frequency.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N = number of subjects dosed with each treatment. Blank cell = no reported AE. One subject, 
randomized to placebo, received one dose of aliskiren on Day 1. Another subject, randomized to 
aliskiren, received placebo on Day 1. Both subjects were counted in the aliskiren group for the 
safety analysis, but were excluded from the PK/PD analysis. 
Table S5. Serum potassium levels. Data are mean±SD. 
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Figure S1. Plasma renin activity (PRA) versus plasma angiotensin (Ang) II and aldosterone in 
subjects treated with placebo, VTP-27999 (75, 150, 300 or 600 mg) or 300 mg aliskiren. 
 
 
 
69 
  
REFERENCES  
1. Klotz S, Burkhoff D, Garrelds IM, Boomsma F and Danser AH. The impact of left 
ventricular assist device-induced left ventricular unloading on the myocardial renin-
angiotensin-aldosterone system: therapeutic consequences? Eur Heart J. 2009;30:805-12. 
2. Fisher ND, Jan Danser AH, Nussberger J, Dole WP and Hollenberg NK. Renal and 
hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 
2008;117:3199-205. 
3. van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, van Gool JM, 
Feelders RA, van den Meiracker AH and Danser AH. Urinary renin, but not angiotensinogen or 
aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of 
renin-angiotensin-aldosterone system blockade in the kidney. J Hypertens. 2011;29:2147-55. 
4. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP and Danser AH. 
Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. 
Hypertension. 2005;46:701-6. 
5. Krop M, van Gool JM, Day D, Hollenberg NK and Jan Danser AH. Evaluation of a direct 
prorenin assay making use of a monoclonal antibody directed against residues 32-39 of the 
prosegment. J Hypertens. 2011;29:2138-46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
  
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
ANGIOTENSIN II TYPE 2 RECEPTOR- AND ACETYLCHOLINE-MEDIATED 
RELAXATION:  THE ESSENTIAL CONTRIBUTION OF FEMALE SEX 
HORMONES AND CHROMOSOMES 
 
 
 
 
 
 
 
Based on: Angiotensin II type 2 receptor- and acetylcholine-mediated relaxation:  
the essential contribution of female sex hormones and chromosomes. Sevá 
Pessôa B, Slump DE, Grefhorst A, van Veghel R, Garrelds IM, Roks AJM, 
Kushner SA, Danser AHJ, van Esch JHM. Manuscript in preparation.  
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ABSTRACT 
Angiotensin II induces vasoconstriction via its type 1 receptors (AT1R), while 
type 2 (AT2) R are believed to be vasodilator. The latter is not a universal 
finding and may be limited to women. AT2R-induced vasodilation, if occurring, 
is mediated via nitric oxide (generated by endothelial NO synthase, eNOS) 
and/or endothelium-derived hyperpolarizing factors (EDHFs). Studies in eNOS 
knockout mice suggest that EDHF predominate in women. To distinguish the 
contribution of female sex hormones and chromosomes to AT2R function and 
EDHF-mediated vasodilation, we made use of the four core genotype (FCG) 
model, where the testis-determining Sry gene has been deleted (Y-) from the Y 
chromosome, allowing XY- mice to develop a female gonadal phenotype. 
Simultaneously, by incorporating the Sry gene onto an autosome, XY-Sry and 
XXSry transgenic mice develop into gonadal males. FCG underwent a sham or 
gonadectomy (GDX) operation, and after 8 weeks, animals were sacrificed and 
iliac arteries were collected to assess vascular function. Vascular function was 
also studied in C57bl/6 males treated with estrogen after GDX. XY-Sry males 
responded more strongly to Ang II than XX females, and the AT2R antagonist 
PD123319 revealed that this was due to a dilator AT2R-mediated effect 
occurring exclusively in XX females. The latter could not be demonstrated in 
XXSry males and XY- females, nor in XX females after GDX, suggesting that it 
depends on both sex hormones and chromosomes. Indeed, treating C57bl/6 
GDX males with estrogen could not restore Ang II-mediated, AT2R-dependent 
relaxation. To block acetylcholine-induced relaxation of iliac arteries obtained 
from FCG XX mice, both eNOS - and EDHF inhibition were required, while in 
FCG XY animals eNOS inhibition alone was sufficient. These findings were 
independent of gonadal sex, and unaltered after GDX. AT2 receptor-induced 
relaxation requires both estrogen and the XX chromosome sex complement, 
while only the latter is required for EDHF. Estrogen treatment of male mice 
confirms that this approach is insufficient to re-introduce AT2 receptor-induced 
relaxation.   
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INTRODUCTION 
It is generally accepted that angiotensin (Ang) II type 2 (AT2) receptors oppose 
Ang II type 1 (AT1)-mediated responses by evoking vasorelaxation, natriuresis, 
antigrowth and anti-inflammatory effects.1 According to some studies, these 
effects occur exclusively in women,2 possibly due to the fact that estrogen 
upregulates AT2 receptors.3 As a consequence, low-dose Ang II even decreases 
blood pressure in young adult female rats, at levels that increase pressure in 
age-matched males.4 Moreover, under certain conditions, e.g. in the 
spontaneously hypertensive rat (SHR), AT2 receptors become AT1 receptor-like,5, 
6 and induce constriction. The mechanism behind this phenotypic change is 
unclear, but might be due to a difference in location of endothelial cell versus 
vascular smooth muscle cell and/or heterodimerization with AT1 receptors.1  
AT2 receptor-mediated vasodilation involves bradykinin type 2 (B2) 
receptor activation, which results in the generation of NO by endothelial NO 
synthase (eNOS) and endothelium-derived hyperpolarizing factors (EDHFs), 
respectively.7, 8 Although the identity of the latter varies according to vessel size, 
species and vascular bed, EDHF-induced relaxation always depends on the 
activation of intermediate-conductance and small-conductance Ca2+-activated 
K+-channels (IKCa, SKCa). Of interest, studies in eNOS KO mice revealed that 
EDHF is the predominant relaxant pathway in females, and as such might 
contribute to the lower incidence of cardiovascular diseases in premenopausal 
women.9  
Sex differences arise from direct effects of gonadal hormones and sex 
chromosome genes. An ideal model to investigate the sex chromosome 
complement (XX versus XY) independently of gonadal sex is the four core 
genotype (FCG) mouse.10 In this model, the Sry gene, which is the dominant 
testis-determining gene, is deleted from the Y chromosome through a natural 
mutation (Y-). As a consequence, the XY- mouse develops ovaries and expresses 
a female gonadal hormone phenotype. Simultaneously, by incorporating the 
Sry gene onto an autosome, XY-Sry and XXSry transgenic mice develop into 
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gonadal males. Unexpectedly, after gonadectomy, XX FCG mice displayed a 
larger blood pressure response upon Ang II infusion than XY mice, suggestive 
for adverse sex chromosome effects encoded within the XX sex chromosome 
complement that contribute to hypertension.11 In the present study, we made 
use of the FCG model to dissect the contribution of gonadal hormones and sex 
chromosome genes to AT2 receptor-mediated vasodilation and the EDHF 
component of acetylcholine-induced relaxation. 
METHODS  
Animals 
C57bl/6J mice (19 males, 8 females; age 8-12 weeks) were purchased from 
Charles River. Four core genotype (FCG) mice (19 XY-Sry  and 22 XXSry 
gonadal males, 23 XX and 23 XY- gonadal females) were bred at the department 
of Neuroscience using XY-Sry males on a C57Bl/6J background (Jackson 
Laboratories) and female C57Bl/6J mice (Harlan). PCR genotyping for the 
presence or absence of the Y chromosome was done as described before using 
DNA isolated from toes (10 days old), and again confirmed after sacrifice (ear).12 
At 10-14 weeks of age, mice were randomized to undergo gonadectomy or sham 
operation via an incision in the midline, followed by removal of the ovaries or 
testes. To study the effect of estrogens, 1-week gonadectomized C57bl/6J 
males (Charles River Laboratories, Maastricht, The Netherlands) were 
randomized to receive a daily subcutaneous injection of 100 μg/kg of 
diethylstilbesterol (DES) (Steraloids Inc., Newport, RI) dissolved in olive oil or 
vehicle (olive oil) during one week. Intact C57bl/6J and FCG mice were 
sacrificed (60 mg/kg i.p. pentobarbital) at 18-22 weeks of age. Treated 
gonadectomized C57bl/6 males were sacrificed at 12-14 weeks of age by 
cardiac puncture under isoflurane anesthesia. Blood from FCG mice was 
obtained immediately prior to sacrifice by cannulation of the hepatic portal vein. 
Uteri were rapidly excised, weighed and stored at -80oC. Tibias were collected 
and cleaned using hydrogen peroxide. Iliac arteries and were removed and 
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either used directly or after overnight storage in cold, oxygenated Krebs-
Henseleit solution.   
Mulvany myographs 
Iliac arteries (diameter ~350 m) were cut into 6 ring segments of 
approximately 1.5-2 mm length and mounted in a Mulvany myograph with 
separated 6-mL organ baths containing gassed (95% O2/5% CO2) Krebs-
Henseleit buffer at 37oC. The tension was normalized to 90% of the estimated 
diameter at 100 mm Hg effective transmural pressure. Following a 30-min 
stabilization period, the maximal contractile response was determined by 
exposing the vessels to 100 mmol/L KCl. Segments were then incubated for 30 
min in fresh buffer in the absence or presence of 100 mol/L L-NAME, 1 
mol/L irbesartan (not in FCG mice), or 1 mol/L PD123319. Next, 
concentration-response curves (CRCs) were constructed to Ang II, endothelin-1 
(ET-1) and phenylephrine. Finally, after a washout period of 30-minutes, 
segments were again incubated for 30 min in fresh buffer with or without 100 
mol/L L-NAME, the SKCa inhibitor apamin (100 nmol/L), and/or the IKCa 
inhibitor TRAM34 (10 µmol/L), and preconstricted with U46619 (100-300 
nmol/L). Thereafter, CRCs to acetylcholine (ACh) were constructed. CRCs for 
Ang II and ACh in presence and absence of L-NAME were performed in the 
same segments, whereas ACh CRCs in presence of TRAM34+apamin and/or L-
NAME were randomized across the remaining segments.  
Data analysis 
Data are expressed as mean+SEM. Statistical analysis between groups for 
basal characteristics was performed by one-way ANOVA, followed by post-hoc 
evaluation according to Bonferroni. Relaxant responses to ACh are expressed 
as a percentage of the contraction to U46619. Contractile responses are 
expressed as a percentage of the contraction to 100 mmol/L KCl. CRCs were 
analyzed as described to obtain Emax and pEC50 (-10logEC50) values. Differences 
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in CRCs within and between groups were tested by general linear model 
ANOVA for repeated measures. P<0.05 was considered significant.  
RESULTS 
Baseline characteristics 
As expected, males had a higher BW than females (Table 1), and gonadectomy 
diminished this difference. Tibia length was similar in all animals. 
Gonadectomy reduced the uterus weight/TL ratio from 5.1±0.6 to 2.0±0.5 
mg/mm in XX females, and from 4.1±0.6 to 1.2±0.2 mg/mm in XY- females 
(P<0.05 for both), thus confirming that gonadectomy was successful.  
Studies in healthy C57bl/6 mice 
Ang II responses in iliac arteries from healthy C57bl/6 males were higher than 
those in arteries from healthy females (P<0.0001; Figure 1). Irbesartan 
abolished all Ang II responses (P<0.001), while PD123319 partially reduced the 
response in males (P=0.013), and enhanced it in females (P=0.003). L-NAME 
enhanced the response to Ang II in females and males, but the increase was 
significant in females only (P<0.001). After L-NAME, Ang II responses in males 
and females were identical. In females, the response after L-NAME was 
identical to that after PD123319, whereas in males, the response after L-NAME 
was increased versus that after PD123319 (P=0.001).  
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Table 1. Body weight (BW) and tibia length (TL) in C57bl/6 and four core genotype mice. 
#P<0.05 vs. corresponding male.   
 
 
 
 
 
 
 
 
Strain C57bl/6 mice Four Core Genotype mice 
SCC XY XX XY- XX XX XY- 
Sry Yes No Yes No Yes No 
Gonadal 
sex 
Male Female Male Female Male Female 
Gonadal 
status 
Intact Intact Intact GDX Intact GDX Intact GDX Intact GDX 
N 7 8 9 10 9 14 10 12 10 13 
BW (g) 28.0+1.1 22.7+0.2# 26.6+0.8 24.4+0.4 23.1+0.7# 23.9+0.5 29.8+1.2 25.5+0.8 21.0+0.5# 21.9+0.4 
TL (mm) 17.1+0.1 16.9+0.1 17.4+0.1 17.4+0.1 17.1+0.1 17.3+0.1 17.6+0.1 17.4+0.1 16.9+0.1 17.2+0.1 
 
 
Studies in FCG mice 
Ang II responses in iliac arteries (Figures 2A & 2B) obtained from FCG XY-Sry 
males (Emax 53±11%) and XX females (Emax 40±10%) were comparable to those 
in healthy C57bl/6 males (Emax 59±9%; Figure 1A) and females (Emax 51±7%; 
Figure 1B). Moreover, like in C57bl/6 females, PD123319 (P=0.054) and L-
NAME (P=0.007) increased the Ang II response identically in XX females, so 
that the response after L-NAME was not different from that after PD123319. 
Like in C57bl/6 males, L-NAME increased the Ang II response in XY-Sry males 
versus PD123319 (P=0.032), while the difference versus control was of 
borderline significance (P=0.057). PD123319 alone marginally decreased the 
response to Ang II (P=NS). Irbesartan was not evaluated in these studies. 
Importantly, all responses in XXSry males and XY- females (Figures 2C & 2D) 
were identical to those in XY-Sry males. Gonadectomy did not change these 
responses (Figures 2E, 2G & 2H), except in XX females (Figure 2F), where 
PD123319 now decreased the response to Ang II instead of enhancing it 
(P=0.001 for difference versus intact XX females; Figure 2B). These data 
indicate that the AT2 receptor-induced relaxant effect requires both estrogen 
and the XX chromosome sex complement. Responses to ET-1 or phenylephrine 
did not display sex hormone or chromosome-dependent differences 
(supplemental Figure).  
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Figure 1. Contractions of iliac arteries, obtained from healthy male and female C57bl/6 mice 
to angiotensin II in the absence (control) or presence of irbesartan, PD123319, or L-NAME. 
Contractions (mean±SEM of n=5-16) have been expressed as a percentage of the response to 
100 mmol/L K+.   
 
ACh relaxed iliac arteries of FCG XX females more strongly than iliac 
arteries of XY-Sry males (P=0.020; Figures 3A & 3B). TRAM34+apamin 
prevented this stronger response in XX females, indicating that it was due to 
EDHF. Near complete blockade was obtained with L-NAME, both in XY-Sry 
males and XX females, and TRAM34+apamin did not exert significant 
additional effects on top of L-NAME. Findings in XXSry males (Figure 3C) 
mimicked those in XX females (i.e., TRAM34+apamin exerting an inhibitory 
effect, P<0.001), while findings in XY- females (Figure 3D) were identical to 
those in XY-Sry males (i.e., TRAM34+apamin having no significant effect). 
Taken together, these findings indicate that ACh-induced EDHF release occurs 
exclusively in XX mice.  
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Figure 2. Contractions of iliac arteries, obtained from FCG mice (XY-Sry males, XX females, XXSry males, and XY- females) before 
(top panels) or after (bottom panels) gonadectomy, to angiotensin II in the absence (control) or presence of PD123319 or L-NAME. 
Contractions (mean±SEM of n=7-13) have been expressed as a percentage of the response to 100 mmol/L K+. 
 
 
 
 
 
 
Observations after gonadectomy (Figures 3E-3H) were essentially the 
same, the only difference being that ACh responses in XX females (Figure 3F) 
versus XY-Sry males (Figure 3E) now were not only larger under control 
conditions (P=0.039), but also in the presence of L-NAME (P=0.022). Moreover, 
TRAM34+apamin exerted an inhibitory effect (P=0.015) on top of L-NAME in XX 
females (Figure 3F), but not in XY-Sry males. A similar tendency (P=0.075) was 
observed for the effect of TRAM34+apamin in the absence of L-NAME in XX 
females. In other words, gonadectomy allowed a better distinction of the EDHF 
response in XX animals, independently of the NO response. Findings in XXSry 
male mice after gonadectomy were identical to those in gonadectomized XX 
females, while findings in gonadectomized XY- females were identical to those 
in gonadectomized XY-Sry males. This is further illustrated in Figure 4, which 
compares all data in gonadectomized animals pooled according to sex 
chromosome complement (i.e., independent of gender). Indeed, Figure 4A 
shows that TRAM34+apamin exert an inhibitory effect both at baseline 
(P<0.0001) and on top of L-NAME (P=0.017) in XX mice, but not XY mice 
(Figure 4B). Moreover, the response to ACh in XX mice (panel 4A) is larger than 
that in XY mice (panel 4B), both at baseline (P=0.022) and after L-NAME 
(P=0.004).  
Studies in gonadectomized male C57bl/6 mice  
Neither PD123319, nor L-NAME, enhanced the Ang II-induced contractions in 
iliac arteries of gonadectomized male C57bl/6 mice (Figure 5). DES treatment 
upregulated the response to L-NAME (P<0.05), but not to PD123319. This 
indicates that estrogen treatment upregulates the NO pathway, but cannot 
induce AT2 receptor-mediated vasodilation. The latter would be in agreement 
with the observation that such vasodilation additionally requires the XX 
chromosome sex complement.  
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Figure 3. Relaxations of iliac arteries, obtained from FCG mice (XY-Sry males, XX females, XXSry males, and XY- females) before 
(top panels) or after (bottom panels) gonadectomy, to acetylcholine in the absence (control) or presence of L-NAME, 
TRAM34+apamin, or L-NAME+TRAM+apamin. Effects (mean±SEM, n=6-13) have been expressed as a percentage of the response to 
U46619. 
 
 
 
DISCUSSION 
This study is the first to show that AT2 receptor-mediated relaxation requires 
the presence of both female sex hormones and the XX chromosome sex 
complement. The EDHF component of ACh-induced relaxation depends on the 
latter only. In contrast, ET-1 and phenylephrine-induced constrictions were sex 
hormone- and sex chromosome-independent. These data imply that the 
protective cardiovascular profile of premenopausal women is not due to 
estrogen only. Moreover, estrogen treatment of men will be insufficient to 
introduce a relaxant AT2 receptor phenotype, as demonstrated in our DES-
treated gonadectomized male mice. 
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Figure 4. Relaxations of iliac arteries, obtained from gonadectomized FCG mice pooled 
according sex chromosome complement (XX vs. XY), to acetylcholine in the absence (control) or 
presence of L-NAME, TRAM34+apamin, or L-NAME+TRAM+apamin. Effects (mean±SEM, n=16-
24) have been expressed as a percentage of the response to U46619.   
 
 A logical consequence of AT2 receptor-mediated relaxation occurring 
exclusively in women is that women will display more modest hypertensive 
responses to Ang II. Animal models fully support this view: not only is the 
pressor response to chronic Ang II infusion much larger in male than in female 
mice,11 but also was the increase in renal blood flow in Sprague-Dawley rats 
greater in females than in males,13 while in SHR Ang II-induced renal 
vasodilation was limited to female rats only.14 The underlying explanation 
might be that that the density of AT2 receptors is larger in women, resulting in 
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a rise in the AT2/AT1 receptor ratio.15, 16 However, although estrogen is known 
to induce AT2 receptor expression,3 this view may be too simplistic. Recent 
studies have shown that moderate cardiac AT2 receptor overexpression in 
transgenic mice protected against maladaptive remodeling and dysfunction, 
whereas a massive, 9-fold overexpression did not yield such positive effects.17 
Thus, more AT2 receptors do not necessarily translate into enhanced protective 
effects. Moreover, under pathological conditions AT2 receptors sometimes 
become AT1 receptor-like,5, 6 and induce constriction. To what degree this 
involves a difference in location (e.g., endothelial cell versus vascular smooth 
muscle cell) and/or heterodimerization with AT1 receptors remains to be 
determined.1, 18 Importantly, in the absence of AT1 receptors, direct AT2 
receptor-mediated dilation does not occur.19 Thus, whether AT2 receptors 
induce dilation depends on the presence of the AT1 receptor, the AT2/AT1 
receptor ratio (and most likely the degree of heterodimerization) and their 
location. Our current study now adds the XX chromosome sex complement to 
this list. 
Of interest is that AT2 receptor-induced dilation is mediated via B2 
receptors, which act through NO and EDHF,20, 21 and that the latter now also 
appears to be determined by the XX chromosome sex complement. Thus, our 
findings on AT2 receptor-induced vasodilation and EDHF may reflect the same 
phenomenon. Unfortunately, investigating the EDHF contribution to AT2 
receptor-mediated dilation in FCG mice is technically challenging, as such 
dilation was observed indirectly only, as an enhanced response to Ang II in the 
presence of PD123319. Studying enhanced responses on top of inhibitors of 
EDHF and NO synthase would have required large additional numbers of 
animals. Instead, we therefore choose to study the contribution of EDHF to 
ACh-induced relaxation. 
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Figure 5. Contractions of iliac arteries, obtained from gonadectomized male C57bl/6 mice 
before (left panel) or after (right panel) treatment with DES, to angiotensin II in the absence 
(control) or presence of PD123319 or L-NAME. Contractions (mean±SEM of n=5-6) have been 
expressed as a percentage of the response to 100 mmol/L K+. 
 
There is not one single EDHF. Multiple EDHF candidates have been 
proposed, ranging from K+, cytochrome-P450 products from arachidonic acid 
(epoxyeicosatrienoic acids) and H2O2 to S-nitrosothiols, and the underlying 
pathways involve IKCa and SKCa in endothelial cells, and inwardly rectifying K+ 
channels, Na+-K+-ATPase and/or large-conductance Ca2+-activated K+-channels 
in vascular smooth muscle cells.22-24 Concomitant blockade of IKCa and SKCa 
with TRAM34 + apamin is the gold standard to distinguish the contribution of 
EDHF, irrespective of what its exact identity is. Studies in eNOS KO mice have 
already revealed that EDHFs are of particular importance in females,9 in full 
agreement with our findings. Obviously, given the multiple EDHF candidates 
that exist, and the fact that their identity varies according to vessel size, 
species and vascular bed, our conclusions at this stage are valid for the mouse 
iliac artery only, and do not necessarily imply that there is no EDHF in men. 
How does the sex chromosome complement relate to AT2 receptor 
function and EDHF? Although the AT2 receptor gene is located on the X 
chromosome, none of the well-known EDHF components are. Yet, the NADPH 
oxidase subunits Nox1 and Nox2 do map to the X chromosome, and as such 
may determine the generation of superoxide-derived H2O2 in a sex 
85 
  
chromosome-dependent manner. Future studies should investigate which 
EDHFs/EDHF pathways are sex chromosome-dependent. Sex hormones play 
an additional, sex chromosome-independent role, at least with regard to AT2 
receptor function. Indeed, estrogens are known to increase angiotensinogen, 
AT2 receptor density and eNOS, while they decrease renin, ACE, AT1 receptor 
density, Nox1 and Nox2.16, 25 These alterations are suggestive for reduced ROS 
formation combined with an upregulation of AT2 receptor stimulation and NO 
release. Our data after DES treatment, showing that NOS inhibition greatly 
increased the response to Ang II, confirm the latter. Simultaneously, they did 
not reveal the re-introduction of an AT2 receptor-mediated relaxant effect in 
male mice after DES exposure. Thus, unlike eNOS upregulation, AT2 receptor-
induced vasorelaxation requires more than estrogen treatment alone. 
Furthermore, testosterone increases renin, ACE and AT1 receptors, and 
downregulates AT2 receptors, thereby favouring Ang II-induced constriction. In 
postmenopausal women the balance will shift towards vasoconstriction, unless 
they receive hormone replacement therapy.25 
In apparent contrast with our data, Ji et al. observed an enhanced 
response to Ang II in gonadectomized FCG XX mice as compared to XY mice, 
despite their earlier observation that females display more modest Ang II 
pressor responses than males.11 They attributed this unexpected finding to 
adverse sex chromosome effects within the XX sex chromosome complement. 
There are no follow-up data that support this concept. Clearly, in view of our 
data, these effects, if occurring, are non-adrenergic, non-ET-1 and non-Ang II-
mediated.   
What are the clinical implications of our findings? It is well-accepted that 
premenopausal women are protected from the development of cardiovascular 
disease in comparison to age-matched men.26 The current study, combined 
with previous data, supports a major role for the renin-angiotensin system 
(RAS) in sex-related differences. Yet, there are no sex-specific recommendations 
for antihypertensive therapy, nor is there currently any evidence that men and 
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women respond differently to RAS blockers. One retrospective study in patients 
with heart failure claimed a higher efficacy of ACE inhibitors in males, and of 
AT1 receptor blockers in females.27 Although this potentially supports the 
importance of AT2 receptor stimulation in women, large prospective studies are 
warranted to confirm such claims.   
 
 
 
 
 
 
 
 
87 
 REFERENCES 
1. Verdonk K, Danser AHJ and van Esch JHM. Angiotensin II type 2 receptor agonists: 
where should they be applied? Expert Opin Investig Drugs. 2012;21:501-13. 
2. Hilliard LM, Mirabito KM and Denton KM. Unmasking the potential of the 
angiotensin AT2 receptor as a therapeutic target in hypertension in men and women: 
what we know and what we still need to find out. Clin Exp Pharmacol Physiol. 
2013;40:542-50. 
3. Baiardi G, Macova M, Armando I, Ando H, Tyurmin D and Saavedra JM. Estrogen 
upregulates renal angiotensin II AT1 and AT2 receptors in the rat. Regul Pept. 
2005;124:7-17. 
4. Sampson AK, Moritz KM, Jones ES, Flower RL, Widdop RE and Denton KM. 
Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial 
pressure attributable to chronic low-dose angiotensin II in female rats. Hypertension. 
2008;52:666-71. 
5. Moltzer E, Verkuil AV, van Veghel R, Danser AHJ and van Esch JHM. Effects of 
angiotensin metabolites in the coronary vascular bed of the spontaneously 
hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation. 
Hypertension. 2010;55:516-22. 
6. You D, Loufrani L, Baron C, Levy BI, Widdop RE and Henrion D. High blood pressure 
reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into 
vasodilation in spontaneously hypertensive rats. Circulation. 2005;111:1006-11. 
7. Batenburg WW, Tom B, Schuijt MP and Danser AHJ. Angiotensin II type 2 receptor-
mediated vasodilation. Focus on bradykinin, NO and endothelium-derived 
hyperpolarizing factor(s). Vascul Pharmacol. 2005;42:109-18. 
8. Batenburg WW, Popp R, Fleming I, de Vries R, Garrelds IM, Saxena PR and Danser 
AHJ. Bradykinin-induced relaxation of coronary microarteries: S-nitrosothiols as 
EDHF? Br J Pharmacol. 2004;142:125-35. 
9. Scotland RS, Madhani M, Chauhan S, Moncada S, Andresen J, Nilsson H, Hobbs AJ 
and Ahluwalia A. Investigation of vascular responses in endothelial nitric oxide 
synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived 
hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation. 
2005;111:796-803. 
10. Arnold AP. Mouse models for evaluating sex chromosome effects that cause sex 
differences in non-gonadal tissues. J Neuroendocrinol. 2009;21:377-86. 
11. Ji H, Zheng W, Wu X, Liu J, Ecelbarger CM, Watkins R, Arnold AP and Sandberg K. 
Sex chromosome effects unmasked in angiotensin II-induced hypertension. 
Hypertension. 2010;55:1275-82. 
12. Xu J, Burgoyne PS and Arnold AP. Sex differences in sex chromosome gene 
expression in mouse brain. Hum Mol Genet. 2002;11:1409-19. 
13. Hilliard LM, Jones ES, Steckelings UM, Unger T, Widdop RE and Denton KM. Sex-
specific influence of angiotensin type 2 receptor stimulation on renal function: a 
novel therapeutic target for hypertension. Hypertension. 2012;59:409-14. 
14. Hilliard LM, Chow CL, Mirabito KM, Steckelings UM, Unger T, Widdop RE and 
Denton KM. Angiotensin type 2 receptor stimulation increases renal function in 
female, but not male, spontaneously hypertensive rats. Hypertension. 2014;64:378-
83. 
15. Silva-Antonialli MM, Tostes RCA, Fernandes L, Fior-Chadi DR, Akamine EH, 
Carvalho MHC, Fortes ZB and Nigro D. A lower ratio of AT1/AT2 receptors of 
angiotensin II is found in female than in male spontaneously hypertensive rats. 
Cardiovasc Res. 2004;62:587-93. 
16. Hilliard LM, Sampson AK, Brown RD and Denton KM. The "his and hers" of the 
renin-angiotensin system. Curr Hypertens Rep. 2013;15:71-9. 
17. Xu J, Sun Y, Carretero OA, Zhu L, Harding P, Shesely EG, Dai X, Rhaleb NE, 
Peterson E and Yang XP. Effects of cardiac overexpression of the angiotensin II type 
2 receptor on remodeling and dysfunction in mice post-myocardial Infarction. 
Hypertension. 2014;63:1251-9. 
18. AbdAlla S, Lother H, Abdel-tawab AM and Quitterer U. The angiotensin II AT2 
receptor is an AT1 receptor antagonist. J Biol Chem. 2001;276:39721-6. 
88 
 19. van Esch JHM, Schuijt MP, Sayed J, Choudry Y, Walther T and Danser AHJ. AT2 
receptor-mediated vasodilation in the mouse heart depends on AT1A receptor 
activation. Br J Pharmacol. 2006;148:452-458. 
20. Batenburg WW, Garrelds IM, van Kats JP, Saxena PR and Danser AHJ. Mediators of 
bradykinin-induced vasorelaxation in human coronary microarteries. Hypertension. 
2004;43:488-92. 
21. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, 
Saxena PR and Danser AHJ. Angiotensin II type 2 receptor-mediated vasodilation in 
human coronary microarteries. Circulation. 2004;109:2296-2301. 
22. Busse R, Edwards G, Félétou M, Fleming I, Vanhoutte PM and Weston AH. EDHF: 
bringing the concepts together. Trends Pharmacol Sci. 2002;23:374-80. 
23. Garland CJ, Hiley CR and Dora KA. EDHF: spreading the influence of the 
endothelium. Br J Pharmacol. 2011;164:839-52. 
24. Batenburg WW, Kappers MHW, Eikmann MJ, Ramzan SN, de Vries R and Danser 
AHJ. Light-induced vs. bradykinin-induced relaxation of coronary arteries: do S-
nitrosothiols act as endothelium-derived hyperpolarizing factors? J Hypertens. 
2009;27:1631-40. 
25. Schunkert H, Danser AHJ, Hense HW, Derkx FHM, Kürzinger S and Riegger GAJ. 
Effects of estrogen replacement therapy on the renin-angiotensin system in 
postmenopausal women. Circulation. 1997;95:39-45. 
26. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC and Banga JD. 
Age at menopause as a risk factor for cardiovascular mortality. Lancet. 
1996;347:714-8. 
27. Hudson M, Rahme E, Behlouli H, Sheppard R and Pilote L. Sex differences in the 
effectiveness of angiotensin receptor blockers and angiotensin converting enzyme 
inhibitors in patients with congestive heart failure--a population study. Eur J Heart 
Fail. 2007;9:602-9. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 SUPPLEMENTAL MATERIAL 
XY
-
Sry
45678910
0
50
100
150
200 Endothelin
Phenylephrine
C
o
n
tr
a
c
ti
o
n
 (
%
 K
+
)
45678910
0
50
100
150
200
-log [Agonist] (mol/L)
C
o
n
tr
a
c
ti
o
n
 (
%
 K
+
)
XX
45678910
0
50
100
150
200
45678910
0
50
100
150
200
-log [Agonist] (mol/L)
XXSry
45678910
0
50
100
150
200
45678910
0
50
100
150
200
-log [Agonist] (mol/L)
XY
-
45678910
0
50
100
150
200
45678910
0
50
100
150
200
-log [Agonist] (mol/L)
A B C D
E F G H
+GDX +GDX +GDX +GDX
 
Supplemental Figure. Contractions of iliac arteries, obtained from FCG mice (XY-Sry males, XX females, XXSry males, and XY- females) 
before (top panels) or after (bottom panels) gonadectomy, to endothelin-1 or phenylephrine. Contractions (mean±SEM of n=3-10) have been 
expressed as a percentage of the response to 100 mmol/L K+. 
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 ABSTRACT 
Modulation of the renin-angiotensin system, in particular of the function of 
the hormones angiotensin II and angiotensine-(1-7), is an important target 
for pharmacotherapy in the cardiovascular system. In the classical view, 
such modulation affects cardiovascular cells to decrease hypertrophy, 
fibrosis, and endothelial dysfunction, and improves diuresis. In this view, 
excessive stimulation of angiotensin II type 1 receptors fulfills a detrimental 
role, as it promotes cardiovascular pathogenesis, and this is opposed by 
stimulation of angiotensin II type 2 and the angiotensin-(1-7) receptor coded 
by the Mas proto-oncogene. In recent years, this view has been broadened 
with the observation that the renin-angiotensin system regulates bone 
marrow stromal cells and stem cells, thus involving hematopoiesis and 
tissue regeneration by progenitor cells. This change of paradigm has 
enlarged the field of perspectives for therapeutic application of existing as 
well as newly developed medicines that alter angiotensin signaling, and now 
stretches beyond cardiovascular therapy. In this article we review the role of 
angiotensin II and angiotensin-(1-7) and their respective receptors in 
hematopoietic and mesenchymal stem cells, and discuss possible 
pharmacotherapeutical implications. 
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 GENERAL INTRODUCTION 
Angiotensin II versus angiotensin-(1-7) 
The renin-angiotensin system (RAS) is a major regulator of renal and 
cardiovascular function and plays a central role in the homeostasis of the 
cardiovascular system and of the hydro-electrolyte balance.1 For a long 
period, research was focussed on production and signaling of angiotensin II 
(Ang II), highlighting angiotensin-converting enzyme (ACE) and renin with 
respect to production, and the angiotensin II type 1 receptor (AT1 receptor) 
with respect to signaling of Ang II. Since Ang II is an important player in 
unfavourable remodeling of cardiovascular tissue, ACE inhibitors (ACEi), AT1 
receptor blockers (ARB) and renin inhibitors are successfully used in 
treatment of cardiovascular disease, and novel tools to further optimize 
intervention in the RAS are being developed.1  
In the past two decades these optimization efforts resulted in the 
identification of novel therapeutic targets within the RAS, including the Ang 
II type 2 receptor (AT2 receptor),2 angiotensin-(1-7) (Ang-(1-7)) and its G-
coupled receptor Mas,3 and angiotensin-converting enzyme 2 (ACE2),4,5 
which is important for Ang-(1-7) formation. An increasing amount of 
evidence shows that Ang-(1-7) is one of the most important hormones of the 
RAS.6 In the cardiovascular system, Ang-(1-7) mainly has opposite actions as 
compared to Ang II, leading to a dichotomy in the RAS, namely the 
proliferative, prothrombotic and vasoconstrictor actions of Ang II versus the 
anti-proliferative, anti-thrombotic and vasodilator actions of Ang-(1-7).7 Ang-
(1-7) can be formed directly from Ang II by ACE2, but also from Ang I. As 
ACE metabolizes Ang-(1-7), ACEi treatment increases Ang-(1-7) levels, and 
this is believed to play an important role in beneficial cardiovascular effects 
of ACEi.7,8 As an alternative, improvement of Ang-(1-7) formation by ACE2 is 
now under consideration as a novel cardiovascular therapy.9 Similarly, 
stimulation of AT2 receptor, a receptor for both Ang II and Ang-(1-7), often 
opposes AT1 receptor signaling, and this principle is being explored for 
cardiovascular therapy with specific AT2 receptor agonists.10 
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 Stem cells: general features and clinical use 
At the same time that novel pharmacological tools within the RAS are being 
found for cardiovascular therapy, a novel target tissue for RAS intervention 
has been identified, namely the bone marrow (BM) and other sources of stem 
cells and progenitor cells. These cells can either be hematopoietic stem cells 
(HSC) or hematopoietic progenitor cells (HPC), or can be mesenchymal stem 
cells (MSC), also called multipotent stromal cells. Many articles use the term 
HSC for cells that are in a very early stage of phenotypic development, still 
allowing differentiation towards diverse lineages, and that may have a 
potential for self-renewal. HPC is then used for cells that are further 
differentiated, and have lost the potential for self-renewal. HSC and HPC 
form cells of the erythroid, myeloid, or lymphoid lines (Fig. 1). Since the 
boundaries between these two hematopoietic populations are not always 
clear, we will here use the term HSC for both populations. Endothelial 
progenitor cells (EPC) and fibrocytes are special HPC types that are involved 
in angiogenesis and fibrosis respectively. MSC have been identified as cells 
that can form a plethora of non-hematopoietic cells, including 
cardiomyocytes, smooth muscle-like cells, renal cell types, connective tissue 
cells, neural cells etc. (Fig. 2). MSC are most abundantly present in BM, fat 
tissue and dental pulp, but can also be present in tissues such as the 
myocardium and the subintima or adventitia of large arteries. Accordingly, 
these cells are under investigation as a tool for tissue regeneration of any 
imaginable kind. Since both HSC, MSC and isolated whole bone marrow are 
interesting for tissue repair, all three sources have been used for cardiac and 
vascular repair. Other precursor cells that may potentially be used for this 
purpose are embryonal stem cells or induced pluripotent stem cells.11 These 
cells can either serve as sources for novel cardiomyocytes or angiogenic cells, 
or act as paracrine cells that favourably affect cardiac remodelling or 
vascular repair. Several clinical studies have been performed with 
autologous BM-derived stem cells showing moderately improved cardiac 
performance in cardiac ischemic diseases.12,13 As to yet, it is not clear which 
stem cell type and which preparation and infusion method gives the best 
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 results, and this is an important research goal. A second important goal is 
upgrading of the stem cells’ abilities to perform its reparative function. For 
this purpose, diverse strategies are being studied,11 and, as will become clear 
from the present review, pharmacological intervention in the RAS may be 
one of them.   
RAS and stem cells: general implications 
The notion that the RAS is involved in regulation of bone marrow and stem 
cells, and in particular hematopoiesis and erythropoiesis, was generated 
already shortly after the introduction of ACE inhibitors in the clinic when in 
1982 two independent groups observed that a high dose of ACE inhibition 
causes anemia and leucopenia.14,15 Later, the presence of all major RAS 
components in BM cells, including stromal cells, HSC / HPC and MSC, was 
confirmed. This led to the concept of a potential autocrine-paracrine 
mechanism for local RAS-mediated regulation of hematopoiesis.16 Another 
important reason to study effects of angiotensins and RAS-modulating 
medicines on BM-derived cells is that in the case of cardiovascular disease 
where RAS modulation is indicated as a treatment, stem or progenitor cells 
are under investigation for application in tissue regeneration, in particular of 
the vascular bed and the myocardium.17-27 Furthermore, inflammation and 
fibrosis have been identified as important targets for RAS modulation, and 
these processes may be related to regulation of HSC and MSC, as will be 
explained later in the article. Dedicated studies have now provided clear 
evidence that ACE-, Ang II / AT1 receptor and Ang-(1-7) / Mas receptor 
activity is involved in hematopoiesis as well as in the formation of 
cardiovascular cells and other somatic cell types from progenitor cells.28  
In the present article we will review the role of Ang II, Ang-(1-7) and 
their respective receptor / signaling pathways in propagation and 
differentiation of HSC and MSC, and discuss possible clinical implications. 
Furthermore, for more extensive discussions regarding ACE substrates and 
metabolites other than Ang II and Ang-(1-7) we refer to previous reviews.29,30 
The present review contains two summarizing figures: Fig. 1 depicts effects 
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 of Ang II and Ang-(1-7) on hematopoietic stem cells and derived progenitors; 
Fig. 2 summarizes effects on mesenchymal stem cells. In addition, we 
provide a table (Table 1) that summarizes beneficial vs. detrimental effects of 
the main angiotensin receptors with respect to cardiovascular disease. 
THE ROLE OF ANG II AND ANG-(1-7) IN HEMATOPOIESIS 
Erythropoiesis 
Soon after the initial studies that uncovered that manipulation of ACE 
activity interfered with erythropoiesis, it became clear that the role of the 
RAS in erythropoiesis is very complex, being involved in virtually every step 
between the hematopoietic stem cell and the fully differentiated erythrocyte. 
When looked at in further detail it was shown that the stimulation of AT1 
receptor increased formation of early erythroid progenitors; an effect that 
requires the presence of erythropoietin.31 Also, genetic manipulation leading 
to overactivity of AT1a receptors in mice results in an increase of 
hematocrit.32 Conversely, AT1 receptor knockout mice show a decrease of 
hematocrit values when compared with wild-type animals.33 The stimulatory 
role of AT1 receptors in erythropoiesis has clinical implications: like ACEi, 
ARB treatment was reported to reduced erythropoiesis in healthy persons, 
and also in patients undergoing hemodialysis.34 
The mechanism of Ang II-mediated regulation of erythropoesis is 
largely unclear. Most of its effects are exerted in the early phases of 
erythropoiesis.31,34 Some authors imply that Ang II acts indirectly via its 
influence on erythropoietin levels,35 or erythropoietin sensitivity,36 while 
others do not observe a link between erythropoietin and Ang II in 
erythropoiesis.37,38 A possible second messenger system via which Ang II 
could be affecting erythropoiesis is the Jak-STAT pathway, which is known 
to be stimulated by Ang II,39 and to be vital in the erythrocyte-stimulating 
action of erythropoietin.40 
Since Ang-(1-7) is degraded by ACE, the anemic effect of ACEi might 
be due to changed Ang-(1-7) levels. However, it was shown that Ang-(1-7) 
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 stimulated erythroid burst-forming units (BFU-E) cultured from mice that 
were treated with the myelosuppressive agent 5-fluorouracil, and reduced 
anemia in breast cancer patients after chemotherapy.41,42 These findings 
suggest that Ang-(1-7) stimulate erythropoiesis, and should counteract the 
anemic effect of ACEi. Apparently, this does not happen, and the question 
remains how important Ang-(1-7) is for erythropoiesis. 
General effects of Ang II on hematopoiesis of white blood cells 
Leucopenia induced by a high dosage of ACE inhibitors as observed early 
after introduction of ACEi15 was an indication that the RAS may be involved 
in the formation of white blood cells (WBC) by HSC. In agreement, genetic 
ablation of ACE in mice leads to perturbations in myelopoiesis, which can be 
reliably recapitulated with ACE inhibition.43 When focusing the attention on 
Ang II, it has been shown that Ang II induces the proliferation of mouse bone 
marrow and human cord blood HSC in vitro. This Ang II effect is elicited in 
part through stimulation of Lin- BM stromal cells and partly mediated by the 
direct stimulation of HSC in the presence of colony stimulating factor 
(CSF).44 AT1 receptors mediate this Ang II effect because losartan blocks it, 
and the presence of AT1 receptor in both HSC and stromal cells is compatible 
with the dual pathway.44 Furthermore, Ang II/AT1 receptor signaling 
promotes the monocyte colony stimulating factor (M-CSF)–mediated 
differentiation/proliferation of BM monocyte-lineage cells. 
Through these general mechanisms Ang II can contribute to regulation 
of WBC hematopoiesis. Strictly spoken, however, AT1R signaling doesn't 
seem to be of great importance for hematopoiesis under normal physiological 
conditions: ACE-KO mice show a block in terminal granulopoiesis which 
leads to a reduction of segmented neutrophils. Monocytes and macrophages 
are at normal levels in ACE-KO and AT1-KO mice, although they are to be 
functionally immature.30,43,45 This would correspond to the fact that ARB 
treatment does not reduce WBC levels. However, as observed recently,30 
under hematopoietic stress Ang II / AT1 receptor signaling has readily visible 
effects. This is noticed for instance after chemotherapy or irradiation, where 
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 Ang II infusion improves the repopulation of bone marrow with HSC cells, 
and thus accelerates restoration of WBC counts. It is with these 
circumstances in mind that the next section, in which we deliberate specific 
HSC subtypes, has to be read.   
Role of Ang II in specific subtypes of white blood cell precursors  
As already indicated, important data on the role of Ang II in regulation of 
HSC comes from studies that explored the restoration of WBC populations 
after irradiation or chemotherapy in animal models. Under such 
circumstances, in vivo Ang II infusion leads to accelerated restoration of total 
blood leucocytes, lymphocytes and platelets, and to increased granulocyte 
macrophage colony forming units (GM-CFU), granulocyte erythroid 
megakaryocyte macrophage colony forming units (GEMM-CFU) and BFU-E 
in in vitro expanded bone marrow cells.46 Therefore, Ang II has a rather 
broad spectrum when it comes to stimulation of HSC. This is in accordance 
with the observation that in the early development of HSC to WBC, i.e. in 
CFU cultured under pan-lineage conditions, Ang II has a proliferative 
effect.30 
This proliferative effect is lost when cells are further differentiated due 
to culturing in lineage-specific media, containing granulocyte-macrophage 
colony-stimulating factor (GM-CSF) with macrophage colony-stimulating 
factor (M-CSF) or granulocyte colony-stimulating factor (G-CSF).43 When the 
HSC has passed the stage of myeloblast, pharmacological or genetically-
induced interruption of AT1 receptor or ACE activity delays myeloid 
differentiation rather than proliferation, as witnessed by an increase in the 
myeloblast / early myelocyte marker CD11b and a decreased development of 
macrophage and neutrophil markers.43 This was observed in vivo in the 
absence of hematopoietic stress. Furthermore, AT1 receptor blockade also 
leads to the decreased differentiation towards dendritic cells of human 
monocyte or murine BM cell cultures.47 AT2 receptor stimulation counteracts 
this AT1 receptor effect. Accordingly, the summed effect of these Ang II 
functions is an accelerated general increase in leucocytes during 
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 hematopoietic stress, and more subtle qualitative changes in populations of 
mature leucocytes, which can be seen in the absence of hematopoietic stress.  
Similar to erythropoiesis, Ang II does not seem to have a stand-alone 
effect in development of WBC, but rather plays a facilitating role, as observed 
during CFU-GM and CFU-GEMM formation. In absence of colony stimulation 
factors (SCF, GM-CSF, IL-3 and EPO) no growth effect of Ang II on these 
colonies was observed, but in their presence, Ang II dose-dependently 
increased CFU-GM and CFU-GEMM formation.44 The factors that are needed 
to allow an Ang II effect are released by Lin- BM stromal cells.44 Also, in the 
absence of M-CSF, cultured BM cells of AT1 receptor KO and WT mice 
showed no difference in myeloid progenitors and promonocytes.45 However, 
the increase of these cell types that finds place upon stimulation with M-CSF 
was attenuated in AT1 receptor KO vs. WT. The facilitating role of Ang II on 
M-CSF was shown to be due to TNF-alpha release from stromal cells which 
increases expression of C-Fms, the receptor for M-CSF, in HSC.45 
Apart from stimulating the myeloid path of hematopoiesis Ang II 
affects the lymphoid development. AT1 receptor stimulation appears to 
promote inflammatory activation of lymphocytes. In addition, Ang II infusion 
leads to a shift of CD4+ T cells (T helper) from Th2 to Th1, which leads to 
increased production of pro inflammatory cytokines (IFN-gamma, IL-2, and 
tumor necrosis factor-beta). Blockade of AT1 receptors decreased this shift 
and led to reduced infiltration of tissues by activated macrophages and T-
cells.48 
Based on the mild effects of ACE/AngII/AT1 receptor on WBC 
population in the absence of hematopoietic stress, it seems that the major 
part of the effect of RAS modulation on inflammation is mainly caused by its 
effects that do not directly relate to hematopoiesis. Ang II is known to induce 
monocyte recruitment to the vascular wall and to stimulate these monocytes 
to release various inflammatory cytokines. It also increases production of 
reactive oxygen species (ROS) which in turn stimulate NF-kappaB signaling 
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 leading to a proinflammatory phenotypes in various cell types. These 
processes are reviewed in detail in other publications.49,50 
The role of Ang-(1-7) in HSC regulation 
The effects of Ang-(1-7) on hematopoiesis are documented in several articles 
and are, in short terms, similar to the effect of Ang II. Ang-(1-7) stimulates 
recovery from irradiation and chemotherapy by increasing proliferation of 
HSC and multi-lineage hematopoietic progenitors.42,46,51 In NOD/SCID mice 
the engraftment and proliferation of human mononuclear cells was increased 
in mice receiving Ang-(1-7) treatment, which also increased numbers of 
differentiated cells of myelomonocytic and B cell lineages.52 Like for Ang II, 
Ang-(1-7) effects are readily visible during hematopoietic stress, but not so 
evidently under normal physiological circumstances. This is reflected in a 
recent study in which toxicological studies with Ang-(1-7) infusion did not 
show apparent effects on blood variables.53  
The role of angiotensin receptor subtypes for Ang-(1-7) effects on 
hematopoiesis has not been investigated. However, our own studies in which 
we used isolated BM mononuclear cells (BM-MNC) from rat and mice, 
suggest that Mas receptors are mediating the proliferative effect of Ang-(1-7) 
on HSC.29,54 Since these tests were done under conditions that promote the 
development of endothelial progenitor cells, they do not provide conclusive 
evidence.  
Endothelial progenitor cells 
Whereas a modest number of studies have addressed the relationship 
between HSC and RAS, some more intensive research has been done on 
endothelial progenitor cells (EPC).28,29 EPC are a special type of HSC or MSC-
derived progenitor cells that develop endothelial-like features in specific 
culturing conditions, and that have been implicated in endothelial repair and 
vasculogenesis.55,56 Vasculogenesis is the formation of new blood vessels 
from progenitor cells such as hemangioblasts, as opposed to angiogenesis, in 
which new vessels originate from sprouting of pre-existing ones. 
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 Vasculogenesis takes place during embryogenesis, but it has been proposed 
that it can also occur during adulthood, which would involve EPC.57  
EPC starting as HSC in the bone marrow are being intensively studied. Their 
recruitment as HSC from the bone marrow to the circulation involves stress-
induced stromal-derived factor-1 (SDF1), which activates proteases that 
degrade the adherence proteins that bind HSC to endosteal cells. 
Subsequently, HSC can migrate to the circulation. Once arrived in the 
vascular lumen they can home as angiogenic monocytes and macrophages 
that pre-process the tissue that requires neovascularization or endothelial 
repair, or as EPC that will form the new endothelium.58 Thus, the process of 
vasculogenesis involves various hematopoietic cell types with varying 
progenitor, myeloid and endothelial cell markers, complicating the 
identification of “true EPC”.28 This identification can either be based on 
immunohistological staining for stem cell and endothelial membrane 
markers, followed by flow cytometry, or by culturing of BM- or blood-derived 
MNC in specialized endothelial culture medium and subsequent colony 
observation or (immuno)histochemical staining. A simple histochemical 
staining for cultured angiogenic cells is combined acetylated low density 
lipoprotein uptake (Ac-LDL uptake; a feature of phagocytotic monocytes, 
macrophages and endothelial cells) with binding to lectin from Bandeiraea 
(Griffonia) simplicifolia-1 (BS1) or Ulex europaeus (Ulex europaeus agglutinin-I: 
UEA-1).55 More specific EPC markers, for cultured as well as freshly obtained 
cells processed for flow cytometry, combine stem cell surface markers c-Kit, 
Sca-1 and CD133 with an endothelial cell (EC) surface marker (e.g. CD34 or 
Flk-1 (mouse equivalent for human kinase domain receptor (KDR) or VEFG 
receptor 2 (VEGFR-2)). With respect to culturing methods, in vitro 
propagation of blood-derived MNC distinguishes early EPC and colony-
forming unit endothelial cells (CFU-EC/CFU-Hill) on the one hand from late 
EPC (comprising outgrowth endothelial cells (OEC) and endothelial colony 
forming cells (ECFC)) on the other hand.57,59-63  Early EPC and CFU-Hill are 
found from 2 days until 3 weeks of culture and might be more related to 
angiogenic monocytes and macrophage since they show low proliferation and 
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 tube formation capacity. Late EPC, appearing from 3 weeks up until 12 
weeks of culture could represent true EPC, displaying highly proliferative 
and tube formation capacity. For further critical reviewing of EPC selection 
criteria we refer to previous publications.28,64,65 
Although the identity of true EPC and their permanent incorporation 
into repaired and newly formed vessels is still a matter of debate, it is evident 
that the various “EPC” contribute to the vascular regeneration and repair 
processes, and thus bear clinical relevance.28,29 In addition, EPC plasma 
levels have been used as a biologic marker for vascular function and 
cumulative cardiovascular risk. It has been shown that the number of CFU-
Hill correlate with brachial endothelial function, measured as reactive 
hyperemia, arterial calcification, with Framingham risk score, and with 
several cardiovascular risk factors.61,66,67 Quantification of cultured EPC 
might be a rather laborious method for prognostic purposes. Instead, 
circulating EPC can be measured with flow cytometry, using CD34 alone or 
in combination with a marker expressed by endothelial cells, often KDR. As 
such, CD34+KDR+ cell levels were shown to be associated with coronary 
artery disease, outcome after angioplasty, and traumatic brain injury, 
although peripheral arterial calcification only correlated with colony number 
of cultured EPC.67-70 In a direct comparison between cultured EPC and 
quantitation with flow cytometry, both methods show association of EPC 
levels with coronary artery disease, but only cultured EPC are predictive for 
progression of the disease.71 Also, an increase of these markers is associated 
with beneficial effects of RAS intervention, as reviewed earlier.28 The use of 
EPC as a standard risk marker in cardiovascular disease is however still 
remote for the daily practice. Hence, EPC remain under investigation for 
regenerative, angiogenic therapy in organs after ischemic events and as a 
prognostic marker during pharmacotherapy directed against vascular 
disease. Since RAS intervention is often used in those cases it is important 
to characterize the effects of angiotensins on EPC.  
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 Role of Ang II, AT1 receptor and AT2 receptor in EPC 
Although the identity of true EPC is still a question28 many studies have 
confirmed the role of angiogenesis-associated progenitor cells, whether they 
are mobilized from BM to peripheral blood or isolated, cultured and re-
injected, in endothelial regeneration, and neovascularization.72 The 
fundamental parts of these processes bear relationship with Ang II signaling 
through AT1 and AT2 receptors. AT1 receptor stimulation can lead to pro-
angiogenic effects and recruitment of EPC, but on the other hand the 
stimulation can reduce EPC proliferation and function. These paradoxical 
effects can be explained from acute as compared to chronic AT1 receptor 
signaling. Acute Ang II signaling is pro-angiogenic. In EPC, this pro-
angiogenic effect depends on NADPH oxidase activation and enhanced VEGF 
anti-apoptotic function through upregulation of VEGF type 2 receptors and 
improved NO release, as well as on PI3/Akt signaling.73-75 The deleterious 
effects of Ang II arises from chronic stimulation, and consists of two 
consecutive phases.76 In the first phase, taking place between day 2 and 5 of 
stimulation of EPC with Ang II, AT1 receptor-mediated increase of NADPH 
oxidase activity leads to ASK-1 – JNK/p38 MAPK – Bax/Bcl2 signaling-
induced apoptosis involving caspase 3.77 The second phase, which is noticed 
from day 5 and onward, involves production of cytotoxic levels of ROS 
leading to cellular senescence.78,79 As a result, chronic treatment with Ang II 
decreases human and mouse EPC numbers and function.68,77-80 Employing 
AT1 receptor KO MNC and BM transplant in wild type and ApoE KO mice, it 
was shown that AT1 receptor signaling affects vascular repair function and 
thus promotes atherogenesis.77 As commented in detail earlier, it is still a 
question if these in vivo vascular effects solely depend on EPC, or involve an 
interplay with inflammatory cells or even BM stromal cells.76 
The role of Ang-(1-7) / Mas receptor signaling in EPC 
Ang-(1-7) was shown to improve endothelial vasodilator and eNOS function 
in various studies.81-94 Although some of these effects depend on the acute 
activation of eNOS or inhibition of NADPH oxidase,95-97 others may point to a 
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 potential role of Ang-(1-7) in endothelial regeneration. Such a role was 
suggested by the observation that Ang-(1-7) improved the recovery of 
HSC,41,42,46 from which EPC are derived. Therefore, dedicated studies to 
explore Ang-(1-7) effects on EPC were performed.54 In adherent rat or mice 
BM-MNC cultures, which most likely resemble early EPC, 7 days of 
treatment with Ang-(1-7) increased AcLDL/lectin-positive cells, which were 
found to be positive also for VEGF type 2 receptors. Mas receptor signaling is 
an important mediator of the stimulatory effect of Ang-(1-7) on BM-MNC and 
EPC because the effect disappeared when Mas receptor signaling was 
prohibited by genetic ablation of Mas or treatment with A779. AT2 receptors 
did not seem to play a role.29 The in vitro stimulatory effect of Ang-(1-7) on 
EPC can explain why we found that in vivo infusion of the peptide in mice 
with myocardial infarction led to an increase in VEGF+ and c-kit+ cells in 
the heart.54 Since local cardiac overexpression of Ang-(1-7) peptide did not 
lead to such an effect, we hypothesized that BM-derived, angiogenesis-
related progenitor cells were recruited to the heart. This potential 
mechanism as well as the consequences for myocardial angiogenesis 
remains to be characterized.   
Several other questions regarding angiogenesis need to be clarified as 
well. Firstly, Ang-(1-7) can also inhibit angiogenesis in vivo 98-101 and tends to 
inhibit in vitro tube formation by human umbilical cord vene endothelial cells 
(HUVEC).102 This principle is now under investigation in the context of 
application of Ang-(1-7) as an anti-cancer therapy.100,103 There can be several 
explanations for such a discrepancy with our findings on EPC. First, it can 
relate to differences in cell types, i.e. EPC versus adult endothelial cells. 
Second, the inhibitory Ang-(1-7) effect on tube formation by HUVEC was not 
dose-dependent, and involved Mas receptors as wells as AT1 receptors.102 
Since these were acute responses, the inhibitory effect of Mas receptors on 
AT1 receptor signaling104 might have inhibited angiogenesis. However, this 
explanation only works if one presumes the presence of spontaneous AT1 
receptor signaling or a paracrine / autocrine RAS. Third, in the sponge 
model for angiogenesis and after tumor implantation the anti-angiogenic 
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 response might involve effects on surrounding cells that produce angiogenic 
factors. The myocardium in our experiments may respond differently to Ang-
(1-7) with respect to the release of angiogenic factors as compared to the 
tissue that surrounds sponges or tumours. In fact, there is evidence that 
tumour angiogenesis markedly differs from that in normal tissues, as 
extensively reviewed elsewhere.105 Fourth, the Ang-(1-7) concentration and 
its relation to the duration of the stimulus may be important. In acute 
studies, such the mentioned study in HUVEC,102 Ang-(1-7) might simply 
display the usual opposite effect Ang II. Instead, our studies in cultured 
MNC and EPC employed chronic stimulation, and again Ang-(1-7) appear to 
be opposite of the Ang II effect, i.e. stimulatory vs. inhibitory. Looking in 
better detail, we found a bell-shaped concentration-dependent effect of a 7-
day Ang-(1-7) treatment, given every 2 days, with a maximal response 
between 10-9 and 10-8 mol/L.54 Similarly, pretreatment with 10-8 mol/L Ang-
(1-7) stimulated porcine BM-MNC to increase tube formation, whilst higher 
concentrations seem to reduce this ability.106 This observation prompts 
another explanation. Recently, it was discovered that Ang-(1-7) leads to Mas 
receptor internalization.107 A continuous presence of Ang-(1-7) concentration 
of 1 nM and higher might induce permanent Mas receptor internalization, 
thus abolishing Mas receptor signaling. This could in turn even promote 
chronic AT1 receptor signaling, thus reducing EPC. Alternatively, Ang-(1-7) 
might be diverted to AT2 receptors, which would suppress angiogenesis.108 
Since Ang-(1-7) is rapidly degraded in the presence of serum,109 the presence 
of Mas receptors at the cell membrane might be warranted when intermittent 
administration of the peptide is used, even at concentrations that are slightly 
higher than 1 nmol/L. 
Regardless of the here mentioned reasons for the paradoxical effects of 
Ang-(1-7) on EPC as compared to angiogenesis, it is clear that in the 
development of pharmacotherapy based on EPC stimulation by Ang-(1-7) it 
will be important to dissect the diverse signaling pathways. This concerns 
both the exploration of the differential function of these pathways as well as 
the development of optimal pharmacotherapy. 
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 Improvement of EPC recruitment with ARB and ACEi. 
The in vivo effects of ARB on EPC generally correspond well with the effects 
that would be predicted from the functions of Ang II and Ang-(1-7) as 
observed in animal or cell culture studies. ARB treatment in animal studies 
raises EPC levels during hypertension,110-112 after nephrectomy113 or 
myocardial infarction,114 in atherosclerosis models,115 and in the ischemic 
hindlimb model.116,117 Although the situation in animal models may quite 
differ from the clinical presentation of patients, the effects of ARB on EPC 
from animals and patients correlate rather well. In patients with type II 
diabetes, ARB treatment alone or as a part of multiple drug therapy was 
proposed to exerts its beneficial cardiovascular effects by increasing the 
number of regenerative EPCs.118,119 In accordance with this idea, ARB 
treatment increased EPC counts, angiogenic factors and endothelial 
vasodilator function in normotensive patients with coronary artery 
disease.120 Similarly, ARB increase EPC in patients with acute coronary 
syndrome.121 The ARB treatment also promotes an increase in EPC levels in 
kidney transplant patients.122 A special role might be performed by 
telmisartan, a combined ARB / PPAR-γ agonist. The PPAR-γ might have 
additional value when stimulation of EPC is concerned,123,124 as was 
discussed in detail in previous reviews.28,29 Together, the data suggest that 
in animal models as well as in patients ARB treatment increases EPC levels, 
thus preserving the endothelium. It seems logical to ascribe these beneficial 
effects to a decrease of EPC apoptosis and senescence caused by excessive 
Ang II / AT1 receptor signaling. 
ACEi have been shown to have beneficial effects in cardiovascular 
disease that are believed to be related to EPC function.61,68,125-130 However, 
the actual number of patient studies that explored effects of ACEi on EPC is 
very limited. ACEi increased the levels, proliferation, migration, adhesiveness, 
and tube formation of EPC that were cultured from blood of patients with 
coronary artery disease.80 In patients with acute coronary syndrome ramipril 
increased circulating EPC as measured by flow cytometry, and its effect on 
EPC was nearly identical to that of ARB telmisartan.121 Very recently, two 
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 studies appeared that claim a stimulatory effect of ACEi on EPC of patients 
with hypertension and acute coronary syndrome, although the 
characterisation of EPC in these studies is limited.131,132 In agreement with 
clinical studies, ACEi increase EPC in several animal models.114,116,117,133,134 
These effects may involve various factors other than angiotensin metabolism, 
as amply discussed elsewhere.28,29 
Differentiation of HSC into fibrocytes 
Fibrocytes are CD34+, CD45+, or CD133+ bone marrow-derived circulating 
cells that co-express collagen I or smooth muscle actin.135 They are derived 
from hematopoietic cells and related to monocytes, and infiltrate organs to 
establish fibrosis. In models of renal fibrosis AT1 receptor mediates increased 
bone marrow fibrocytes, increased renal infiltration and stimulates collagen I 
production in cultured fibrocytes. AT2 receptor counteracts these effects. 
Recruitment of fibrocytes to the kidney involves CXCL16, a ligand for the 
receptor CXCR6.136 However, it is not certain if this relates to Ang II 
signaling. 
With respect to cardiac remodeling, it was shown that Ang II infusion 
promotes cardiac fibrosis through the recruitment of fibrocytes in mice.137,138 
Since chemokine (C-C motif) receptor 2 (CCR2) KO abrogated the Ang II 
effect, the chemokine (C-C motif) ligand (CCL2), also known as monocyte 
chemotactic protein-1 (MCP-1), is apparently required for Ang II-induced 
fibrocyte recruitment. Blood pressure is not involved, since CCR2 knockout 
did not change this variable. MCP-1 is an important stimulator of monocytes, 
dendritic cells and T cells, and therefore these data show an important 
relationship between inflammatory response and Ang II-induced fibrosis. It 
should be noted, however, that the recruitment of fibrocytes by Ang II to the 
myocardium is not necessarily detrimental. CCR2 knockout, which ablates 
this Ang II effect, leads to less fibrosis, but also to an exaggerated ventricular 
dilatation and a worsened systolic function. The fibrotic response seems to 
provide the necessary matrix to support the hypertrophied myocardium.137 
Therefore, to obtain clinical benefit from suppression of Ang II-induced 
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 fibrosis one should also prevent myocardial hypertrophy to avoid myocardial 
dilation, which is detrimental. 
Mesenchymal stem cells from bone marrow 
Mesenchymal stem cells are non-hematopoietic progenitor cells that are able 
to form many diverse cell types, amongst which cells with features of 
adipocytes, cardiomyocytes, fibroblasts, endothelial cells vascular smooth 
muscle cells and renal cells, which all bear relevance for cardiovascular 
disease and therapy. They are found in many different tissues, including the 
bone marrow. Given the pluripotency of MSC these cells may play a role in 
diverse physiological and therapeutical processes. We here outline the role of 
RAS in various of these processes. 
Cardiomyocyte formation from MSC 
BM-MSC were shown to be able to develop cardiomyocyte features through 
reprogramming of the genetic program by in vitro treatment with 5-
azacytidine, a DNA-demethylating agent.139 This finding was an important 
step towards the principle that autologous MSC transplantation could be 
used for cardiac repair, and led to clinical trials. Meta-analyses have shown 
that the small trials conducted thus far show only limited benefit, which has 
prompted novel research on optimization of stem cell therapy.140,141  
Optimization studies include issues like cell type that is used, number of 
grafted cells, moment of injection, but also the effect of pharmacological 
modulation, including RAS components. Ang II was shown to promote 
differentiation of rat BM-MSC to cardiomyocytes in vitro, and have an 
additive effects to 5-azacytidine.142 Thus, Ang II treatment might reduce the 
culture time of BM-MSC allowing earlier grafting of the differentiated 
cultures.  
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 Figure 1: Diagrammatical 
representation of the effects of Ang II 
(blue lettering) and Ang-(1-7) (green 
lettering) on hematopoietic cells. The 
direction of the effect of Ang II, Ang-
(1-7) or angiotensin receptor 
stimulation is indicated with “+”, 
being stimulatory, or “-”, being 
inhibitory. The involved receptor, if 
known, is mentioned between curved 
brackets: (AT1R) = AT1 receptor 
signaling; (AT2R) = AT2 receptor 
signaling. Straight black arrows 
indicate effects on differentiation or, 
when specifically indicated, on 
maturation. Cell cycle diagrams 
indicate a proliferative effect. Curved 
arrows originating from stromal cells 
represent paracrine effects. Digits 
between square brackets refer to the 
articles that directly shows the 
angiotensin effect. 
 Further characterisation of the involved receptor subtypes came from a 
study in which human BM-MSC (Yub623) were stimulated to differentiate to 
cardiomyocytes by co-culturing on murine cardiomyocytes for 2 weeks.143 
Various ARB’s were shown to equally improve BM-MSC differentiation, apart 
from telmisartan that had additional effectiveness because of its pleiotropic 
actions as a PPAR-γ agonist. The effect was independent from the co-
cultured murine cells. AT2 receptor antagonist PD123319 alone was without 
effect, but it reduced the effect of candesartan. Since also Ang II alone did 
not stimulate differentiation in this study, unless given together with 
candesartan, it was concluded that the differentiation of BM-MSC to 
cardiomyocytes was mediated through AT2 receptors. Because ACE 
inhibition mimicked ARB effects a local RAS in BM-MSC was proposed, as 
was to be expected from previous PCR studies on rat BM-MSC.16 However, 
the fact that renin inhibitor aliskiren was without effect in human BM-MSC 
suggests that not all RAS components may be present in relevant amounts 
in those cells. Therefore, it cannot be excluded that ARB’s, when given in the 
absence of exogenously applied Ang II, might have unknown pleiotropic 
effects, especially when applying the high concentration (3 µmol/L) used in 
this particular study. 
The Ang II-induced differentiation of BM-MSC to cardiomyocytes 
theoretically is in accordance with the observation that Ang II stimulates 
cardiac extracellular matrix remodelling through recruitment of fibrocytes.137 
In the context of physiological remodelling these effects of Ang II would be 
complementary to each other if there is a need for increased myocardial 
mass, for instance to improve physical performance, because they would 
provide a balanced increase of myocytes and extracellular matrix. Such a 
remodeling would beneficially influence cardiac performance. Whether Ang 
II-induced BM-MNC differentiation into cardiomyocytes occurs, as well as 
the question if this is in balance with fibrocyte recruitment, remains to be 
investigated in models for physiological cardiac remodelling. An exaggerated 
AT1 receptor-mediated response may, however, cause stiffening of the 
myocardium and relative ischemia, a concept that fits in the general 
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 paradigm of pathological remodelling due to high blood pressure or ischemia. 
Blockade of AT1 receptor binding of Ang II and concurrent redirection of Ang 
II towards AT2 receptors would inhibit this detrimental response, because it 
restores the equilibrium between differentiation of MSC into fibrocytes and 
cardiomyocytes.  
ARB treatment can also be combined with BM-MSC grafting. Indeed, 
in the rat myocardial infarction model it was shown that pretreatment of 
BM-MSC with ARB improved the therapeutic effect of BM-MSC grafting on 
systolic heart function.143 This was further improved by oral administration 
of ARB. However, oral ARB intake combined with non-pretreated BM-MSC 
grafting did not have an additive effect compared to the single ARB treatment. 
Therefore, pretreatment of BM-MSC with ARB or AT2 receptor agonists may 
be the most optimal condition for cardiac repair. It should be noted however 
that BM-MSC that are injected for cell therapy in the myocardium are only 
transiently present, as observed in mice, and the fusion with resident 
cardiomyocytes might be poor.144 This has favoured the concept that BM-
MSC are therapeutic primarily due to a paracrine function.145 Therefore, it is 
important to explore these paracrine factors and the impact of RAS 
modulation thereupon. 
Neural repair 
Similar to cardiac ischemia, BM-MSC grafting has been tested for brain 
ischemia.146 In the mouse mid-cerebral artery occlusion (MCA) model, BM-
MSC grafting improved survival, ischemic lesion volume, neurological score 
and cerebral edema. Cerebral blood flow and TNFα measurements suggest 
that reduction of inflammation rather than a pro-angiogenic effect is 
responsible for the effect of BM-MSC grafting. BM-MSC from AT2 receptor KO 
mice, however, did not improve neurological variables, and even showed a 
trend to worsen survival. Pretreatment with the ARB valsartan restored the 
survival effect of BM-MSC grafting. These results imply that AT1 receptor 
signaling, when not counteracted by AT2 receptor, is detrimental for BM-
MSC repair function. ROS-mediated pro-inflammatory AT1 receptor signaling 
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 could be the provocative stimulus in the case where AT2 receptor KO cells 
seem to worsen the outcome. Since AT2 receptor signaling results in NF-
kappaB-mediated neural repair and neural differentiation of embryonic stem 
cells through stimulation of methyl methanesulfonate-sensitive 2 
release,147,148 it would be worthwhile to study if these mechanisms are also 
involved in BM-MSC grafting. 
BM-MSC grafting is believed to represent a new intervention technique 
for patient with stroke,149,150 and AT1 receptor blockade might provide 
further improvement. Pretreatment of mice with valsartan in a dose without 
a blood pressure effect led to comparable improvement of neurological score 
and better blood flow than BM-MSC grafting.146,151 Other ARB show 
comparable results to valsartan.152 Further neuroprotective effects of ARB 
were shown in hypertensive patients, who show less stroke-related events 
when ARB treatment was applied, leading to a better prognosis.153 In acute 
stroke, animal models also show improved recovery with ARB treatment.154-
156 However, in patient studies of acute stroke ARB treatment was not at all 
effective, showing even a tendency towards adverse effects, which might 
relate to a hypersensitivity of the patients towards blood pressure 
lowering.156,157 Therefore, optimization of RAS treatment in acute ischemia 
might benefit from (pre)clinical research to interaction with endogenous as 
wells as grafted BM-MSC. 
Adipogenesis 
Adipogenesis, the formation of fat tissue, is importantly implicated in 
metabolic syndrome and cardiovascular risk. As extensively reviewed 
elsewhere.158,159 Adipose tissue contains a complete RAS needed for Ang II 
production and signaling. The physiological importance of this local RAS 
extends to the entire organism, contributing to both local and systemic 
regulation of RAS. This is believed to contribute to obesity, diabetes, 
metabolic syndrome and cardiovascular disease. The adipose tissue can be 
roughly divided in two compartments, the visceral and the subcutaneous 
adipose tissue. Adipose tissue can form part of normal physiology as an 
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 energy storage compartment. This healthy fat tissue contains small insulin-
sensitive adipocytes that store fat until use as an energy source. These cells 
produce anti-inflammatory effectors, such as adiponectin. Adipose tissue 
can also be related to diabetes and metabolic syndrome, and in this case is 
featured by the occurrence of large insulin-resistant adipocytes.160 These 
large adipocytes release pro-inflammatory factors amongst which TNF-α, a 
key player in insulin resistance, diabetes and metabolic syndrome. Obesity 
is associated with large adipocytes and an activated adipose tissue RAS, and 
it is believed that obesity thus contributes to cardiovascular disease.158  
Adult adipocytes may arise from two sources: pre-adipocytes in the fat 
tissue and MSC from various sources, including the bone marrow. In pre-
adipocytes the role of Ang II and its respective receptors is matter for a 
complicated debate that involves culture  conditions, type of adipogenic 
stimulus, phase of differentiation, etcetera.161,162 A feasible concept of Ang II-
mediated dysregulation of adipogenesis in diabetes and metabolic syndrome 
is that AT1 receptor stimulation prevents insulin-induced differentiation of 
pre-adipocytes into adult small adipocytes, and that as a consequence the 
pool of large adipocytes increases.163 Compared to research in pre-adipocytes, 
research in MSC differentiation to adipocytes is relatively young. It was 
shown that human BM-MSC cultured under adipocyte-inducing conditions, 
all key Ang II-related RAS components are expressed. Thus, Ang II seems to 
enhance differentiation into adipocytes through AT1 receptors in an 
autocrine fashion.161 This effect is inhibited by AT2 receptor. Since 
expression of AT2 receptor is rather high in MSC that are cultured under the 
given conditions, the blockade of adipogenesis by AT2 receptors was readily 
visible when the antagonist PD123319 was added. However, since 
exogenously given Ang II mimicked the AT2 receptor-mediated blockade of 
differentiation, AT1 receptor signaling is dominant when only the locally 
produced Ang II is present.  
Given the complicated manner in which AT1 receptor and AT2 receptor 
signaling is involved in differentiation of MSC and pre-adipocytes, as well as 
the question what fate will fall upon MSC with respect to formation of small 
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 vs. large adipocytes, it is in this moment hard to establish the importance of 
BM-MSC differentiation in therapeutic effects of RAS modulation. Further 
studies will require BM-MSC-specific RAS component knockout cell culture 
or mouse models, as was previously suggested also for adipose tissue.158 
Culturing conditions and metabolic status will be important issues in such 
studies. 
The importance of Ang-(1-7) / Mas axis in adipose tissue is only 
beginning to be uncovered. Ang-(1-7) and ACE2 are present in adipose 
tissue,164,165 and ACE2 is regulated by dietary fat.165 Also, Ang-(1-7) and the 
Mas receptor were reported to have an impact on fat and glucose metabolism, 
adiponectin levels and on insulin sensitivity of adipocytes.166,167 Moreover, 
the peri-aortic fat may play a role in Ang-(1-7)-induced vasodilations.168 
Therefore, research to the role of Ang-(1-7) in BM-MSC differentiation into 
adipocytes is warranted. 
MSC with vascular smooth muscle cell traits 
Vascular smooth muscle-like cells can be derived from both BM stem cell 
pools as well as MSC populations present in the adipose tissue. In mouse 
studies it was shown that Ang II stimulates the expression of typical smooth 
muscle cell markers in cultured adherent BM-MNC and MSC from adipose 
tissue through AT1 receptors.169,170 Similar results were obtained with MNC 
derived from peripheral blood of rabbits.171 In adipose tissue MSC it was 
shown that this effect is mediated by TGF-β receptor stimulation and 
subsequent Smad2 and ERK activation.170 Replacement of wildtype with 
GFP-labeled BM in mice showed that GFP-positive α-smooth muscle cell 
actin (α-SMA) -positive cells incorporated in the neointima of damaged 
femoral arteries of wild-type C57bl/6 mice.169 The recruitment of such cells 
was stimulated by Ang II infusion, and inhibited by AT1 receptor blockade. 
Since neointima formation followed a similar pattern it was concluded that 
Ang II-induced differentiation of BM progenitors to vascular smooth muscle 
cells (VSMC) contributes to neointima formation. Indeed, BM-derived cells 
that express typical VSMC markers had been implicated in neointima 
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 formation before.172,173 In ApoE KO mice with LacZ-positive BM it was shown 
that local vascular production of SDF1α, a ligand for chemokine (C-X-C 
motif) receptor type 4 (CXCR4) that is important for chemoattraction of 
various BM-derived cells, plays a central role in homing of the VSMC-like 
cells to the neointima. Recently, a study that explored the effect of 
replacement of normal with AT1 receptor KO BM in wild-type mice showed a 
connection between Ang II and SDF1α signaling.174 AT1 receptor KO led to 
diminished plasma levels and neointimal incorporation of Lin- BM-derived 
progenitor cells, and decreased neointima formation. Although no specific 
VSMC markers were used in this study it was proposed that lack of AT1 
receptor signaling leads to decreased VSMC progenitor recruitment. This 
seemed to depend on decreased SDF1α release by local platelets at the site of 
injury due to the absence of AT1 receptor signaling in those platelets. 
Therefore, AT1 receptor signaling may affect neointimal homing of VSMC-like 
cells from BM in two ways: through increased differentiation of progenitor 
cells into VSMC-like cells and attraction of progenitor cells through 
stimulation of platelet-derived SDF1α. 
It should be noted, however, that VSMC-like progenitor cells may not 
undergo complete differentiation into adult vascular smooth muscle cells. 
Some studies show that, when injected in the ischemic myocardium, BM 
stem cells / BM-MSC with VSMC traits are not incorporated in vessels.175,176 
Indeed, in earlier studies it was suggested that mesenchymal stem cells 
develop a smooth muscle cell-like contractile apparatus to form myoid cells 
that use this apparatus in their function to support hematopoiesis of 
inflammatory cells.177 Interestingly, it was recently shown that BM-derived 
cells that incorporate into neointima and atherosclerotic lesions and express 
α-SMA are also expressing monocyte/macrophage markers.178 Therefore, 
VSMC-like cells originating from the BM, and perhaps also from adipose 
tissue, may play a pro-inflammatory role, rather than that they represent a 
pool of progenitor cells that will permanently differentiate into adult VSMC. 
This might explain why we found that all BM-derived cells in neointima after 
stenting expressed inflammatory cell markers.179 The importance of such 
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 cells may of course be significant: the effect of Ang II on stimulation of the 
development of the VSMC-like cells that support or possess traits of 
inflammatory cells may be another example of the versatility of this peptide 
as a pro-inflammatory factor. Exploration of the role of AT2 and Mas 
receptors on these cells would be of great interest. Also of importance is 
further exploration of the link with SDF1α-CXCR4 signaling in pro-
atherogenic environments, since blockade of this pathway in inflammatory 
cells leads to increased plaque formation in ApoE KO mice,180 which is in 
sharp contrast with the earlier discussed decrease of neointima formation in 
injured arteries of wild-type mice.174 It is essential to discover how these 
contrasting findings would translate to AT1 receptor blockade effects in a 
clinical setting. Finally, α-SMA expression in MSC might be part of a 
transition towards development of connective tissue.181  
Renal progenitor cells 
BM-derived progenitor cells may play a role in the remodeling of renal tissue. 
About a decade ago it was shown, with the help of replacement of wild-type 
BM with GFP+ BM in mice, that BM-derived cells incorporate into the 
glomerular mesangium of the kidney.182 GFP+ mesangial cells increased over 
time after BM replacement, suggesting a long lasting, if not permanent 
residence of these cells. Although some of these cells express macrophage 
and lymphocyte markers, a large part of these cells do not appear to be 
leucocytes. Like MSC these cells express α-SMA, and therefore might 
represent pools of mesangial cells that contribute to glomerular vasomotor 
control. In accordance with this idea, isolated and cultured GFP+ cells 
contracted upon exposure to Ang II.182 
 Another α-SMA-expressing cell type that is associated with the 
glomerulus is the juxtaglomerular cell, present at the intersection of the 
distal convoluted tubule and the afferent arteriole of the glomerulus. These 
cells contain renin granules that can be release in reaction to low blood 
pressure or low filtrate osmolarity. The resulting increase in Ang II 
production causes normalization of blood pressure and filtrate osmolarity. It 
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 was recently shown that BM-MSC can develop into renin-expressing 
granular cells that resemble juxtaglomerular cells, and that subsequently 
start to increase α-SMA-expression.183 This process is under the control of 
liver x receptor α (LXRα) stimulation. This observation has shifted the 
paradigm of the origin of juxtaglomerular cells from being a VSMC-derived 
cell towards a MSC-derived cell that actually develops VSMC-like features in 
a later phase of differentiation. Perhaps even, a part of the BM-derived GFP+ 
glomerular cells that were observed in the fate-tracking experiment in mice 
might have developed in juxtaglomerular cells, but this was not explicitly 
explored.182 Since the VSMC-like features develop relatively late during MSC 
differentiation it is tempting to speculate that this phenotype is a result of 
autocrine Ang II signaling following renin upregulation. Thus, Ang II might 
contribute to the development of cell types that release renin, control 
glomerular blood flow or both. This in turn would implicate an involvement 
in hypertension and renal disease.  
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 Figure 2: Diagram showing effects of Ang II (blue lettering) on 
mesenchymal stem cells. The direction of the effect of Ang II or 
angiotensin receptor stimulation is indicated with “+”, being 
stimulatory on either differentiation, proliferation, or use in 
regenerative therapy. The involved receptor is mentioned 
between curved brackets: (AT1R) = AT1 receptor signaling; 
(AT2R) = AT2 receptor signaling. Square brackets indicate 
references that directly show the Ang II (receptor) effects. 
Clinical implications or possible applications are mentioned in 
boxes. 
 
 GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
There is a growing body of evidence that Ang II and Ang-(1-7) can affect 
proliferation and differentiation of BM-HSC and BM-MSC. The observed 
effects imply that RAS modulation in these cells can be used to inhibit 
cardiac, vascular and renal fibrosis as well as neointima formation, to 
improve renal function, to improve blood pressure control and organ 
perfusion, and to induces cardiac and renal repair. Beyond the 
cardiovascular system, RAS modulation in these cells can beneficially 
influence adipogenesis, neural repair, connective tissue formation, and 
wound healing, but foremost, stimulation of the Ang-(1-7) / Mas signaling 
axis is now under evaluation as an anti-cancer therapy with the combined 
benefit of improving hematological recovery after chemotherapy or irradiation. 
For a large part, signaling mechanisms remain to be investigated, especially 
in relation to the stage of differentiation  of HSC and MSC, to the culture 
conditions (in vitro) or surrounding tissue (in vivo), and to the 
pathophysiological context. Such information might lead to more refined 
pharmacotherapy, while novel drugs for stimulation of specific angiotensin 
receptor subtypes are already being developed. 
With respect to these novel drugs, the emerging ACE2/Ang-(1-7)/Mas 
receptor axis-oriented drugs are of particular interest. Since Ang-(1-7) 
promotes post-chemotherapy or –irradiation hematopoiesis in the absence of 
a pressor effect, the peptide is now under evaluation for hematological 
recovery of cancer patients. This already involves clinical trials with TXA127, 
an Ang-(1-7)-containing drug formulation.184 The paradoxical effect of Ang-
(1-7) on angiogenesis and its potential dependency on a delicate balance in 
stimulation of specific receptor subtypes was discussed. Several attempts 
have been made to specifically improve Ang-(1-7) signaling, for example 
through infusion of cyclodextrin-enveloped Ang-(1-7)185 or increased ACE2 
expression.186 Even more specific are the non-peptide analogue CGEN-856S 
187 or the thioether-bridged Ang-(1-7) analogue called cyclic Ang-(1-7),188,189 
which are specific Mas receptor agonists. Infusion of cyclic Ang-(1-7) has 
shown promise in rat models as an intervention for acute respiratory 
119 
 syndrome or after myocardial infarction.190,191 It will be of major interest to 
perform comparative studies on native Ang-(1-7) versus these specific Mas 
receptor agonists, and to unravel their effects on EPC and other progenitor 
cells. 
 As discussed, the AT2 receptor is importantly involved in Ang II effects 
on progenitor cells. Through its effect on HSC and MSC, AT2 receptor 
stimulation may have beneficial effects on fibrosis by inhibiting fibrocyte 
development, prevention of heart failure by promoting myocardial 
regeneration, and improvement of neural repair. Therefore, the design of AT2 
receptor agonists may be an important development. Currently, two agonists 
are being explored, the non-peptide drug Compound 21 (C21) and Ang II 
with single β-amino-acid substitutions.10,192 C21 has shown promise in the 
rat model of myocardial infarction by improving systolic and diastolic 
function, and by anti-apoptotic and anti-inflammatory effects.193 Also it was 
found that C21 alone or in combination with losartan may improve 
endothelial function and vascular composition; by reducing oxidative stress, 
collagen content, fibronectin, and inflammatory cell infiltration in stroke-
prone spontaneously hypertensive rats.194 The development of β-amino-acid 
Ang II analogues awaits further in vivo characterisation, with respect to 
pharmacokinetic aspects as well as therapeutic effects. Interaction with stem 
cell therapy is certainly one of the most relevant issues that can be 
addressed in further studies with these AT2 receptor agonists. 
Another relevant goal for future research is further characterisation of 
α-SMA-expressing cells types formed by MSC in response to Ang II. It will be 
important to study the relation between tissue localization and culture 
conditions and the final phenotype and function that such cells will assume, 
which comprises VSMC, connective tissue and neointimal cell types, pro-
inflammatory cell types, mesangial cells or juxtaglomerular cells. Without 
any doubt this feature of Ang II-AT1 receptor signaling will play a role in 
clinical effects of RAS modulation on arterial and renal remodelling, and 
perhaps on blood pressure control. Futhermore, the formation of connective 
tissue cells from MSC is being explored for application in tissue engineering 
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 related to wound healing and repair of cartilage.195 This may represent a 
novel research field in which to explore the role of RAS. It will be a major 
challenge to chart the versatile effect of Ang II, and possibly also other 
angiotensins, such as Ang-(1-7), on this route of MSC differentiation.  
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Table 1. Summary of beneficial or detrimental effects of angiotensin receptor signalling effects in bone marrow stem cells. 
 HSC MSC 
  beneficial detrimental beneficial detrimental 
 
 
 
 
AT1 receptor 
 
 
 
 
Improves HSC proliferation 
under hematopoietic 
stress46 
 
 
Pro-angiogenic EPC 
stimulation 74,75 
 
 
 
 
 
 
 
EPC apoptosis 
and senescence 
77-79  
 
Fibrocyte-related 
fibrosis 135,137,138  
 
 
 
 
 
 
 
 
 
Neointima formation or 
inflammation by VSMC-like 
progenitor cells 169-171 
 
Promotes adipocyte formation 
161  
 
Inhibits cardiomyocyte 
formation 143 
 
Inhibits neural repair by MSC 
after brain ischemia 146 
 
 
 
AT2 receptor 
Counteracts fibrocytes 135  Promotes cardiomyocyte 
formation 142,143  
Inhibits adipocyte 
formation 161 
Improved neural repair 
by MSC after brain 
ischemia 146 
 
Ang-(1-
7)/Mas 
receptor 
Improves HSC proliferation 
under hematopoietic stress 
41,42,46,51  
Increases early EPC 54 
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 ABSTRACT 
Background: Angiotensin-(1-7) improves cardiac function and remodelling 
after myocardial infarction (MI). This may involve recruitment of hematopoietic 
progenitor cells that support angiogenesis. However, angiotensin-(1-7) is 
rapidly metabolised in plasma and tissue. Here we investigated in mice the 
effect of a metabolically stable angiotensin-(1-7) analogue, cyclic angiotensin-
(1-7), 1) on progenitor cell recruitment and 2) on the heart post-MI, when given 
in the angiogenesis phase of remodelling. 
Methods and results: Angiogenic progenitor cell recruitment was measured by 
flow cytometry 24h and 72h after a daily bolus injection of cyclic angiotensin-
(1-7) in healthy C57BL/6 mice. Furthermore, mice underwent MI or sham 
surgery, and subsequently received saline or 2 different doses of cyclic 
angiotensin-(1-7) for 3 or 9 weeks.  
Cyclic angiotensin-(1-7) increased circulating hematopoietic progenitor 
cells at 24h but not 72h. Post-MI, cyclic angiotensin-(1-7) diminished 
cardiomyocyte hypertrophy, and reduced myogenic tone, without altering 
cardiovascular function or cardiac histology at 9 weeks. Importantly, cyclic 
angiotensin-(1-7)-treated mice presented reduced cardiac capillary density at 3 
weeks after MI, but not after 9 weeks. Finally, cyclic angiotensin-(1-7) 
decreased tube formation by cultured HUVECs.  
Conclusions: Our results suggest that cyclic angiotensin-(1-7), when given 
early after MI, recruits progenitor cells, but does not lead to improved 
angiogenesis, most likely because it simultaneously exerts anti-angiogenic 
effect in adult endothelial cells. Apparently, optimal treatment with cyclic 
angiotensin-(1-7) depends on the time point of onset of application after MI.   
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 INTRODUCTION 
The renin-angiotensin system (RAS) is a major physiological regulator of blood 
pressure and volume homeostasis and consequently it is involved in the 
pathogenesis of cardiovascular diseases.1 The classical treatment of heart 
failure and hypertension is directed at inhibition of the angiotensin II (Ang II)-
producing enzymes renin and angiotensin-converting enzyme (ACE), and of the 
Ang II type 1 (AT1) receptor. In an attempt to further optimize pharmacological 
RAS modulation, alternative intervention strategies have emerged and among 
them stimulation of angiotensin-(1-7) (Ang-(1-7)) function is one of the most 
attractive.2 Ang-(1-7) is generated by ACE2. By stimulating its own receptor, 
the AT1-7/Mas receptor,3 Ang-(1-7) exerts anti-fibrotic, anti-proliferative, anti-
thrombotic, and anti-hypertensive effects, i.e., effects that generally oppose 
those of Ang II. . 
 The beneficial effects of Ang-(1-7) or ACE2 upregulation in cardiovascular 
tissue are well-documented. In rat models, Ang-(1-7) infusion or ACE2 
overexpression preserves cardiac and endothelial function in heart ischemia 
and failure, prevents renal and cardiovascular anomalies in hypertension and 
diabetes, and exerts protective effects in cardiopulmonary disease.3-8 A779, a 
Mas receptor antagonist, blocks Ang-(1-7)-stimulated collagen production in 
cardiac cells and attenuates the antihypertensive and antiproteinuric effects of 
captopril and hydralazine.9-11 After myocardial infarction (MI), Ang-(1-7) 
prevented endothelial dysfunction12 and alterations in the structure and 
hemodynamic function of the heart.13 The anti-hypertrophic effect of Ang-(1-7) 
was also observed in rats displaying cardiac hypertrophy following 
isoproterenol exposure.13 In-vitro, the hypertrophic effect of isoproterenol was 
blocked by AVE-0991, an Ang-(1-7) receptor agonist.14 Moreover, Ang-(1-7) 
increases the formation of endothelial progenitor cells from bone-marrow (BM)-
derived hematopoietic cells through AT1-7/Mas receptors in vitro as well as 
cardiac endothelial growth-factor-positive (VEGF+) cells in vivo in a mouse MI 
model,15 and promotes tube formation in cultured pig BM-derived angiogenic 
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 cells at low concentrations.16  Studying the Ang-(1-7) – AT1-7/Mas receptor 
axis is therefore a crucial point for improving cardiac function and remodeling, 
in particular in relation to neovascularization.  
 Although beneficial effects of Ang-(1-7) have been observed in animal 
models of cardiovascular disease, its native form also stimulates AT1 receptors 
at high concentrations and is rapidly metabolized in tissue and plasma.3 
Consequently, Ang-(1-7) may not be optimal for use in patients. Hypothetically, 
cyclic Ang-(1-7) (cAng-(1-7)), an Ang-(1-7) analogue that is resistant to 
metabolism and acts as a specific agonist for AT1-7/Mas receptors, is a more 
promising compound for clinical cardiovascular therapy.17 We recently showed 
beneficial effects of 8-week treatment of cAng-(1-7) on endothelial function and 
cardiac remodeling on MI rat model,18 suggesting that cAng-(1-7) is a promising 
new agent in treating MI. In this study and our seminal study with native Ang-
(1-7),12 therapy was started 2 weeks after induction of MI. This might not be 
the optimal time point for stimulation of angiogenesis by recruitment of 
progenitor cells, which, in patients, takes place in the first week after MI.19 
Moreover, in the previous study with cAng-(1-7) the animals did not develop 
heart failure, possibly due to too small infarct size. Therefore, it is still not 
known if cAng-(1-7) can prevent heart failure, which remains a therapeutic 
challenge. On the basis of all previous data, we hypothesize that cAng-(1-7) will 
recruit angiogenic progenitor cells, and will improve cardiac neovascularization 
thereby suppressing early remodelling and preventing heart failure.  
METHODS 
Animal studies 
Male wild-type C57Bl/6 mice were put on standard mouse chow and water, 
available ad libitum. Housing was at room temperature with a 12h light - 12h 
dark cycle. After at least one week of acclimatization in the caretaking facility, 
the mice either underwent a sham procedure or coronary ligation to induce left 
ventricular MI. Osmotic minipumps (model 1004, Alzet) were implanted 
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 subcutaneously immediately after surgery for MI and the mice received saline, 
5µg/kg/day (cAng-(1-7)-5) or 50µg/kg/day of cAng-(1-7) (cAng-(1-7)-50) 
continuously. For the 9 weeks group the animals were divided in sham, saline 
and 2 doses of cAng-(1-7) and for the 3 weeks groups we focused on the 
highest dose of cAng-(1-7)  (50µg/kg/day of cAng-(1-7)) only. cAng-(1-7) was 
provided by Lanthiopharm BV, Groningen, the Netherlands and Tarix 
Pharmaceuticals, USA. After 3 or 9 weeks, hemodynamic function was 
measured with a 1F pressure-volume catheter (PVR-1035, Millar) under 
isoflurane anaesthesia.20 To measure the effect of cAng-(1-7) on progenitor cell 
recruitment, two studies were performed in non-infarcted male wild-type 
C57Bl/6 mice, the first enabling us to get an impression of the time frame of 
effects and to make a comparison to native Ang-(1-7), and the second to 
confirm possible effects at the most relevant time point. In the first study, mice 
(n=4/group) received daily subcutaneous injections of saline, cAng-(1-7) 
(50µg/kg), or native Ang-(1-7) (500µg/kg). After 24h or 72h, the mice were 
euthanized and blood and bone-marrow were collected for fluorescence-
activated cell sorting (FACS) analysis. Since in the first study cAng-(1-7) tended 
to increase c-kit-, Sca-1- and Flk-1-positive cells after 24 hours in blood, in the 
second study we focused on cAng-(1-7) (50µg/kg) effects vs. saline after 24 
hours, and increased the n-number to 13/group. For both the first and second 
study, the percentage of progenitors in the total pool of mononuclear cells was 
first assessed.  Data were normalized by expressing them as % of the mean % 
of the saline-treated animals.21 All animal studies were performed according to 
Dutch guidelines and approved by the institutional animal care committee. 
Cardiac histology 
The hearts were collected and fixed in 4% paraformaldehyde solution. After 
fixation, the slices were dehydrated and paraffin-embedded. Gomori’s staining 
was used to visualize individual cardiomyocytes. Only transversally cut cells in 
the surviving myocardium of the left ventricle showing a nucleus were used to 
determine the cardiomyocyte area. Sirius-red staining was used to determine 
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 MI size and fibrosis. Fibrosis was scored outside the infarction and infarction 
border zone. Cardiac vascular density was assessed by Lectin staining 
(Isolectin B4 (BSI-B4), L5391, Sigma). Briefly, endogenous peroxidase was 
blocked with 0.3% hydrogen peroxide, and the lectin antibody was diluted in 1% 
bovine serum albumin in PBS were applied and incubated overnight at 4◦C. 
Positive staining was visualized using diaminobenzidine, and nuclei were 
counterstained with haematoxylin. Negative controls were obtained by omitting 
the antibody from the incubation procedure. 
Table 1: Animal data. 
  Animals BW(g) HW/BW (mg/g) 
 
3 weeks 
treatment 
Sham 7 27.84±2.65 4.14±0.27 
MI+saline 5 27.44±2.73 4.98±0.73 
MI+cAng-(1-7)-50 8 26.50±1.62 5.69±0.60* 
     
 
9 weeks 
treatment 
Sham 12 30.38±3.50 4.45±0.67 
MI+saline 12 30.59±1.66 4.88±0.62 
MI+cAng-(1-7)-5 9 30.22±1.91 5.16±0.72 
MI+cAng-(1-7)-50 8 30.26±1.85 5.05±0.64 
     
Data are expressed as mean ± SD. HW: heart weight, BW: body weight. MI + cAng-(1-7)-5: 
infarcted animals treated with 5µg/kg/day of cAng-(1-7). MI + cAng-(1-7)-50: infarcted animals 
treated with 50µg/kg/day of cAng-(1-7). *p<0.05 vs Sham group (1-way ANOVA followed by 
Dunnett’s post hoc test).  
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 Vascular function 
Thoracic aortic endothelial function was measured by Mulvany myograph as 
described previously.18 Briefly, mice thoracic aortas (diameter ~800µm) were 
cut in ring segments of ~2 mm length. The aortic rings were mounted in 
Mulvany myograph organ baths and pre-incubated for 30 minutes after which 
tension was normalized by adjusting the diameter length to 90% of the length 
at which the equivalent of 100 mmHg blood pressure is reached. Subsequently, 
acetylcholine (Ach) concentration-response curves were constructed after 
preconstriction with U46619 (100 µmol/L).  
Myogenic tone 
Mesenteric arteries were used to determine the myogenic tone as described 
previously.22 Briefly, each pressure level from 20 to 160 mmHg was maintained 
for 5 min, and the vessel diameter was then measured. Myogenic tone was 
expressed as [(D1 − D2)/D1]·100, where D1 is the difference in diameter between 
consecutives pressure points in Ca2+-free buffer and D2 is the difference in 
diameter in Ca2+-containing buffer. 
FACS analysis 
Mononuclear cell suspensions (~2x107 cells/mL) of blood and BM were 
obtained by density centrifugation using Lympholyte-Mouse (CL5030, 
Cedarlane). Isolated cells were incubated with antibodies against Flk-1 (VEGF-
R2, Ly-73, 560070, BD Pharmingen), c-kit (CD117, 553869, BD Pharmingen), 
Sca-1 (Ly6A/E, 553335, BD Pharmingen), following a previously used protocol 
that avoided overlap with Lin- cells in the dot plots.21 Flow cytometric analysis 
with a mononuclear gate was performed on a FACSCanto or BD LSR II (BD 
Biosciences). Data analysis occurred with the help of Flowjo and Infinicyte 
software. 
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 Figure 1. FACS analysis 
results of blood samples (A, 
B, C, and D)  and bone 
marrow (E, F, G, and H) 
from non-infarcted animals 
treated with saline or cAng-
(1-7) for 24h. A and E, 
percentage of hematopoietic 
progenitor cells (c-kit 
positive cells). B and F, 
percentage of positive cells 
for stem cells markers (Sca-
1). C and G, percentage of 
double positive cells for Sca-
1 and c-kit markers. D and 
H, percentage of positive 
cells for EPC marker (Flk-1 
positive cells). cAng-(1-7): 
non-infarcted animals 
treated with 50µg/kg/day of 
cAng-(1-7). Data have been 
expressed as a percentage 
of the mean % in saline-
treated animals (see 
Methods section). 
Percentages of measured 
cells out of total 
mononuclear cells in saline-
treated mice  were 0.24%, 
2.00%, 0.20%, and  0.005% 
in blood samples versus 
1.03%, 1.75%, 0.46%, and 
0.08% in bone marrow 
samples for the c-kit, Sca-1, 
Flk-1, and Sca-1/c-kit 
double-positive cells 
respectively.  *p<0.05 vs. 
saline (1-way ANOVA 
followed by Dunnett’s post-
hoc test).  
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 Endothelial tube formation 
Primary cultures of human umbilical vein endothelial cells (HUVEC) were 
cultured in EGM-2 medium (Lonza). Cells from passages 4 to 7 were used 
throughout the study. 15-well μ-slides (Ibidi GmbH) were coated with 10 μL of 
Matrigel (Cell Biolabs). To analyze the effect of cAng-(1-7) on endothelial tube 
formation in vitro, 3x103 and 6x103 cells per well were incubated with 10-10 to 
10-7 M of cAng-(1-7) for 6 h. The total number of tubes was measured using CL 
Vision32 software (Clemex Analyse).  
Statistical analysis 
The results are expressed as mean±SD. One-way analysis of variance (ANOVA) 
followed by correction for multiple comparisons with post-hoc tests was used to 
compare the groups. Differences in concentration-response curves to ACh were 
tested by general linear model for repeated measures. P<0.05 was considered 
significant.  
RESULTS 
FACS analysis of progenitor cells   
After a 24h treatment with cAng-(1-7), levels of cells positive for Sca-1 were 
significantly increased in blood samples of non-infarcted animals, and c-kit-
positive cells also tended to increase (Fig. 1A, B). Double-positive cells were 
also significantly increased at this time point (Fig. 1C). In contrast, at 24h, 
cAng-(1-7)-treated animals presented no effects on levels of cells positive for the 
endothelial marker Flk-1 (Fig. 1D). No triple-labeled cells were observed, most 
likely due to the already very low amounts of Sca-1/ckit double-positive and 
Flk-1 single positive cells. Furthermore, after cAng-(1-7) treatment for 72h, the 
Flk-1-, c-kit- and Sca-1-positive cell levels were no longer different from those 
in saline-treated mice (Supplemental Material Fig. S1). In bone marrow, at 24h 
after injection, cAng-(1-7) treatment tended to decrease c-kit-single-positive 
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 cells, but none of the cell types changed significantly. Native Ang-(1-7) did not 
change progenitor cell levels (n=4; data not shown). 
 
Figure 2. Histological 
analysis of ventricular 
cardiomyocyte area on 3 
weeks (A) and 9 weeks 
(B) treated groups. 
Representative pictures 
of sham (C), saline (D) 
and cAng-(1-7)-treated 
animals (E). MI + cAng-
(1-7)-5: infarcted 
animals treated with 
5µg/kg/day of cAng-(1-
7). MI + cAng-(1-7)-50: 
infarcted animals 
treated with 
50µg/kg/day of cAng-(1-
7). *p<0.05 vs. sham (1-
way ANOVA followed by 
Dunnett’s post-hoc test). 
 
 
 
 
Weight relations and histological characteristics 
All animal groups showed similar body weights (BW) during the 3 and 9 weeks 
treatments. However, at 3 weeks, the heart-weight/body-weight ratio (HW/BW) 
tended to be higher in the MI + saline group than in the sham group (p=0.069; 
Table 1). Remarkably, a 3-week treatment with cAng-(1-7)-50 increased this 
ratio even further (Table 1), and results after 9 weeks were similar. However, 
significance was not reached due the small n-number per group. We therefore 
combined all MI animals into one group, and subdivided them according to 
treatment (saline vs. cAng(1-7)). Under those conditions, HW/BW was 
significantly increased after MI, and cAng(1-7) did not alter this. Repeating the 
analysis with tibia length instead of body weight yielded the same result (data 
not shown). However, left ventricular cardiomyocyte area was higher in the MI 
+ saline group than in the sham group, and this difference disappeared in the 
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 presence of cAng-(1-7) (Fig. 2A, B), although the difference between saline and 
cAng-(1-7)-treated MI animals could not be statistically confirmed. Coronary 
ligation led to large infarctions and increased intercellular fibrosis outside the 
infarct area, and both remained unaffected by cAng-(1-7) (Fig. 3). Vascular 
density near the infarcted area did not change after MI (Fig. 4), but tended to 
decrease in the surviving myocardium remote from the infarction area after 
saline treatment (Fig. 4C, not significant) 3 weeks after MI. Treatment with 
cAng-(1-7) led to a further decrease, becoming statistically significant as 
compared to sham-operated controls (Fig. 4C). 9 weeks after MI the differences 
in vascular density had disappeared (Fig. 4B, D).  
 
Table 2: Hemodynamic data after 3 weeks treatment. 
 3 weeks treatment 
  MI 
 Sham saline cAng-(1-7)-50 
Animals 6 4 4 
HR (min-1) 515.60 ± 42.76 534.30 ± 43.17 454.30 ± 84.07 
SV (µL) 10.41 ± 4.54 4.65 ± 1.90* 3.26 ± 1.71* 
CO (mL/min) 5201 ± 2197 2487 ± 978.9* 1883 ± 422.9* 
EF (%) 49.63 ± 20.27 25.47 ± 12.48 19.35 ± 21.67 
Data are expressed as mean ± SD. HR: heart rate. SV: stroke volume. CO: cardiac output. EF: 
ejection fraction. MI + cAng-(1-7)-50: infarcted animals treated with 50µg/kg/day of cAng-(1-7). 
*p<0.05 vs Sham group (1-way ANOVA, Dunnett’s post-hoc). 
 
Hemodynamics  
Both infarcted saline- and cAng-(1-7)-treated groups showed no differences 
with regard to blood pressure versus sham animals (Tables 2 and 3). 
Furthermore, heart rate, end-systolic and end-diastolic pressure, stroke 
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 volume, cardiac output, ejection fraction, and cardiac contractility were not 
altered by MI nor by cAng-(1-7) treatment after 3 weeks (not shown) or 9 weeks 
(Table 3). 
Vascular function and myogenic tone 
The aortic endothelial function was not significantly altered by the infarction 
after 9 weeks and cAng-(1-7) treatment showed no additional effects (Fig. 5A). 
However, pressure-induced contraction of mesenteric arteries tended to be 
enhanced at 9 weeks after MI vs. non-infarcted animals, while cAng-(1-7) 
treatment prevented this effect (Fig. 5B). 
Endothelial tube formation 
HUVEC cultured for 6h formed less tubes in the presence of cAng-(1-7) 
treatment in a dose-dependent manner (Fig. 6: p<0.001 GLM-repeated 
measures for dose). 
DISCUSSION 
In the present study we explored if cAng-(1-7) would be able to improve 
recruitment of angiogenesis-supporting progenitor cells and thus improve 
neovascularization of the surviving myocardium after MI to prevent heart 
failure.  The results show that although cAng-(1-7) can increase circulating 
hematopoietic progenitor cells after 24 hours, the effects lasted only shortly 
and had disappeared after 72 hours. Moreover, neither circulating Flk-1-
positive cells, nor vascular density in the myocardium of infarcted mice 
increased after chronic cAng-(1-7) administration. Rather, vascular density was 
reduced by cAng-(1-7) 3 weeks after MI in the surviving hyperthrophied 
myocardium remotely from the scar tissue, and normalized again at 9 weeks 
after MI. cAng-(1-7) reduced myocyte hypertrophy and prevented the increase 
of peripheral myogenic tone without showing an effect on aortic endothelial 
function. Despite the large infarctions, hypertrophy and increased fibrosis, 
cardiac function was not worsened 9 weeks after MI so that an effect on heart 
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 failure could not be effectively measured. Since myocyte dimensions were 
increased 9 weeks after MI but vascular density was similar to that of sham-
operated animals, the surviving mice had apparently compensated for cardiac 
hypertrophy by increasing neovascularization, thus maintaining proper 
hemodynamic function. Implicitly, this means that cAng-(1-7) delayed 
restoration of vascular density, as observed at 3 weeks post-MI. This is most 
likely due to its anti-angiogenic effect on adult endothelial cells (reduced tube 
formation by HUVECs), its short-lasting (1 day) effect on Sca-1- and c-kit-
positive progenitor cells, and the absence of an effect on Flk-1-positive cells. 
Since cAng-(1-7) demonstrates potentially beneficial effects such as reduction 
of hypertrophy and a decrease of myogenic tone, the compound is still eligible 
for exploration as a drug to prevent heart failure after MI. However, our results 
suggest that it is more optimal to administer cAng-(1-7) after the cardiac 
angiogenesis phase, as we did in our previous studies.12, 18 
The increase of hematopoietic progenitor cells due to cAng-(1-7) is in 
accordance with previous studies showing that Ang-(1-7) analogues improve 
restoration of circulating blood cells in models of hematopoietic stress.23-26 Our 
current results, which do not represent conditions of hematopoietic stress, 
indicate that cAng-(1-7) swiftly recruits progenitor cells causing a tendency of 
lowering of such cells in the bone marrow. Apparently, this recruitment does 
not result in de novo progenitor cell formation, so that the effect is shortlasting. 
We were unable to detect an increase in Flk-1-positive cells. It is therefore 
unlikely that cAng-(1-7) increases hematopoietic cells that support 
angiogenesis. Although our previous study predicted such an effect of native 
Ang-(1-7), showing an increase of cardiac cKit- and VEGF-positive cells,15 
native Ang-(1-7) also has anti-angiogenic properties in HUVEC, and on this 
basis it is now exploited as anti-cancer therapy.27, 28 Conversely, Ang-(1-7) 
analogues have shown beneficial effects on wound repair, which is largely 
dependent on angiogenesis.29 Apparently, HUVEC as a model for tube 
formation might be predictive for tumor and cardiac angiogenesis, but not for 
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 all other vascular beds. An example is stroke, in which native Ang-(1-7) has 
shown benefit, although this was largely contributable to an anti-inflammatory 
effect.30-32 
 
Figure 3. Histological 
analysis of myocardial 
infarction. Myocardial 
infarction area on 3 weeks 
(A) and 9 weeks (B) treated 
groups. Fibrosis on 3 
weeks (C) and 9 weeks (D) 
treated groups. 
Representative pictures of 
sham (E), saline (F) and 
cAng-(1-7)-treted animals 
(G). MI + cAng-(1-7)-5: 
infarcted animals treated 
with 5µg/kg/day of cAng-
(1-7). MI + cAng-(1-7)-50: 
infarcted animals treated 
with 50µg/kg/day of cAng-
(1-7). *p<0.05 vs. sham (1-
way ANOVA followed by 
Dunnett’s post-hoc test). 
**p<0.05 vs. sham (t-test 
followed by Mann-Whitney 
post-hoc test). 
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 Table 3: Hemodynamic data after 9 weeks of treatment. 
 9 weeks treatment 
  MI 
 Sham saline cAng-(1-7)-5 cAng-(1-7)-50 
Animals 10 5 7 7 
HR (min-1) 503.10±36.28 472.30±62.30 488.20±27.84 506.70±20.49 
ESP (mmHg) 79.72±18.78 79.14±24.75 75.63±15.63 90.71±26.07 
EDP (mmHg) 6.60±8.20 8.27±6.77 7.33±8.09 6.18±3.19 
SV (µL) 8.83±2.84 7.06±3.24 10.14±3.95 6.27±2.37 
CO (mL/min) 4584±1679 3441±1871 5012±2069 3190±1233 
EF (%) 42.93±19.42 40.99±9.80 42.65±22.04 43.27±32.50 
dP/dTmax (mmHg/s) 6514±1487 6692±2021 6050±747.1 6090±1495 
dP/dTmin (mmHg/s) -6391±2073 -7170±2046 -5405±1038 -6231±2941 
Data are expressed as mean ± SD. HR: heart rate. ESP: end-systolic pressure. EDP: end-
diastolic pressure. SV: stroke volume. CO: cardiac output. EF: ejection fraction. dP/dT max: 
peak rate of pressure rise. dP/dT min: peak rate of pressure decline. MI + cAng-(1-7)-5: 
infarcted animals treated with 5µg/kg/day of cAng-(1-7). MI + cAng-(1-7)-50: infarcted animals 
treated with 50µg/kg/day of cAng-(1-7). 
 
In the present study we observed a decrease in left ventricular myocyte 
size. This observation is in agreement with our recent study in a rat model in 
which treatment with cAng-(1-7) was started two weeks after MI.18 The 
previous study showed a decrease of HW/BW after cAng-(1-7) treatment. This 
indicates that indeed the effect of the drug is more optimal when started later 
after MI. Still, fibrosis could not be prevented, which is in disagreement with 
effects of native Ang-(1-7) in the DOCA salt, angiotensin II infusion, and 
isoproterenol infusion models of cardiac hypertrophy.33-36 However, these 
models are either blood pressure-dependent, and/or are not based on ischemia, 
or are models of lifetime overexpression of Ang-(1-7), which is not translatable 
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 to clinical use in myocardial infarction. One study applying cyclodextrin-
enveloped Ang-(1-7) shows reduced collagen I mRNA levels, but did not actually 
evaluate fibrosis nor mention the ventricular region that was sampled for PCR 
analysis, which precludes comparison.37 A study with AVE0991, a claimed 
Ang-(1-7) analogue, shows that this drug can reduce fibrosis in infarcted hearts, 
which is partly reversible by A779; however the microphotographs in this study 
confusingly represent the infarcted zone.38 Studies dedicated to effects of 
ischemia-induced fibrosis show that ACE2 overexpression can reduce fibrosis, 
without demonstrating however that this is due to enhanced Ang-(1-7) 
formation.39, 40 Therefore, although ACE2/Ang-(1-7)/Mas stimulation has 
shown promise as an antifibrotic treatment in several conditions41-43 the role of 
Ang-(1-7) in ischemia-induced fibrosis is still unclear. At this point we cannot 
determine if native Ang-(1-7) would be more effective against fibrosis than 
cAng-(1-7). Moreover, MI increases vascular permeability, leading to edema.44 
Since fibrosis and HW/BW were not different after cAng-(1-7) treatment, 
despite the reduced left ventricular myocyte size, it seems reasonable to 
conclude that the increased HW/BW was due to edema.  
In our previous studies in rats we observed improvement of endothelial 
function.12, 18 We were not able to observe this in the present study in mice, 
possibly because of the lack of clear endothelial dysfunction in the aortic 
segments used in the present study. However, we have observed a 
normalization of myogenic tone in mesenteric arteries. It is well known that 
after MI animals can develop an increased myogenic tone, and that blockade of 
AT1 receptors can abolish this increase instantaneously.45 The effect of chronic 
Ang-(1-7) on myogenic tone was never studied before. We show that after MI 
also in the absence of heart failure myogenic tone has a tendency to increase, 
and that after MI the myogenic tone is effectively reduced by chronic cAng-(1-7) 
treatment. Both AT1 receptor signalling as well as myogenic tone are well-
known to be modulated by NO released from the endothelium.45 
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 Figure 4.  Cardiac vascular 
density determined by 
lectin staining. Vessel 
density at infarcted border 
area on 3 weeks (A) and 9 
weeks treated groups (B). 
Vessel density at remote 
myocardium area on 3 
weeks (C) and 9 weeks (D) 
treated groups. 
Representative pictures of 
sham (E), saline (F) and 
cAng-(1-7)-treated animals 
(G). MI + cAng-(1-7)-5: 
infarcted animals treated 
with 5µg/kg/day of cAng-
(1-7). MI + cAng-(1-7)-50: 
infarcted animals treated 
with 50µg/kg/day of cAng-
(1-7). *p<0.05 vs. sham (1-
way ANOVA followed by 
Dunnett’s post-hoc test). 
 
 
 
 
 
 
 
 
 
 
Furthermore, Ang-(1-7) antagonizes Ang II-induced vasoconstrictions in 
organ bath experiments independently from NO when given at concentrations > 
1 µmol/L.46, 47 This can involve inhibition of transactivation of epithelial growth 
factor receptors, which is importantly involved in myogenic tone.48, 49 To our 
knowledge the effect of chronic Ang-(1-7) administration in vivo on ex vivo 
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 vascular responses to Ang II, and its relation to plasma levels, has not been 
evaluated yet. Neither is there any direct evidence for the involvement of Mas 
receptors in myogenic tone. It is therefore not clear how Ang-(1-7)/Mas 
signalling decreases myogenic tone, but this might be a relevant question in 
relation to treatment of cardiovascular disease. 
 
Figure 5. Aortic endothelial 
function and mesenteric 
myogenic tone on 9 weeks 
treated groups. A, 
concentration-response 
curve of U46619-
preconstricted thoracic 
aorta to acetylcholine (Ach) 
on 9 weeks treatment 
groups. B, myogenic tone 
performed on mesenteric 
arteries from animals 
treated for 9 weeks. MI + 
cAng-(1-7)-5: infarcted 
animals treated with 
5µg/kg/day of cAng-(1-7). 
MI + cAng-(1-7)-50: 
infarcted animals treated 
with 50µg/kg/day of cAng-
(1-7). *p<0.05 vs. MI + 
saline (general linear model 
for repeated measures).   
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 Figure 6. Tube formation 
assay performed on HUVEC 
cultured for 6h with cAng-(1-
7) at densities of 3x103 
cells/well and 6x103 
cells/well. Representative 
pictures of control (B) and 
cAng-(1-7)-treted cells (C). 
n=8 (control); n=6 (cAng-(1-7) 
doses). *p<0.05 vs. control (1-
way ANOVA followed by 
Dunnett’s post-hoc test). 
 
 
 
 
 
 
CONCLUSIONS 
This study suggests that cAng-(1-7) given early after myocardial infarction 
might not lead to improved angiogenesis, mainly due to an anti-angiogenic 
effect on adult endothelial cells. It is recommended that after MI Ang-(1-7) 
analogues are administered after the neovascularization phase. However, the 
full potential of cAng-(1–7) as an experimental drug still needs to be explored in 
diverse cardiac diseases models, and be compared to effects of other Ang-(1-7)-
Mas-stimulating drugs such as ACE2 activators, Nor-Leu3 Ang-(1-7), 
CGEN856S, cyclodextrin-encapsulated Ang-(1-7) and AVE0091.2 Abolishment 
of myogenic tone, as a mechanism to reduce workload, is an important new 
topic in such studies.  
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 SUPPLEMENTAL MATERIAL 
Figure S1. FACS 
analysis results of 
blood samples (A, B, C, 
and D)  and bone 
marrow (E, F, G, and H) 
from non-infarcted 
animals treated with 
saline or cAng-(1-7) for 
72h. A and E, 
percentage of 
hematopoietic 
progenitor cells (c-kit 
positive cells). B and F, 
percentage of positive 
cells for stem cells 
markers (Sca-1). C and 
G, percentage of double 
positive cells for Sca-1 
and c-kit markers. D 
and H, percentage of 
positive cells for EPC 
marker (Flk-1 positive 
cells). cAng-(1-7): non-
infarcted animals 
treated with 
50µg/kg/day of cAng-
(1-7). Data have been 
expressed as a 
percentage of the mean 
in saline-treated 
animals (see Methods 
section).  
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CHAPTER 6 
 
DEVELOPMENT OF THE LOCAL RENIN-ANGIOTENSIN SYSTEM DURING 
DIFFERENTIATION OF MESENCHYMAL STEM CELLS  
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on: Development of the local renin-angiotensin system during 
differentiation of mesenchymal stem cells. Sevá Pessôa B, van der Eerden B, van 
der Leije C, Schreuders-Koedam M, Musterd-Bhagghoe U, Jan Danser AH, van 
Leeuwen H, Roks AJM. Manuscript in preparation.  
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 Abstract 
Introduction: The renin-angiotensin system (RAS) performs a pivotal role in 
cardiovascular homeostasis and disease. Chronic RAS activation, ie. the 
excessive increase of activity of the hormone angiotensin II (Ang II) through Ang 
II type 1 (AT1) receptors, is the main mechanism for pathogenic effects. Ang II 
type 2 (AT2) receptors and the hormone angiotensin-(1-7) (Ang-1-7), which acts 
through Mas receptors, counteract these AT1 receptor-mediated effect. Recently, 
stem and progenitor cells have been implicated in cardiovascular disease and 
effects of RAS modulation, but not much is known how RAS is involved in 
diverse stages of progenitor cell differentiation. Our aim was to study the 
presence and activity of RAS components in stem cells in relation to their 
differentiation. 
Methods: Bone marrow-derived human mesenchymal stem cells (hMSC) were 
cultured in propagation medium or differentiation medium (adipogenic and 
osteogenic). The time-resolved expression of RAS components (micro-array) and 
the response to Ang II and Ang-(1-7) was studied. 
Results: hMSC on propagation medium showed expression of AT1 receptors, 
angiotensinogen, angiotensin receptor-asscoiated protein (ATRAP), neutral 
endopeptidase (NEP) and prolyl endopeptidase (PEP) mRNA. Of these 
components, AT1 receptors, angiotensinogen and NEP increased significantly 
after addition of differentiation medium, the increase beginning at various time 
points.AT2 and Mas receptors, angiotensin-converting enzyme (ACE), ACE2, 
renin and chymase mRNA was not expressed. Undifferentiated hMSC on 
proliferation medium did not respond to Ang II. 3 days after addition of 
adipogenic medium hMSC responded to Ang II, as visualized by increased Erk 
and decreased Akt phosphorylation, while on osteogenic medium only Erk 
phosphorylation was increased. All Ang II effects were mediated by AT1 
receptors, not AT2, whereas Ang-(1-7) had no effects. Ang II given at 
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 concentrations of 1 and 100 nM dose-dependently increased differentiation of 
hMSC into adipocytes measured after 20 days. 
Conclusion: Undifferentiated hMSC do not express functional AT1 receptors. 
Differentiation initiates the capacity of Ang II-AT1 signaling. The direction of 
differentiation (adipogenic vs osteogenic) determines which second messenger 
is involved. AT2 and Mas receptor signaling was not induced by differentiation. 
A full expression spectrum of RAS compenents was never accomplished. Based 
on expression profile of the RAS components and receptor functionality 
differentiated hMSC resemble adult visceral fat adipocytes and osteoblasts. 
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 INTRODUCTION 
The renin-angiotensin system (RAS) is known as a major system involved in the 
pathogenesis of cardiovascular diseases, mostly via the hormone angiotensin II 
(Ang II) through Ang II type 1 (AT1) receptors.1 On the other hand, Ang II type 2 
(AT2) receptors and the hormone angiotensin-(1-7) (Ang-1-7), which acts 
through Mas receptors, counteract these AT1-mediated effect.2 The effects of 
angiotensins take place not only directly through modulation of cardiovascular 
tissue and function, but also in association with modulation of extracellular 
matrix, adipose tissue, inflammatory cells, and glucose metabolism.3 This 
implies that many cell types other than cardiovascular might be involved.  
Since the presence of RAS components in bone marrow (BM) cells was 
confirmed, studies have shown effects of RAS modulation on proliferation of 
stem and progenitor cells.4 Among others, these studies determined the 
inhibitory effect of Ang II on adipogenesis in pre-adipocytes, which might 
involve even effects on mesenchymal stem cells (MSC) that are either 
undifferentiated or in an early phase of differentiation.5-8 Adipose tissue is 
believed to play an important role in cardiovascular disease, as it would 
contribute to RAS activation and to metabolic disease.9 Well-known are also 
the effects of Ang II on endothelial progenitor cells, in which the hormone can 
either stimulate angiogenesis or cause senescence, thus prohibiting proper 
angiogenic function, depending on the duration of stimulation.10 In addition, 
we have previously shown that Ang-(1-7)/Mas signaling promotes formation of 
endothelial progenitor cells from blood and bone marrow-derived mononuclear 
cells in vitro, while according to Than et al. such signaling may also regulate 
pre-adipocytes via activation of the PI3K/Akt pathway and inhibition of 
MAPK/ERK pathways.11,12  
The consequent results of such studies open new possibilities to optimize 
therapies using RAS modulation as a way to favorably change the phenotype of 
stem and progenitor cells. However, for the better exploration of this potential it 
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 is important to determine how the function of the AT1 and AT2 receptors, as 
well as the hormone Ang-1-7 and its receptor Mas, relate to the stage of 
development of stem cells during their differentiation phases from becoming 
progenitor cells up until the point at which differentiation has been completed. 
As to yet this is an unexplored terrain. In the present study we therefore 
explored expression of RAS components starting from undifferentiated MSC up 
until a progressed phase of differentiation. In addition, we have studied effects 
of Ang II and Ang-(1-7), and the involvement of the relevant angiotensin 
receptors. To determine whether development of a functional RAS is dependent 
on the course of differentiation towards diverse cell types, we have compared 
two differentiation conditions. The first condition is differentiation towards 
adipocytes, from which it is known that the RAS should at some point in the 
differentiation process become involved. The second condition is differentiation 
towards osteogenic cells. This might be important for cardiovascular disease in 
relation to calcification of arteries involving aging of vascular smooth muscle 
cells, leading to an osteogenic phenotype.13 PI3K/Akt and MAPK/ERK signaling 
were used as a read-out for angiotensin signaling, since it is known that these 
pathways are involved in angiotensin-mediated growth and differentiation 
effects in pre-adipocytes.12  
METHODS 
Propagation of MSC 
Human MSCs (hMSC) derived from BM (Lonza Benelux BV, Breda, 
Netherlands, cat.#PT2501) were characterized and selected by flow cytometry-
based sorting using specific MSC markers (CD105, CD166, CD29, and CD44), 
and exclusion on hematopoeitic lineage markers (CD14, CD34 and CD45), 
showing multiple differentiation abilities under an atmosphere of 5% CO2, 
incubated at 37oC. Medium was changed every 3-4 days. The growth medium 
used for proliferation consisted of mesenchymal stem cell growth medium 
(hMSC medium), i.e. α-MEM with 10% heat inactivated fetal calf serum (HI-
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 FCS), 2%  penicillin-streptomycin (PLS, 5000 U/ml penicillin and 5000 U/ml of 
streptomycin) and 1.8 mM calcium chloride. This medium keeps the MSC 
undifferentiated.  
 
Differentiation of MSC towards adipocytes  
To produce differentiation medium we combined α-MEM (without phenol red 
and calcium chloride; Invitrogen), with 10% charcoal-treated fetal calf serum 
(CT FCS, Invitrogen), 2% penicillin-streptomycin (PLS, 5000 U/ml penicillin 
and 5000 U/ml of streptomycin) and 0.18% 1 M calcium chloride. 
Subsequently, pH was adjusted to 7.5 with 10 M sodium hydroxide. hMSCs 
were differentiated into lipid vesicle-containing adipocytes within 1 to 2 weeks 
by incubation with 1 mM dexamethasone, 30 mM indomethacin, and 250 mM 
3-isobutyl-1-methylxanthine. Refreshments took place 3 times a week. The 
adipogenic differentiation was assessed by histology of lipid-containing vesicles, 
Oil Red-O staining (ORO). At different intervals (Day 5, 10, 14, 17 and 20) after 
treatment with adipocytic growth factors, the wells were checked for the 
presence of adipocytes. Sufficient amounts of adipocytes to perform reliable 
analyses (10% or more of total number of cells) were present from day 17 to 20 
after addition of adipogenic medium, assuming stationary quantities. At each of 
the two time points we performed quantitative analyses from three independent 
experiments with duplo observations. To this end, cells were washed twice with 
PBS and fixed with 10% formalin in PBS. After washing once with 60% iso-
propanol, the wells were incubated for 30 minutes with filtered ORO working 
solution which contains 3 parts of saturated ORO solution with 2 parts of Milli-
Q water, filtered through a 0.2 µm filter. For cell count DAPI nuclear staining 
was used. Cell counting was performed on pictures taken from each well, using 
3 pictures per well. Pictures were obtained with a fluorescence microscope 
(Axiovert 200M, 100x, Axiovision 4.6 software). Since the numbers of 
adipocytes showed considerable variability from culture cluster were expressed 
as % of adipocytes in cultures that were not treated with angiotensin (baseline 
control).  
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 Differentiation of MSC towards osteogenic cells 
To evoke osteogenesis hMSC medium was supplemented with 0.1 μM 
dexamethasone and 10 mM M β-glycerophosphate. Refreshments took place 3 
times a week. 
Erk and Akt phosphorylation experiments 
To test angiotensin signalling, cells were exposed to hMSC, adipogenic or 
osteogenic differentiation medium for 3 days. To compare propagation medium 
with differentiation medium (p)ERK and (p)Akt measurement the cells were 
stimulated for 5 or 15 minutes with 100 nML of the angiotensins as indicated 
in the results. To test the involvement of angiotensin receptor subtypes, cells 
were preincubated with the AT1 receptor antagonist irbesartan (100 nM) or the 
AT2 antagonist PD123319 (100 nM) for 10 minutes before Ang II (1 and 100 nM) 
was added. hMSC homogenate was used to quantify ERK (Cell Signaling, 
cat.#9102S, rabbit, 1:2000 diluted), phosphorylated ERK (pERK) (Cell Signaling, 
cat.#9102S, rabbit, 1:2000 diluted), Akt (Cell Signaling, cat.#9272, rabbit, 
1:1000 diluted), phosphorylated Akt (pAkt) (Cell Signaling, cat.#4060, rabbit, 
1:2000 diluted) proteins by standard Western blot techniques under 
denaturating conditions. To verify the uniformity of the protein load and 
transfer efficiency across the test samples, the membranes were re-probed for 
β-actin (Millipore cat.#MAB1501, clone C4, 1:50000 diluted). The secondary 
anti-body goat anti-rabbit (BioRad) was used at 1:2000 dilution. Signal were 
detected by an enhanced chemiluminescent substrate for detection of HRP 
(SuperSignal CL-HRP substrate system, Thermo Scientific, cat.#32106).  
Exposed films were scanned and then analyzed quantitatively with ImageJ 
software (rsb.info.nih.gov/ij/). Band densities of the protein of interest were 
corrected for β-actin expression. The average of these corrected values for 
samples taken before stimulation was set at 100%, and subsequently values of 
all samples were expressed relatively to this level. For the time-resolved 
western blot determining angiotensin-induced phosphorylation 4 individual 
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 experiments for adipogenic, osteogenic as well as propagation medium were 
performed with single observations of each treatment condition per 6-well 
culture plate (baseline, Ang II, and Ang-(1-7); 5 and 15 minutes for each 
treatment). Therefore, no variance could be obtained for the baseline controls 
that were set at 100% for this experiment. For the experiments applying Ang II 
in combination with antagonists, all measurement were performed in duplo per 
plate, allowing calculation of the variance of the baseline controls. 
Micro array protocol  
Microarray analysis was performed by means of Illumina Human HT-12 v3 
BeadChip (Illumina, Inc, Eindhoven, The Netherlands) human whole-genome 
expression array, as described before.14 In short, RNA of 3 biologic replicates 
for baseline conditions under propagation medium (0 hour) and each time 
point after addition of differentiation medium was isolated condition. The 
Illumina TotalPrep RNA Amplification Kit (Ambion, Austin, TX, USA) was used 
for RNA amplification, after which single-stranded cDNA was generated with 
the use of T7 oligo(dT) primer followed by double-strand synthesis. 
Subsequently, biotin-labeled cRNA was  produced with the use of T7 RNA 
polymerase, and 750 ng was hybridized for each array according to the 
standard protocol, using streptavadine-Cy3 label for signal quantification (GE 
Healthcare, Piscataway, NJ, USA).  Slides were scanned on an iScan and 
analyzed using GenomeStudio (both from Illumina, Inc.). Background was 
subtracted from the raw data using GenomeStudioV2010.1 (Gene Expression 
Module 1.6.0, Illumina), and data were processed using the Bioconductor 
R2.10.0 Lumi package (www.bioconductor.org). The data were as transformed 
by variance stabilization and quantile normalization. Probes that were detected 
at least five times in the experiments (Illumina detection p value < .01) were 
considered to be expressed and were further analyzed. The RAS components 
available on his array were angiotensinogen, angiotensin-converting enzyme 
(ACE), ACE2, AT1 receptor, AT2 receptor, Mas receptor, prolylendopeptidase 
(PEP), neutral endopeptidase (NEP), and angiotensin receptor-associated 
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 protein (ATRAP). The mean level of expression of detectable genes was set on 1 
for undifferentiated hMSC (i.e. the 0 hour point), and all mRNA levels are 
expressed relatively to this initial level. 
qPCR protocol 
Total RNA isolation was performed in samples taken from hMSC cultures, 
taken from a different donor, on proliferation medium (day 0), and day 9 and 
19 after addition of differentiation medium, using the NucleoSpin RNA II kit 
(Machery- Nagel). RNA was reverse transcribed by use of the Quantitect Rev. 
Transcription Kit (Qiagen). Four nanograms of cDNA was amplified by real-time 
polymerase chain reaction (qPCR). Each reaction was performed in duplo with 
SYBR Green PCR Master Mix (Applied Biosystems). The following primers were 
used:  human MAS1 (Forward 5’-TGTGGAGAGGTGCCTGTCAGTCC-3’;  Reverse 
5’-GCCCACAGAAGGGCACAGACC-3’), human AGTR-1 (AT1 receptor) (Forward 
5’-GTCCCGCCTTCGACGCACAA-3’; Reverse 5’-AACTGGCCAAGCCTGCCAGC-3’), 
human AGTR-2 (AT2 receptor) (Forward 5’-TCCAACAGAAGCTCCGCAGTGTG-3’; 
Reverse 5’-AGAGAACTGCTTTTCCGGCAAGACA-3’). β-actin correction was 
performed as an endogenous control (Ct values ≥31 were excluded). The 
relative amount of genomic DNA in DNA samples was determined as RQ = 2(-
ΔΔCt). 
Statistical analysis 
The change in mRNA levels as detected by the micro-array was tested with the 
general linear model for repeated measures (GLM-RM) on one factor, being the 
individual gene product, using the mRNA levels at each time point as 
dependents. To test if at each time point after addition of differentiation 
medium the mRNA levels were different from those before treatment (the 0 hour 
time point), one-way ANOVA with Dunnett post-hoc test was used. For the 
time-resolved western blot determining angiotensin-induced phosphorylation 
one-sample t-test against the value 100 was used. For the experiments 
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 applying Ang II in combination with antagonists one-way ANOVA with Dunnett 
post-hoc test against control was applied. 
RESULTS 
Time-resolved expression pattern of RAS components 
hMSC showed only detectable levels of AT1 receptor, angiotensinogen, ATRAP, 
NEP and PEP which changed all five after addition of adipogenic medium 
(p<0.05, GLM-RM). NEP and AT1 receptor mRNA expression significantly 
increased starting resp. from 1 and 2 days after addition of adipogenic medium 
(Figure 1). Angiotensinogen mRNA levels were in general very low, sometimes 
undetectable, before and the first days after addition of adipogenic medium, 
increasing significantly, and being always detectable, from day 7 (Figure 1). 
Levels  of the angiotensin receptor - modulating protein ATRAP were always 
detectable and although changing significantly overall in time (p<0.05 GLM-RM 
and one-way ANOVA without Dunnett post-hoc test), levels remained relatively 
constant, differing only significantly, but always very modestly, from 
undifferentiated cells 12 hours, 1 day and 25 days after addition of adipogenic 
medium (Figure 1). In addition, changes in ATRAP and PEP expression were 
inconsistent, showing increases as well as decreases depending on the time 
point. Levels of ACE, ACE2, renin, chymase, cathepsin G, AT2 receptor and 
Mas receptor mRNA remained beyond the detection limit. To assess which of 
the receptors might be important for effects of angiotensins on adipogenic 
hMSC, the presence of the angiotensin receptors was checked in duplo samples 
from an independent experiment with qPCR on propagation medium (day 0), 
and day 9 and day 19 after addition of adipogenic medium. This study 
confirmed the array data, showing detectable level of AT1 receptors (Ct ranging 
from 26.3 to 27.5), and levels that increased by 3.8 and 4.4 times on day 9 and 
day 19 respectively, whereas mRNA of AT2 receptor was very low (Ct value ~ 34) 
and Mas receptor mRNA was undetectable. 
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 When looking at changes in RAS components after addition of osteogenic 
medium, similar results were obtained as for adipogenic medium (Figure 2). 
ATRAP expression increased (GLM-RM p<0.05), but again this change was 
modest. Also, qPCR for the various receptors performed in duplo samples 
obtained from an independent experiments obtained in hMSC of a different 
donor confirmed an increase of AT1 receptors of 1.8 and 10.8 fold of baseline at 
days 9 and 19 respectively, whereas AT2 and Mas receptor mRNA was very low 
or undetectable.  
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Figure 1. Expression of RAS 
components in triplo samples of 
undifferentiated hMSC (0 hours) 
and MSC at different time points 
after addition of adipogenic 
differentiation medium. 
Expression was measured in 
parallel samples in triplo by 
illuminex micro-array. Panel titles 
indicate the RAS component that 
was tested. *p<0.05 (one-way 
ANOVA with Dunnett post-hoc test 
versus undifferentiated hMSC (0 
hours)). 
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Figure 2. Expression of RAS 
components in triplo samples of 
undifferentiated hMSC (0 hours) 
and MSC at different time points 
after addition of osteogenic 
differentiation medium. Expression 
was measured in parallel samples 
in triplo by illuminex micro-array. 
Panel titles indicate the RAS 
component that was tested. 
*p<0.05 (one-way ANOVA with 
Dunnett post-hoc test versus 
undifferentiated hMSC (0 hours)). 
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ERK and Akt phosphorylation during Ang II and Ang-(1-7) propagation and 
differentiation phases 
Ang II-exposed cells appeared to present lower pERK/ERK ratios when grown 
on propagation medium (Figure 3A). Nevertheless, taken separately, ERK and 
pERK were unchanged when hMSC were not differentiated (Figure 3A). No 
changes in Akt or pAkt were observed (Figure 3C). Also, Ang-(1-7) did not 
changes (p)ERK or (p)Akt (Figure 3B,D). On adipogenic or osteogenic medium, 
however, Ang II unambiguously increased pERK and pERK/ERK (Figure 4A, 
5A), an effect that appeared optimal between 5 and 15 minutes after addition of 
Ang II. Moreover, Akt phosphorylation tended to decrease (Figure 4C: p=0.06 
pAkt/Akt 15 minutes vs. value 100%, one sample t-test, Figure 5C) 15 minutes 
after addition of Ang II. Although Ang-(1-7) appeared to result in lower pERK 
levels in hMSC under osteogenic circumstances, this was not observed when 
correcting for total ERK levels (Figure 4B). Also, under all other conditions Ang-
(1-7) did not have any effect (Figure 4D, Figure 5B, 5D). Based on this outcome 
and for further functional validation that of the micro-array, experiments to 
explore involved receptors as a of the micro-array results were performed on 
adipogenic medium with Ang II only, using 15 minutes as the time point of 
read-out.  
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 Figure 4. Analysis of 
ERK and Akt 
expression during the 
adipogenic 
differentiation 
condition. Adipogenic 
medium cultured cells 
were treated with Ang 
II (A and C) or Ang-(1-
7) (B and D). The 
exposition to Ang II or 
Ang-(1-7) were done for 
5 or 15 minutes. N=4 
observations per time 
point *: p<0.05, one-
sample t-test versus 
the value of 100%. 
 
 
 
Figure 3. Analysis of 
ERK and Akt pathways 
during the propagation 
conditions. The cells 
were treated with Ang II 
(A and C) or Ang-(1-7) (B 
and D) for 5 or 15 
minutes. N=4 
observations per time 
point *: p<0.05, one-
sample t-test versus % of 
control. 
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Figure 5. Analysis of 
ERK and Akt expression 
during the osteogenic 
differentiation 
condition. Osteogenic 
medium cultured cells 
were treated with Ang II 
(A and C) or Ang-(1-7) 
(B and D). The 
exposition to Ang II or 
Ang-(1-7) were done for 
5 or 15 minutes. N=4 
observations per time 
point *: p<0.05, one-
value t-test versus % of 
control. 
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 Receptor subtypes involved in the Ang II effects 
Western blot analysis revealed that Ang II, given for 15 minutes, dose-
dependently increased ERK phosphorylation versus baseline, i.e. cells not 
treated with Ang II, significance being detectable at the concentration of 100 
nM Ang II (Figure 6A). Antagonists PD123319 and irbesartan changed by their 
own pERK/ERK levels (p<0.05 one-way ANOVA, Dunnett post-hoc test). 
PD123319 did not block the Ang II response, whereas irbesartan did. Moreover, 
Ang II treatment decreased Akt phosphorylation (Figure 6B). The antagonists 
did not have an effect on their own (P=NS, one-way ANOVA), but irbesartan 
blocked the response to 1 nM Ang II, while PD123319 did not affect the Ang II 
responses. 
A      B 
 
 
 
 
 
 
 
 
Figure 6. Western blot analysis of ERK/pERK (A) and Akt/pAkt (B). Cells were exposed to 1 
nM or 100 nM Ang II, with AT1 and AT2 receptors blockers (n=4 per experiment, except 
irbesartan + 1 nM Ang II: n=3), or without (n=4 for 1 nM, and n=8 for 100 nM Ang II). *: p<0.05, 
one-way ANOVA with Dunnett post-hoc vs. baseline. testvalue t-test versus baseline. *: p<0.05, 
one-way ANOVA versus baseline. 
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 Effects of Ang II and Ang-(1-7) on MSC differentiation into adipocytes 
Adipocyte numbers assessment at day 17 and 20 after addition of adipogenic 
medium to hMSC (Figure 7A) showed that only Ang II given at 1 or 10 nM each 
2 days significantly increased adipocyte development (Figure 7B), whilst Ang-
(1-7) had no effect (Figure 7C).   
 A 
 
 
 
 
 
 
 B      C 
 
 
 
 
 
 
 
 
Figure 7. Oil Red-O staining on hMSC grown in adipogenic differentiation medium for 20 days 
(A). Cells were exposed to 1 nM, 10 nM or 100 nM of Ang II (B), Ang-(1-7) (C), or vehicle (control) 
for 17 to 20 days. The number of positive cells were compared to control, which was set at 
100%. Positive ORO cells were counted and divided by the amount of DAPI-stained nuclei. N=6 
observations per concentration obtained in 3 independent experiments *: p<0.05, one-value t-
test against the value 100. 
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 DISCUSSION 
Prompted by the possibility to optimize therapies using RAS modulation by 
targeting of stem and progenitor cells, we set out to study if angiotensin effects 
depends on the differentiation process. Our present findings demonstrate that 
stem cell marker-selected, early undifferentiated BM-derived hMSC, do not 
express RAS components. Although AT1 receptors and ATRAP were 
demonstrated at the mRNA level, AT1 receptor signaling could not be observed, 
implying that protein levels might be very low. AT1 receptors, however, rapidly 
increased upon addition of differentiation medium, permitting signaling. This 
effect seems to be ubiquitous: it is observed on adipogenic as well as osteogenic 
medium, and AT1 signaling has been observed by others in endothelial 
progenitor cells, as discussed previously.10,15 Another important conclusion is 
that under the conditions that were used here hMSC do not develop a complete 
RAS since Mas and AT2 receptors, ACE, ACE2, renin, chymase and cathepsin G 
do not appear to be expressed. Also, functional AT2 and Mas receptors do not 
appear to be present during development into adipogenic or osteogenic cells, 
which is confirmed by our functional experiments. The finding is in contrast 
with an earlier report showing that rat culture-selected, adherent rat BM-
derived cells, which were high in CD90 but low in haematopoietic markers CD4 
and CD11b, expressed more RAS members.16 However, the use of CD90, or 
thymus cell antigen-1, as an MSC marker is questionable, since it is used also 
as a hematopoietic lineage marker, and in addition shows species-related 
differences.17,18 The results implicate that cells forming the niche of MSC 
express a wide array of RAS components, and selection markers importantly 
influence the interpretation of results. 
When focusing on adipogenic differentiation, in general, the AT1 receptor 
appears to inhibit differentiation of adult adipose tissue, leading to increased 
adipose tissue, which can be reduced by blockade of AT1 signaling.19 AT2 
receptors appear to have the opposite effect of AT1 receptors, but only act in the 
presence of high lipid levels, as found in ApoE knockout mice.19 For adipocytes 
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 it is known that the RAS components that are expressed display regional 
differences.20 In comparison to isolated human adipocytes, the RAS in our in 
vitro differentiated BM-derived hMSC appear to largely mimick visceral 
(perirenal, omental and mammary) adipocytes, which show both 
angiotensinogen and AT1 receptor expression, but not AT2 receptors.21,22 Adult 
human adipocytes also express ACE, unlike hMSC-derived cells in our study, 
but are low on chymase and do not show renin expression, which resembles 
the phenotype described in the current study. Our observations in adipogenic 
differentiation of hMSC are largely opposite to those reported in an earlier 
publication by Matsushita et al., who observed a lowering of AT1 receptors and 
angiotensinogen, and an increase of AT2 receptors during differentiation, and 
also demonstrated ACE and renin expression.23 These findings were previously 
reported to be also in contrast with other studies.20 These contrasts might have 
different explanations. Firstly, this previous study did not report the number 
cycles needed to observe PCR signals, making it hard to determine if expression 
levels were relevant. Secondly, the origin, purity and donor preconditions of the 
hMSC were not reported, but this might be relevant as well: AT2 receptors are 
expressed in whole adipose tissue or in 3T3-L1 cells, a mouse fibroblast with 
adipogenic ability when grown under the specific adipogenic medium, and, in 
contrast to what is observed in vivo in ApoE knockout mice, lacking this 
receptor in an otherwise wildtype genotype increases adipogenesis.12,20,24-26 
Thirdly, the AT2 antagonist PD123319 partly blocks Ang II in cultured human 
adipocytes or hMSC-derived adipocytes when both compounds were used in 
very high concentrations (1 or 10 µM).23,27 Unfortunately, more relevant, lower 
concentrations, which waarant specifity, were not used. However, AT2 receptor 
expression appears to be lost during the development from a preadipocyte into 
an adipocyte.28 Therefore, the role of AT2 receptors in relation to the cell type in 
which it is present, the location of the adipose tissue compartment, and the 
metabolic conditions in the organism needs to be further explored.  
Similarly, according to a previous study Mas receptor appear to be 
present on subcutaneous (pre)adipocytes,12 but we could not detect mRNA for 
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 Mas receptor in hMSC-derived adipocytes. Unfortunately, in this previous 
study Ang-(1-7) and A779 were used in very high concentrations of 1 and 10 
µM respectively, raising concerns as to the specificity and physiological 
relevance of such findings. In addition, subcutaneous fat and visceral fat are 
different in their role in (patho)physiology, where visceral fat relates to the 
classical concept of obesity-related cardiovascular disease risk, and it is known 
that also the RAS is differentially expressed in these two compartments.29 
When studying visceral fat it has been shown that Mas receptor knockout in 
mice leads to adaptation of this tissue and Ang-(1-7) was reported to stimulate 
glucose uptake in adipocytes derived thereof, which was reversed by the Ang-
(1-7) antagonist A779.30,31  Nevertheless, to our knowledge the Mas receptor, 
although present,32 was not extensively quantified in visceral adipose tissue, 
nor has it been demonstrated on isolated visceral adipocytes. We did not 
observe Ang-(1-7) signaling. Also, in the present study we have also looked at 
expression of NEP and PEP. Both enzyme metabolize Ang II into Ang-(1-7).33 
PEP did not seem to develop a specific expression pattern after addition of 
differentiation medium. However, NEP clearly showed an increase. Since Ang-
(1-7) signaling was not present, it seems logical to conclude that if NEP acted 
here as a modulator of Ang II signaling. However, The relative time course of 
expression of RAS-related does not seem to follow a pattern that suggests any 
specific relationship with local Ang II generation; angiotensinogen is increasing 
much later than NEP, and renin, ACE, chymase and cathepsin G are anyhow 
not expressed in differentiating hMSC. Also, ATRAP is not showing strong 
changes or any specific pattern in relation to AT1 receptors or other RAS 
members. Therefore, there does not seem to be any concerted regulation of the 
various genes.  
In summary, hMSC-derived seem to develop an angiotensin receptor 
profile that predominantly resembles that of visceral fat-derived adipocytes, 
and not that of subcutaneous adipocytes or the mouse fibroblast-derived 3T3-
L1. It seems most likely that effects of AT2 and Mas receptor in visceral fat do 
not occur within the adipocytes but rather in communication with other cell 
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 types within the niche, or even with other organs as suggested before.20 The 
extrapolation of receptor interaction studies performed in  3T3-L1 or skin-
derived adipocytes is therefore not a straightforward task. Also, the use of very 
high angiotensin or receptor antagonist concentrations should in general be 
avoided.  
The role of the RAS in osteogenic cells is far less studied than in the case 
of lipid metabolism. Studies in humans to the effect of classical RAS inhibitors 
on bone fractures appear to point at protection of bone but are not uniformly 
confirmative.34 Yet, in animal models Ang II appears to increase the formation 
of osteoclasts from BM-derived mononuclear cells, and to induce an 
osteoclasts-activating phenotype of human osteoblasts, all through AT1 
receptors.35  Differentiated osteoblast from newborn mice contain both AT1 and 
AT2 receptors, whereas osteoclasts contain only low numbers of AT1 
receptors.36 In osteoblasts from humans Ang II was reported to induce pERK 
and pAkt, which takes place through AT1 receptors only.35 Also in osteoblast-
rich cell populations isolated from newborn rat calvaria Ang II responses only 
take place via AT1 receptors.37 Paradoxically, in mice with an activated RAS due 
to transgenic overexpression of human renin and angiotensinogen the 
induction of osteoclast activation by osteoblasts is AT2 receptor-dependent, and 
inhibited by AT1 receptors.36 Thus far, an explanation for this conversion is 
lacking. Our differentiated hMSC, which should obtain an osteoblast-like 
phenotype, only express AT1 receptors, which resembles features of human and 
rat, but not mouse osteoblasts. Differentiated hMSC lack the effect of Ang II on 
pAkt observed in human osteoblasts, although until now osteoblasts were only 
tested with a high concentration of 1 µM Ang II.35  
Osteogenic differentiation is also a feature of vascular smooth muscle cell 
(VSMC) induced by high phosphate levels and promoted by cellular aging.13,38 
In a model mimicking vascular calcification in chronic kidney disease the AT1 
receptor antagonist olmesartan has shown anti-calcification effects.39 Although 
that might relate to attenuation of increased plasma phosphate levels, it has 
been shown that in cultured human VSMC 100 µM olmesartan decreases 
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 calcium deposition in the cells in the absence of Ang II. Others have shown 
that Ang II given at relevant concentrations increases the calcifying effect of 
receptor activator of nuclear factor κB ligand (RANKL) in VSMC in vitro and in 
ovariectomized, ApoE knockout mice.40 Also, a possible involvement of 
magnesium channels and of calcification inhibitor matrix Gla protein has been 
proposed.3,41  
The presence of Mas receptors or of angiotensin-(1-7) have never been 
tested directly on osteogenic cells, although the peptide reduces calcification 
markers in a rat model of vascular calcification induced by vitamin D3 plus 
nicotine. Whether this was a local vascular effect of Ang-(1-7) and if it involved 
Mas receptors was not clear from this study.42 Furthermore, osteoclastogenesis 
induced by prostate tumor cells in an metastasis model in SCID mice is 
reduced by Ang-(1-7), but this is presumably an indirect effect exerted via the 
tumor cells.43 As to date there has not been a comprehensive comparative 
study of expression of RAS components in differentiated osteogenic vs. 
differentiating hMSC, and the role of MSC in vascular calcification is not 
known, Nevertheless, hMSC might be an appropriate model to further study 
the role of RAS under osteogenic or calcifying conditions. 
With respect to studies exploring other differentiation paths of MSC, we 
have recently summarized the involvement of RAS in effects of MSC on 
vascular and cardiac progenitor cells, and on healing properties in the stroke 
model.4 Several studies have shown that AT1, AT2, and Mas receptors influence 
the behavior of progenitor cells, but for all these studies the same question 
applies: are local receptors in the cells involved, or is their niche of origin and 
homing determining the impact of the RAS? The answer to this question can 
importantly contribute to the design of interventional strategies that combine, 
either obligatory or voluntarily, the stem cell with RAS modulating therapies.  
  
179 
 REFERENCES 
1. Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol. 
2010;7:431-41. 
2. Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ, Raizada MK. 
Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in 
cardiovascular diseases. Hypertension. 2010;55:207-13. 
3. Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. Angiotensin II and vascular 
injury. Curr Hypertens Rep. 2014;16:431. 
4. Durik M, Pessoa BS, Roks AJM. The renin-angiotensin system, bone marrow and 
progenitor cells. Clinical Science. 2012;123:205-223. 
5. Matsushita K, Wu Y, Okamoto Y, Pratt RE, Dzau VJ. Local renin angiotensin expression 
regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension. 
2006;48:1095-102. 
6. Fuentes P, Acuna MJ, Cifuentes M, Rojas CV. The anti-adipogenic effect of angiotensin 
II on human preadipose cells involves ERK1,2 activation and PPARG phosphorylation. 
Journal of Endocrinology. 2010;206:75-83. 
7. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in 
vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes. 
2002;51:1699-707. 
8. Brucher R, Cifuentes M, Acuna MJ, Albala C, Rojas CV. Larger anti-adipogenic effect of 
angiotensin II on omental preadipose cells of obese humans. Obesity (Silver Spring). 
2007;15:1643-6. 
9. Thatcher S, Yiannikouris F, Gupte M, Cassis L. The adipose renin-angiotensin system: 
role in cardiovascular disease. Mol Cell Endocrinol. 2009;302:111-7. 
10. Roks AJ. Angiotensin II Deteriorates Endothelial Progenitor Cells: Good Intentions With 
Bad Consequences. Hypertension. 2011;58:356-8. 
11. Wang Y, Qian C, Roks AJ, Westermann D, Schumacher SM, Escher F, Schoemaker RG, 
Reudelhuber TL, van Gilst WH, Schultheiss HP, Tschope C, Walther T. Circulating 
rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial 
infarction. Circ Heart Fail. 2010;3:286-93. 
12. Than A, Leow MK, Chen P. Control of adipogenesis by the autocrine interplays between 
angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways. 
Journal of Biological Chemistry. 2013;288:15520-31. 
13. Nakano-Kurimoto R, Ikeda K, Uraoka M, Nakagawa Y, Yutaka K, Koide M, Takahashi T, 
Matoba S, Yamada H, Okigaki M, Matsubara H. Replicative senescence of vascular 
smooth muscle cells enhances the calcification through initiating the osteoblastic 
transition. Am J Physiol Heart Circ Physiol. 2009;297:H1673-84. 
14. Drabek K, van de Peppel J, Eijken M, van Leeuwen JP. GPM6B regulates osteoblast 
function and induction of mineralization by controlling cytoskeleton and matrix vesicle 
release. J Bone Miner Res. 2011;26:2045-51. 
15. Roks AJ, Rodgers K, Walther T. Effects of the renin angiotensin system on 
vasculogenesis-related progenitor cells. Curr Opin Pharmacol. 2011;11:162-74. 
16. Strawn WB, Richmond RS, Ann Tallant E, Gallagher PE, Ferrario CM. Renin-
angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br 
J Haematol. 2004;126:120-6. 
17. Calloni R, Cordero EA, Henriques JA, Bonatto D. Reviewing and updating the major 
molecular markers for stem cells. Stem Cells Dev. 2013;22:1455-76. 
18. Lee TC, Lee TH, Huang YH, Chang NK, Lin YJ, Chien PW, Yang WH, Lin MH. 
Comparison of Surface Markers between Human and Rabbit Mesenchymal Stem Cells. 
PLoS One. 2014;9:e111390. 
19. Iwai M, Tomono Y, Inaba S, Kanno H, Senba I, Mogi M, Horiuchi M. AT2 receptor 
deficiency attenuates adipocyte differentiation and decreases adipocyte number in 
atherosclerotic mice. Am J Hypertens. 2009;22:784-91. 
180 
 20. Cassis LA, Police SB, Yiannikouris F, Thatcher SE. Local adipose tissue renin-
angiotensin system. Curr Hypertens Rep. 2008;10:93-8. 
21. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM. Co-expression of 
renin-angiotensin system genes in human adipose tissue. J Hypertens. 1999;17:555-60. 
22. Sarzani R, Marcucci P, Salvi F, Bordicchia M, Espinosa E, Mucci L, Lorenzetti B, 
Minardi D, Muzzonigro G, Dessi-Fulgheri P, Rappelli A. Angiotensin II stimulates and 
atrial natriuretic peptide inhibits human visceral adipocyte growth. Int J Obes (Lond). 
2008;32:259-67. 
23. Matsushita K, Wu Y, Okamoto Y, Pratt RE, Dzau VJ. Local renin angiotensin expression 
regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension. 
2006;48:1095-1102. 
24. Gupte M, Boustany-Kari CM, Bharadwaj K, Police S, Thatcher S, Gong MC, English VL, 
Cassis LA. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am 
J Physiol Regul Integr Comp Physiol. 2008;295:R781-8. 
25. Lu H, Boustany-Kari CM, Daugherty A, Cassis LA. Angiotensin II increases adipose 
angiotensinogen expression. Am J Physiol Endocrinol Metab. 2007;292:E1280-7. 
26. Weiland F, Verspohl EJ. Variety of angiotensin receptors in 3T3-L1 preadipose cells and 
differentiated adipocytes. Horm Metab Res. 2008;40:760-6. 
27. Skurk T, van Harmelen V, Hauner H. Angiotensin II stimulates the release of 
interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-
kappaB. Arterioscler Thromb Vasc Biol. 2004;24:1199-203. 
28. Mallow H, Trindl A, Loffler G. Production of angiotensin II receptors type one (AT1) and 
type two (AT2) during the differentiation of 3T3-L1 preadipocytes. Horm Metab Res. 
2000;32:500-3. 
29. Strazzullo P, Galletti F. Impact of the renin-angiotensin system on lipid and 
carbohydrate metabolism. Curr Opin Nephrol Hypertens. 2004;13:325-32. 
30. Mario EG, Santos SH, Ferreira AV, Bader M, Santos RA, Botion LM. Angiotensin-(1-7) 
Mas-receptor deficiency decreases peroxisome proliferator-activated receptor gamma 
expression in adipocytes. Peptides. 2012;33:174-7. 
31. Liu C, Lv XH, Li HX, Cao X, Zhang F, Wang L, Yu M, Yang JK. Angiotensin-(1-7) 
suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes. 
Acta Diabetol. 2012;49:291-9. 
32. Santos SH, Fernandes LR, Mario EG, Ferreira AV, Porto LC, Alvarez-Leite JI, Botion LM, 
Bader M, Alenina N, Santos RA. Mas deficiency in FVB/N mice produces marked 
changes in lipid and glycemic metabolism. Diabetes. 2008;57:340-7. 
33. Seva Pessoa B, van der Lubbe N, Verdonk K, Roks AJ, Hoorn EJ, Danser AH. Key 
developments in renin-angiotensin-aldosterone system inhibition. Nat Rev Nephrol. 
2013;9:26-36. 
34. Butt DA, Mamdani M, Gomes T, Lix L, Lu H, Tu K, Hypertension Outcome ST. Risk of 
Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-
Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly. J Bone 
Miner Res. 2014;29:2483-8. 
35. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, 
Yoshikawa H, Ogihara T, Morishita R. Angiotensin II accelerates osteoporosis by 
activating osteoclasts. FASEB J. 2008;22:2465-75. 
36. Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita S, Nimura Y, Ishida J, 
Fukamizu A, Ikeda K. Activation of renin-angiotensin system induces osteoporosis 
independently of hypertension. J Bone Miner Res. 2009;24:241-50. 
37. Hiruma Y, Inoue A, Hirose S, Hagiwara H. Angiotensin II stimulates the proliferation of 
osteoblast-rich populations of cells from rat calvariae. Biochem Biophys Res Commun. 
1997;230:176-8. 
38. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. 
Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 
2000;87:E10-7.  
181 
 39. Iijima K, Ito Y, Son BK, Akishita M, Ouchi Y. Pravastatin and olmesartan synergistically 
ameliorate renal failure-induced vascular calcification. J Atheroscler Thromb. 
2014;21:917-29. 
40. Osako MK, Nakagami H, Shimamura M, Koriyama H, Nakagami F, Shimizu H, Miyake T, 
Yoshizumi M, Rakugi H, Morishita R. Cross-talk of receptor activator of nuclear factor-
kappaB ligand signaling with renin-angiotensin system in vascular calcification. 
Arterioscler Thromb Vasc Biol. 2013;33:1287-96. 
41. Jia G, Stormont RM, Gangahar DM, Agrawal DK. Role of matrix Gla protein in 
angiotensin II-induced exacerbation of vascular calcification. Am J Physiol Heart Circ 
Physiol. 2012;303:H523-32. 
42. Sui YB, Chang JR, Chen WJ, Zhao L, Zhang BH, Yu YR, Tang CS, Yin XH, Qi YF. 
Angiotensin-(1-7) inhibits vascular calcification in rats. Peptides. 2013;42:25-34. 
43. Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, Tallant EA, 
Gallagher PE. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces 
osteoclastogenesis. Prostate. 2013;73:71-82. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
182 
  
 
 
 
 
 
 
 
 
CHAPTER 7 
 
SUMMARY, CONCLUSION AND PERSPECTIVES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
183 
 SUMMARY AND CONCLUSION 
It is widely accepted that the renin-angiotensin system (RAS) plays a major role 
in the progression of cardiovascular and kidney disease, for instance by 
influencing blood pressure and fluid homeostasis. Classically, this role 
concerns angiotensin (Ang) II-Ang II type 1 (AT1) receptor-aldosterone 
interaction. Yet, new drugs are now emerging that act beyond this classical 
axis. This is important because currently existing drugs (ACE inhibitors, AT1 
receptor antagonists and mineralocorticoid receptor antagonists), when given 
separately, often result in a so-called Ang II or aldosterone escape, while in 
combination their side-effect profile is unattractive. This thesis evaluated the 
various novel concepts, i.e., the interference with the ‘alternative RAS’.  
Chapter 1 summarizes our current knowledge regarding the alternative 
RAS, focusing among others on renin, Ang II type 2 (AT2) receptors, 
angiotensin-(1-7) (Ang-(1-7)) and the Mas receptor. Subsequently, Chapter 2 
describes the results obtained with the new renin inhibitor VTP-27999 in salt-
depleted healthy volunteers. Although on the one hand, given its identical 
potency but much larger bioavailability, VTP-27999 may block renin at lower 
oral doses than aliskiren, too much renin inhibition with VTP-27999 turned 
out to be detrimental. Surprisingly, this was accompanied by a rise in 
extrarenal RAS activity, due to the fact that VTP-27999, like aliskiren, 
accumulates in the kidney. This results in excessive renal RAS suppression, 
inducing massive renin rises that can no longer be suppressed after 24 hours 
by the remaining VTP-27999 levels in blood. Clearly therefore, renin inhibition 
has an upper limit, and more is not necessarily better. 
In Chapter 3, we analyzed the contribution of the AT2 receptor to the 
Ang II-induced vasoconstrictor effects in the four core genotype mouse model. 
This allowed us to establish that the dilator effects of AT2 receptors, occurring 
exclusively in women, depend on both female sex hormones and the XX 
chromosome sex complement. The latter was also required for the non-NO-
mediated dilator effect of acetylcholine. Since AT2 receptors induce vasodilation 
via bradykinin type 2 receptors, which also link to NO and non-NO dilator 
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 pathways, these two findings may be related. To what degree these phenomena 
contribute to the cardiovascular protection in premenopausal women remains 
to be determined. Moreover, they raise the possibility of sex-specific therapies, 
despite the fact that, at this moment, there is no evidence that RAS blockers 
act differently in males and females.    
Chapter 4 discusses the potential role of the RAS in the regulation of 
hematopoiesis and tissue regeneration by progenitor cells. It concludes that 
Ang-(1-7), via Mas-receptor activation, affects the proliferation and 
differentiation of stem cells. Chapter 5 has investigated this possibility in the 
post-myocardial infarction model in mice, making use of a stable Ang-(1-7) 
analogue, cyclic Ang-(1-7). This compound diminished cardiomyocyte 
hypertrophy and myogenic tone, without affecting cardiovascular function. It 
increased circulating progenitor cells, albeit without endothelial markers. 
Unexpectedly, restoration of cardiac capillary density lagged behind in cyclic 
Ang-(1-7)-treated animals. Moreover, the drug reduced tube formation by 
endothelial cells in vitro. In conclusion, cyclic angiotensin-(1-7), when given 
early after myocardial infarction, recruits progenitor cells, but this does not 
lead to improved angiogenesis, most likely because it simultaneously exerts an 
anti-angiogenic effect in adult endothelial cells.  
Finally, Chapter 6 shows that Ang II effects mediated via AT1 receptors 
were absent in mesenchymal stem cells, but appeared as soon as these cells 
became adipogenic or osteogenic progenitor cells. Ang-(1-7)-induced effects 
could not be observed under any condition, and the same was true for AT2 
receptor-mediated effects. The underlying reason appeared to be that 
adipogenic and osteogenic progenitor cells exclusively express AT1 receptors at 
sufficient levels to warrant receptor signaling.  
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 PERSPECTIVES 
Many years ago, Packer asked the question why the kidneys release renin in 
patients with heart failure, the answer being that they do everything possible to 
preserve renal function and glomerular filtration, apparently at the expense of 
the hemodynamic burden on the heart.1 This situation mimics our findings 
with VTP-27999, where the kidneys also respond to renal RAS suppression by 
releasing very large quantities of renin, resulting in elevations (above pre-drug 
levels) of plasma renin activity, Ang II and aldosterone. This implies that renin 
inhibitors should be dosed optimally and not necessarily maximally. Moreover, 
future studies should now investigate to what degree this phenomenon also 
underlies the detrimental effects of dual RAS blockade with RAS blockers other 
than renin inhibitors.  
Simultaneously, we need to know whether females respond differently to 
RAS blockade as compared to males. If AT2 receptor-mediated vasodilation 
truly occurs in premenopausal women only, their preferred RAS blocker might 
be an AT1 receptor antagonist, because such a drug would allow exclusive AT2 
receptor stimulation. Our data do not strongly support a role for AT2 receptor 
agonists as antihypertensive agents, except perhaps in premenopausal women. 
In fact, AT2 receptors may even be contractile in men (Chapter 3), and might 
also induce pain.2 
Our results suggest that Ang-(1-7) might be more effective after the 
angiogenic remodeling phase when it concerns post-myocardial infarction 
treatment.3 The anti-angiogenic effect of such compounds could also be 
interesting for the treatment of cancer, as shown by other researchers,4,5 but 
the occurrence of cardiovascular events requiring an angiogenic response 
might limit the clinical use of Ang-(1-7) in such patients. Moreover, after >25 
years of preclinical research on the effects of Ang-(1-7)/Mas axis stimulation, 
we now need clinical data comparing such stimulators with classical RAS 
blockers, either alone or on top of these drugs. This would also require the 
definite choice of an optimal Mas receptor stimulant, taking into consideration 
the short half-life of Ang-(1-7) itself.  
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  Rodgers et al.6 have suggested that Ang-(1-7) offers great potential in 
stimulating platelet recovery following myelosuppression by improving 
hematopoietic progenitor cell pools. In addition, we made similar observations 
for endothelial progenitor cells.7  Obviously, the underlying signaling pathways 
should be scrutinized further. Moreover, as our current data indicate, this 
should always be performed in the context of comparison with effects on adult 
cells. Remaining issues to be studied are effects on progenitor cells evoked 
through angiotensin effects on the surrounding niche, such as bone marrow 
stroma cells or cardiovascular cells. Additionally, we need to know the impact 
of cardiovascular and metabolic diseases on the responses of stem and 
progenitor cells to angiotensins.  
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 SAMENVATTING EN CONCLUSIES  
Het is een algemeen geaccepteerd gegeven dat het renine-angiotensine systeem 
(RAS) een grote rol speelt bij het ontstaan van cardiovasculaire en renale 
ziekten, bijvoorbeeld door de beïnvloeding van de bloeddruk middels regulatie 
van bloedvatmotoriek en de waterbalans. Van oudsher concentreert deze rol 
zich op de angiotensine (Ang) II-Ang II type 1 (AT1) receptor-aldosteron 
interactie. Er zijn nu echter nieuwe medicijnen die ook aangrijpen buiten deze 
traditionele as. Dit is belangrijk, want de bestaande geneesmiddelen (ACE 
remmers, AT1 receptor antagonisten en mineralocorticoïd receptor 
antagonisten), indien apart gegeven, resulteren niet in een blijvende 
onderdrukking van  (de effecten van) Ang II of aldosteron door het optreden van 
compenserende mechanismen. Bovendien is er sprake van een zeer ongunstig 
bijwerkingenprofiel wanneer een combinatie van deze ‘klassieke’ medicijnen 
gebruikt wordt. Dit proefschrift evalueert de diverse nieuwe concepten, en met 
name het  ingrijpen op dit ‘alternatieve RAS’.  
Hoofdstuk 1 bevat een beknopt overzicht van de huidige kennis over het 
alternatieve RAS, waarbij de nadruk ligt op renine, Ang II type 2 (AT2) 
receptoren, angiotensine-(1-7) (Ang-(1-7)) en de Mas receptor. Vervolgens 
beschrijft hoofdstuk 2 de resultaten die behaald zijn met de nieuwe renine 
remmer VTP-27999 in gezonde vrijwilligers tijdens een laag zout dieet. Hoewel 
enerzijds, vanwege een gelijke potentie bij een veel hogere biologische 
beschikbaarheid, VTP-27999 renine bij een lagere orale dosis blokkeert dan 
aliskiren, blijkt teveel renine remming door VTP-27999 nadelig te zijn. 
Verrassend genoeg ging dit gepaard met een toename van RAS activiteit buiten 
de nier. Dit heeft te maken met het feit dat VTP-27999, zoals aliskiren, zich 
ophoopt in de nier. Een dergelijke ophoping resulteert in excessieve renale RAS 
onderdrukking, zodat, dankzij het wegvallen van de lokale negatieve feedback 
van Ang II, er een enorme afgifte van renine op gang komt. Na 24 uur zijn de 
overgebleven hoeveelheden VTP-27999 in het bloed niet langer voldoende om 
dit renine onderdrukt te houden. Hierdoor is het duidelijk dat renine remming 
190 
 een bovengrens heeft, en dat een hogere dosis renine remmer niet 
noodzakelijkerwijs beter is. 
In hoofdstuk 3 is het aandeel van de AT2 receptor in de door Ang II 
veroorzaakte bloedvat-vernauwende effecten onderzocht in het zogenaamde 
‘four-core genotype’  muismodel. Dit is een muismodel waarbij de invloed van 
geslachtschromosomen onafhankelijk van het geslacht zelf kan worden 
bestudeerd. Dit hielp ons om vast te stellen dat de verwijdende effecten van AT2 
receptoren, die alleen bij vrouwen voorkomen, afhankelijk zijn van zowel 
vrouwelijke geslachtshormonen als van de aanwezigheid van beide X-
chromosomen. Dit laatste was ook een vereiste voor het non-NO-gemedieerde 
bloedvatverwijdende effect van acetylcholine. Aangezien AT2 receptoren 
bloedvatverwijding veroorzaken middels bradykinine type 2 receptoren, welke 
ook gelieerd zijn aan NO en niet-NO verwijdende mechanismen, zouden deze 
twee bevindingen gerelateerd kunnen zijn. In hoeverre deze fenomenen 
bijdragen aan de cardiovasculaire bescherming die geldt voor premenopausale 
vrouwen dient nog nader onderzocht te worden. Wel bieden ze de mogelijkheid 
voor geslacht-specifieke therapieën, ondanks het feit dat er momenteel geen 
bewijs bestaat dat RAS remmers zich anders gedragen in mannen en vrouwen.  
Hoofdstuk 4 bespreekt de potentiële rol van het RAS in de regulatie van 
bloedcelvorming en weefselvernieuwing door stamcellen. De conclusie luidt dat 
Ang-(1-7), via Mas-receptor activatie, de proliferatie en differentiatie van 
stamcellen beïnvloedt. Hoofdstuk 5 onderzocht de implicaties van deze 
mogelijkheid in het post-myocardiale infarctmodel in muizen, waarbij gebruik 
gemaakt is van een stabiel Ang-(1-7) analoog, cyclisch Ang-(1-7). Deze stof 
verminderde de hypertrofie van cardiomyocyten en de myogene tonus van 
arteriolen na het infarct, zonder echter de pompfunctie van het hart te 
beïnvloeden. Cyclisch Ang-(1-7) vergrootte het aantal bloedcelvormende 
circulerende stamcellen, maar niet die met endotheliale eigenschappen. Een 
onverwacht effect was dat het herstel van de cardiale capillaire dichtheid 
achterbleef in de dieren die met cyclisch Ang-(1-7) behandeld waren. Bovendien 
verminderde het medicijn de zogenaamde tube vorming, i.e., de primitieve 
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 voorlopers van bloedvaten, door endotheelcellen in vitro. Hieruit kunnen we 
concluderen dat cyclisch angiotensine-(1-7), wanneer het na een hartinfarct 
toegediend wordt, stamcellen activeert, maar dat dit niet leidt tot een 
verbeterde angiogenese, waarschijnlijk omdat het tegelijkertijd een anti-
angiogeen effect heeft op volwassen endotheelcellen. 
Tenslotte wordt in hoofdstuk 6 aangetoond dat de Ang II effecten die 
gemedieerd worden via AT1 receptoren afwezig waren in mesenchymale 
stamcellen, maar wel optraden zodra deze cellen adipogene of osteogene 
stamcellen werden. Ang-(1-7)-geïnduceerde effecten werden onder geen enkele 
omstandigheid gevonden, en hetzelfde gold voor AT2 receptor-gemedieerde 
effecten. De onderliggende reden hiervoor lijkt te zijn dat adipogene en 
osteogene stamcellen alleen AT1 receptoren in voldoende mate tot expressie 
brengen om receptor signallering in gang te zetten.  
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 VOORUITZICHTEN 
Vele jaren geleden stelde dr. Milton Packer de vraag waarom zoveel renine door 
de nier geproduceerd wordt in patiënten met hartfalen. Het antwoord luidde 
dat al het mogelijke gedaan wordt om de nierfunctie en glomerulaire filtratie te 
behouden, schijnbaar ten koste van de hemodynamische belasting van het 
hart.1 Deze situatie komt overeen met onze bevindingen met VTP-27999, waar 
de nieren ook reageren op renale RAS onderdrukking door de afgifte van 
enorme hoeveelheden renine, hetgeen resulteert in verhoging (boven pre-
medicatieniveau) van de plasma renine activiteit, Ang II en aldosteron. Dit wijst 
erop dat renine remmers vooral optimaal en niet per se maximaal gedoseerd 
zouden moeten worden. Bovendien zouden toekomstige studies nu moeten 
onderzoeken of ditzelfde fenomeen wellicht ten grondslag ligt aan de nadelige 
effecten van duale RAS blokkade met andere RAS blokkers dan renine remmers.  
Tegelijkertijd moet nu onderzocht worden of vrouwen daadwerkelijk 
anders reageren op RAS blokkade dan mannen. Als AT2 receptor-gemedieerde 
vasodilatatie inderdaad alleen voorkomt bij premenopausale vrouwen, zou bij 
hen de voorkeur uitgaan naar het gebruik van een AT1 receptor antagonist als 
RAS blokker, omdat een dergelijk medicijn de mogelijkheid biedt van exclusieve 
AT2 receptor stimulatie. Onze data ondersteunen niet de brede toepassing van 
AT2 receptor agonisten als antihypertensieve middelen, behalve wellicht bij 
premenopausale vrouwen. AT2 receptor stimulatie kan zelfs constrictie van 
bloedvaten veroorzaken bij mannen (Hoofdstuk 3), en ook pijnprikkels 
verhogen.2 
Onze resultaten suggereren dat Ang-(1-7) analoga effectiever zullen zijn 
na de angiogene remodelleringsfase van de hartspier die normaal volgt op het 
hartinfarct.3 De anti-angiogene eigenschappen van dergelijke stoffen kunnen 
ook interessant zijn voor de behandeling van kanker, hetgeen reeds door 
diverse onderzoekers aangetoond is.4,5 Echter, indien cardiovasculaire 
gebeurtenissen bij patiënten gelijktijdig een angiogene respons vereisen, zou dit 
het klinisch gebruik van Ang-(1-7) analoga beperken. Na meer dan 25 jaar 
preklinisch onderzoek naar de effecten van Ang-(1-7)/Mas receptor stimulantia 
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 is er bovendien sterkte behoefte aan klinische data die zulke stimulantia 
vergelijken met de traditionele RAS blokkers, zowel bij enkelvoudig gebruik als 
in combinatie. In dat geval dient er ook een definitieve keuze gemaakt te 
worden voor de optimale Mas receptor agonist, waarbij de korte halfwaardetijd 
van Ang-(1-7) zelf in beschouwing genomen moet worden.  
Rodgers et al.6 hebben geopperd dat Ang-(1-7) veel potentie heeft wat 
betreft het induceren van bloedplaatjesherstel na myelosuppressie, met name 
door het verhogen van de hematopoiëtische stamcelvoorraden. Eerder vonden 
we zelf dat de stof ook de groei van endotheel stamcellen bevordert.7 Uiteraard 
dienen de onderliggende signaleringscascades eerst verder ontrafeld te worden. 
Zoals onze huidige resultaten al aangeven, dient dit altijd uitgevoerd te worden 
in de context van een vergelijking met de effecten op volwassen cellen. Wat 
tevens nog nader onderzocht dient te worden is hoe stamcellen de effecten van 
angiotensines op de omliggende niche (o.m. beenmerg stroma cellen of 
cardiovasculaire cellen) beïnvloeden. Daarnaast dienen we te weten wat de 
impact van cardiovasculaire en metabole ziekten is op de reacties van 
stamcellen op angiotensines. 
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